use of a stable formulation comprising an iduronate-2-sulfatase protein (i2s), formulation comprisin

专利摘要:
METHODS AND COMPOSITIONS FOR DISTRIBUTION IN THE CNS OF IDURONATE-2-SULPHATASE The present invention provides, among other things, compositions and methods for the delivery to the CNS of lysosome enzymes for effective treatment of diseases by storing lysomes. In some embodiments, the present invention includes a stable formulation for direct intrathecal administration to the CNS comprising an iduronate-2-sulfatase (I2S) protein, salt and a polysorbate surfactant for the treatment of Hunters syndrome.
公开号:BR112012033214B1
申请号:R112012033214-7
申请日:2011-06-25
公开日:2020-11-03
发明作者:Gaozhong Zhu；Kris Lowe；Zahra Shahrokh；James Christian；Rick Fahrner；Jing Pan；Teresa Leah Wright；Pericles Calias
申请人:Shire Human Genetic Therapies, Inc.；
IPC主号:

专利说明:

CROSS REFERENCE WITH RELATED REQUESTS
[0001] This application claims priority over US Provisional Patent Applications serial numbers 61 / 358,857, filed on June 25, 2010; 61 / 360,786, filed on July 1, 2010; 61 / 387,862, deposited on September 29, 2010; 61 / 435,710, deposited on January 24, 2011; 61 / 442,115, filed on February 11, 2011; 61 / 476,210, filed on April 15, 2011; and 61 / 495,268, deposited on June 9, 2011; the entirety of which is incorporated herein by reference.
[0002] This order refers to US orders entitled "CNS Delivery of Therapeutic Agents," filed on the same date; "Methods and Compositions for CNS Delivery of Heparan N-Sulfatase," filed on the same date; "Methods and Compositions for CNS Delivery of Arylsulfatase A," deposited on the same date; "Methods and Compositions for CNS Delivery of β-Galactocerebrosidase," deposited on the same date; "Treatment of Sanfilippo Syndrome Type B," filed on the same date; the entirety of which is incorporated herein by reference. FUNDAMENTALS
[0003] Enzyme replacement therapy (Tre) involves the systemic administration of enzymes from and / or natural or protein-derived recombinants to an individual. Approved therapies are generally administered to individuals intravenously and are generally effective in treating the somatic symptoms of the underlying enzyme deficiency. As a result of the limited distribution of the enzyme and / or intravenously administered protein in cells and tissues of the central nervous system (CNS), the treatment of diseases, having a CNS etiology has been especially challenging because the enzymes administered and / or proteins intravenously do not adequately cross the blood-brain barrier (BBB).
[0004] The blood-brain barrier (BBB) is a structural system, composed of endothelial cells that works to protect the central nervous system (CNS) from harmful substances in the blood stream, such as bacteria, macromolecules (eg, proteins) ) and other hydrophilic molecules, limiting the diffusion of substances through the BBB and into the underlying cerebrospinal fluid (CSF) and CNS.
[0005] There are several ways to get around BBB to improve brain delivery of a therapeutic agent including direct intracranial injection, transient permeabilization of BBB and modification of the active agent to alter tissue distribution. Direct injection of a therapeutic agent into brain tissue completely ignores the vasculature, but suffers mainly from the risk of complications (infection, tissue damage, immune responsive) incurred by intracranial injections and poor diffusion of the active agent from the administration site. To date, direct administration of proteins to the brain substance has not achieved a significant therapeutic effect due to diffusion barriers and the limited volume of therapy that can be administered. Diffusion-assisted convection has been studied through catheters placed in the brain parenchyma using slow, long-term infusions (Bobo, et al., Proc. Natl. Acad. Sci. USA 91, 2076-2080 (1994); Nguyen, et al J. Neurosurg. 98, 584-590 (2003)), but no approved therapy currently uses this approach for long-term therapy. In addition, intracerebral catheter placement is very invasive and less desirable as a clinical alternative.
[0006] Intrathecal injection (IT), or the administration of proteins to the cerebrospinal fluid (CSF), has also been attempted, but has not yet yielded therapeutic success. A major challenge in this treatment has been the tendency of the active agent to attach the ependymal lining of the ventricle very tightly which has prevented subsequent diffusion. Currently, there is no product approved for the treatment of genetic brain disease by administration directly to CSF.
[0007] In fact, many believed that the diffusion barrier on the surface of the brain, as well as the lack of effective and convenient delivery methods, were too great a barrier to achieving the appropriate therapeutic effect on the brain for any disease.
[0008] Many diseases of lysosomal storage affect the nervous system and thus demonstrate unique challenges in treating these diseases with traditional therapies. There is often a large accumulation of glycosaminoglycans (GAGs) in the neurons and meninges of affected individuals, leading to various forms of CNS symptoms. To date, no symptoms of CNS resulting from a disorder of lysosomes have been successfully treated by all available means.
[0009] Thus, there is still a great need to effectively deliver therapeutic agents to the brain. More particularly, there is a great need for more effective delivery of active agents to the central nervous system for the treatment of lysosome storage disorders. SUMMARY OF THE INVENTION
[0010] The present invention provides an effective and less invasive approach to direct delivery of therapeutic agents to the central nervous system (CNS). The present invention, in part, based on the unexpected discovery that a replacement enzyme (eg, iduronate-2-sulfatase (I2S)) for a lysosomal storage disease (eg, Hunters' syndrome) can be introduced directly to the cerebrospinal fluid (CSF) of an individual in need of treatment at a high concentration (for example, greater than about 3 mg / ml, 4 mg / ml, 5 mg / ml, 10 mg / ml or more) such that The enzyme effectively and extensively diffuses over several surfaces and penetrates several regions throughout the brain, including deep regions of the brain. Most surprisingly, the present inventors have demonstrated that such high protein concentration delivery can be achieved using simple saline or stock-based formulations and without inducing substantial, adverse effects, such as severe immune response, on the individual. Therefore, the present invention provides a highly efficient, clinically desirable and patient-friendly approach to direct delivery of the CNS for the treatment of various diseases and disorders that have CNS components, in particular, lysosome storage diseases. The present invention represents a significant advance in the field of CNS targeting and enzyme replacement therapy.
[0011] As described in detail below, the present inventors have successfully developed stable formulations for effective intrathecal (IT) administration of an iduronate-2-sulfatase protein (I2S). It is, however, found that several stable formulations described herein are generally suitable for the delivery of CNS of therapeutic agents, including various other lysosomal enzymes. In fact, stable formulations according to the present invention can be used for the delivery of CNS through various techniques and routes including, but not limited to, intraparenchymal, intracerebral, cerebral intraventricular (ICV), intrathecal (e.g. , IT-lumbar, IT-cisterna magna) administrations and any other techniques and routes for injection directly or indirectly to the CSF and / or CNS.
[0012] It is also envisaged that several stable formulations described here are generally suitable for the delivery of CNS from other therapeutic agents, such as therapeutic proteins, including various replacement enzymes for diseases by storage of lysosomes. In some embodiments, a replacement enzyme can be a synthetic, recombinant, activated or natural gene.
[0013] In several embodiments, the present invention includes a stable formulation for the intrathecal administration of direct CNS composed of a protein capable of iduronate-2-sulfatase (I2S), salt and a Polysorbate surfactant. In some embodiments, the I2S protein is present in concentrations ranging from approximately 1- 300 mg / ml (for example, 1-250 mg / ml, 1-200 mg / ml, 1-150 mg / ml, 1-100 mg / ml, or 1-50 mg / ml). In some embodiments, the I2S protein is present at or up to a selected concentration from 2 mg / ml, 3 mg / ml, 4 mg / ml, 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, 100 mg / ml, 150 mg / ml, 200 mg / ml, 250 mg / ml, or 300 mg / ml.
[0014] In various embodiments, the present invention includes a stable formulation of any of the embodiments described in this document, wherein the I2S protein comprises an amino acid sequence SEQ ID NO: 1. In some embodiments, the I2S protein comprises an amino acid sequence of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% identical to SEQ ID NO: 1. In some embodiments, the stable formulation of any of the embodiments described in this document includes a salt. In some embodiments, the salt is NaCl. In some embodiments, NaCl is present as a concentration ranging from approximately 0-300 mM (for example, 0-250 mM, 0-200 mM, 0-150 mM, 0-100 mM, 0-75 mM, 0- 50 mM, or 0-30 mM). In some embodiments, NaCl is present in a concentration that ranges from approximately 137-154 mM. In some embodiments, NaCl is present at a concentration of approximately 154 mM.
[0015] In various embodiments, the present invention includes a stable formulation of any of the embodiments described in this document, wherein the surfactant Polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, Polysorbate 80 and the combination thereof. In some embodiments, Polysorbate surfactant is polysorbate 20. In some embodiments, polysorbate 20 is present in a concentration that ranges from approximately 0-0.02%. In some embodiments, polysorbate 20 is present at a concentration of approximately 0.005%.
[0016] In various embodiments, the present invention includes a stable formulation of any of the embodiments described in this document, wherein the formulation most comprises a buffering agent. In some embodiments, the buffering agent is selected from the group consisting of phosphate, acetate, histidine, succinate, Tris and their combinations. In some embodiments, the buffering agent is phosphate. In some embodiments, the phosphate is present in a concentration not exceeding 50 mM (for example, not greater than 45 mM, 40 mM, 35 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, or 5 mM) . In some embodiments, the phosphate is present in a concentration not exceeding 20 mM. In several aspects, the invention includes a stable formulation of any of the embodiments described, wherein the formulation has a pH of approximately 3-8 (for example, approximately 4-7.5, 5-8, 5-7.5, 5-6.5, 5 -7.0, 5.5-8.0, 5.5-7.7, 5.5-6.5, 6-7.5, or 6-7.0). In some embodiments, the formulation has a pH of approximately 5.5-6.5 (for example, 5.5, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5). In some embodiments, the formulation has a pH of approximately 6.0.
[0017] In various embodiments, the present invention includes stable formulations of any of the embodiments described in this document, wherein the formulation is a liquid formulation. In various embodiments, the present invention includes a stable formulation of any of the embodiments described in this document, wherein the formulation is formulated as a lyophilized powder.
[0018] In some embodiments, the present invention includes a stable formulation for intrathecal administration, consisting of a protein capable of iduronate-2-sulfatase (I2S) in concentrations ranging from about 1-300 mg / ml, NaCl in the concentration of about 154 mM, polysorbate 20, at a concentration of approximately 0.005%, and a pH of approximately 6.0. In some embodiments, the I2S protein is at a concentration of approximately 10 mg / ml. In some embodiments, the I2S protein is at a concentration of approximately 30 mg / ml, 40 mg / ml, 50 mg / ml, 75 mg / ml, 100 mg / ml, 150 mg / ml, 200 mg / ml, 250 mg / ml, or 300 mg / ml.
[0019] In several aspects, the present invention includes a container consisting of a single dosage form of a stable formulation in various embodiments described herein. In some embodiments, the container is selected from an ampoule, a test tube, a bottle, a cartridge, a reservoir, a lio-jet or a pre-filled syringe. In some embodiments, the container is a pre-filled syringe. In some embodiments, the pre-filled syringe is selected from borosilicate glass syringes with baked silicone, coating, borosilicate glass syringes with powdered silicone, or plastic resin syringes without silicone. In some embodiments, the stable formulation is present in a volume of less than about 50 ml (for example, less than about 45 ml, 40 ml, 35 ml, 30 ml, 25 ml, 20 ml, 15 ml, 10 ml , 5 ml, 4 ml, 3 ml, 2.5 ml, 2.0 ml, 1.5 ml, 1.0 ml, or 0.5 ml). In some embodiments, the stable formulation is present in a volume of less than about 3.0 mL.
[0020] In various aspects, the present invention includes methods for treating hunter's syndrome, including the stage of administration intrathecally to an individual in need of treatment, a formulation according to any of the modalities described herein.
[0021] In some embodiments, the present invention includes a method for treating hunter's syndrome, including a step of administration intrathecally to an individual in need of treatment a formulation composed of a protein capable of iduronate-2-sulfatase (I2S) in concentrations ranging from about 1-300 mg / ml, NaCl at a concentration of about 154 mM, polysorbate 20, at a concentration of approximately 0.005% and a pH of approximately 6.
[0022] In some embodiments, intrathecal administration results in no substantial adverse effect (eg, severe immune response) on the individual. In some embodiments, intrathecal administration results in no substantial T cell-mediated adaptive immune response in the individual.
[0023] In some embodiments, intrathecal administration of the formulation results in the delivery of the I2S protein from various target tissues to the brain, spinal cord, and / or peripheral organs. In some embodiments, intrathecal administration of the formulation results in delivery of the I2S protein to target brain tissues. In some embodiments, target brain tissues comprise neurons of and / or white matter in gray matter. In some modalities, the I2S protein is delivered to neurons, glial cells, meningeal cells and / or perivascular cells. In some embodiments, the I2S protein is still delivered to neurons in the spinal cord.
[0024] In some embodiments, intrathecal administration of the formulation further results in systemic delivery of the I2S protein to peripheral target tissues. In some modalities, in the peripheral target tissues are selected from the liver, kidney, heart and / or spleen.
[0025] In some embodiments, intrathecal administration of the formulation results in the location of cellular lysosomes in target tissues of the brain, spinal cord neurons and / or peripheral tissues. In some embodiments, intrathecal administration of the formulation results in a reduction of the storage gag in target tissues of the brain, spinal cord neurons and / or peripheral target tissues. In some embodiments, GAG storage is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 time, 1.5 times, or 2 times compared to a control (for example, pre-treatment GAG storage in the individual). In some embodiments, intrathecal administration of formulation results in reduced vacuolization in neurons (for example, at least 20%, 40%, 50%, 60%, 80%, 90%, 1 time, 1.5 times, or 2 times in comparison with a control). In some embodiments, neurons form Purkinje cells.
[0026] In some embodiments, intrathecal administration of the formulation results in increased I2S enzyme activity in target tissues of the brain, spinal cord neurons and / or peripheral target tissues. In some embodiments, the enzyme activity of I2S is increased at least 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times compared to a control (for example , the endogenous enzyme activity pre-treatment in the individual). In some embodiments, the increase in I2S enzyme activity is at least approximately 10 nmol / hr / mg, 20 nmol / hr / mg, 40 nmol / hr / mg, 50 nmol / hr / mg, 60 nmol / hr / mg, 70 nmol / hr / mg, 80 nmol / hr / mg, 90 nmol / hr / mg, 100 nmol / hr / mg, 150 nmol / hr / mg, 200 nmol / hr / mg, 250 nmol / hr / mg, 300 nmol / hr / mg, 350 nmol / hr / mg, 400 nmol / hr / mg, 450 nmol / hr / mg, 500 nmol / hr / mg, 550 nmol / hr / mg or 600 nmol / hr / mg.
[0027] In some modalities, the enzymatic activity of I2S is increased in the lumbar region. In some embodiments, the increase in I2S enzymatic activity in the lower back is at least approximately 2000 nmol / hr / mg, 3000 nmol / hr / mg, 4000 nmol / hr / mg, 5000 nmol / hr / mg, 6000 nmol / hr / mg, 7000 nmol / hr / mg, 8000 nmol / hr / mg, 9000 nmol / hr / mg, or 10,000 nmol / hr / mg.
[0028] In some embodiments, intrathecal administration of formulation results in reduced intensity, severity, or delayed frequency or onset of at least one symptom or characteristic of the hunter's syndrome. In some modalities, at least one symptom or characteristic of the hunter's syndrome is cognitive; white matter lesions; dilated perivascular spaces in the cerebral parenchyma, ganglia, corpus callosum, brain stem and / or atrophy; and / or ventriculomegally.
[0029] In some modalities, intrathecal administration occurs once every two weeks. In some embodiments, intrathecal administration takes place once a month. In some modalities, intrathecal administration occurs once every two months. In some modalities, the administration interval is twice a month. In some modalities, the administration interval is once a week. In some modalities, the administration interval is twice or several times a week. In some embodiments, administration is continuous, such as through a continuous infusion pump. In some embodiments, intrathecal administration is used in conjunction with intravenous administration. In some modalities, intravenously it is not more frequent than once a week. In some modalities, intravenously it is not more frequent than once every two weeks. In some modalities, intravenously it is not more frequent than once a month. In some modalities, intravenously it is not more frequent than once every two months. In certain incorporations, intravenous administration is more frequent than monthly administration, such as twice a week, weekly, fortnightly, or twice monthly.
[0030] In some modalities, intravenous and intrathecal administrations are carried out on the same day. In some embodiments, intravenous and intrathecal administrations are not performed within a certain period of time from the other, as not within at least 2 days, within at least 3 days, within at least 4 days, within at least at least 5 days, within at least 6 days, within at least 7 days, or within at least one week. In some modalities, intravenous and intrathecal administrations are performed at alternate times, as alternate administrations weekly, each week, twice a month or monthly. In some embodiments, an intrathecal administration replaces an intravenous administration on an administration schedule, such as on an intravenous administration schedule weekly, biweekly, twice monthly, or monthly, each third, fourth or fifth administration on that list can be replaced by one intrathecal administration instead of intravenous administration.
[0031] In some modalities, intravenous and intrathecal administrations are performed sequentially, such as performing intravenous administrations first (for example, weekly, biweekly, twice monthly, or monthly dosing for two weeks, one month, two months, three months , four months, five months, six months, a year or more) then confront (for example, weekly, biweekly, twice monthly, or monthly dosing for more than two weeks, one month, two months, three months, four months, five months, six months, a year or more). In some modalities, intrathecal administrations are performed first (for example, weekly, biweekly, monthly, twice monthly, once every two months, once every three months, dosing for two weeks, one month, two months, three months, four months, five months, six months, one year or more) followed by intravenous administrations (for example, weekly, biweekly, twice monthly, or monthly dosing for more than two weeks, one month, two months, three months, four months, five months, six months, a year or more).
[0032] In some embodiments, intrathecal administration is used in the absence of intravenous administration.
[0033] In some embodiments, intrathecal administration is used in the absence of simultaneous immunosuppressive therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The drawings are for illustrative purposes only, not for limitation.
[0035] Figure 1 is an exemplary illustration showing IT-delivered I2S detected in the neurons of the cerebral cortex and the cerebellar cortex, including I2S in a layer of meningeal cells, covering the brain surface (arrowhead) after intrathecal injections of 3 I2S doses (arrows). I2S IHC staining in 2 brains from the injected dose was the weakest (not shown in the photo). No positive I2S spots were observed for any type of cells in the brain of vehicle control animals. 40X.
[0036] Figure 2 is an exemplary illustration showing reversal of the pathology in the brain of I2S knockout (IKO) rats after injection of intrathecal-lumbar I2S. He stained brain tissues showed numerous cell storage vacuoles (arrows) in the vehicle's control animals. Cellular vacuolization was reduced across the brain in both dose 2 (not shown in the photo) and 3 injected doses of rats. There was a marked reduction in the 3 injected dose ones. 40X.
[0037] Figure 2 is an exemplary illustration showing immunohistochemical staining of LAMP-1, where there is a strong reduction in lysosome activity in the brains after 2 doses (photo does not show) and 3 doses of I2S treatment compared to vehicle rats controlled. The reduction was characterized by the intensity of lighter staining in regions throughout the brain and the decrease in the number of positive LAMP-1 cells. 40X.
[0038] Figure 3 is an exemplary illustration showing results of morphometry of a comparison of the average positive area of LAMP-1 between the wild-type (WT), the vehicle is not treated and I2S rats (doses of 2 and 3) in Cerebral cortex (cortex), caudate nucleus (CP), thalamus (TH), white matter (WM) and cerebellum (CBL) confirmed that there were significant reductions in positive LAMP-1 staining in all areas of the brain assessed. Data are represented as the mean ± s.d. # P <0.05; * P <0.01; ** P <0.001.
[0039] Figure 4 shows the exemplary electron micrographs of brain cells showing pathological improvements at the ultrastructural level. Neurons in the vehicle treated mice had lamellar inclusions, body structures such as zebra and vacuoles containing granular storage material (insertion), which was reduced in I2S injected mice. Oligodendrocytes from vehicle-treated rats showed large electron-lucent storage vacuoles (arrow) while oligodendrocytes from injected I2S mice had minimal vacuolization. Scale bar: in neurons, 2pm; in oligodendrocytes, 500 nm.
[0040] Figure 5 depicts the exemplary immunohistochemistry results demonstrating that I2S detected in the sinusoidal cells of the intrathecal injections follow the 3-dose liver of the I2S. 2S IHC stain on 2 injected dose liver was the weakest (not shown in the photo). No positive I2S spots on the liver of a controlled animal vehicle. 40X.
[0041] Figure 6 depicts the exemplary tissue of the liver. Severe cell vacuolization and abnormally high lysosome activity is revealed by HE staining and strong LAMP-1 immunostaining has been found in vehicle-controlled animals in relation to WT ones. Marked reduction in cell vacuolization and immunostaining LAMP-1 was found after intertecal treatment with 3 and 2 doses (not shown in the photo), of the treatment of I2S. Staining revealed intracytoplasmic vacuolization was to disappear almost completely with an almost normal liver cell structure. H&E, 40X; LAMP-1, 20X.
[0042] Figure 7A -F illustrates exemplary data comparing aggregation by HPLC-SEC for saline and phosphate formulations (all with 0.01% Polysorbate-20): 1 month at <-65 ° C and 40 ° C
[0043] Figure 8 illustrates the exemplary data comparing the aggregation by the HPLC-SEC method for saline and phosphate formulations (all with 0.01% Polysorbate-20): 6 months at -65 ° C and 25 ° C
[0044] Figures 9A-F illustrate exemplary data comparing aggregation by the HPLC-SEC method for saline and phosphate formulations (all with 0.01% Polysorbate-20): 24 months at -65 ° C and 2 to 8 ° C .
[0045] Figure 10 illustrates the exemplary data comparing rates by the SAX-HPLC method for saline and phosphate formulations (all with 0.01% Polysorbate-20): baseline versus 1 month at 40 ° C.
[0046] Figure 11 illustrates the exemplary data comparing rates by the SAX-HPLC method for saline and phosphate formulations (all with 0.01% Polysorbate-20): baseline versus 6 months at 25 ° C.
[0047] Figure 12 illustrates the exemplary data comparing rates by the SAX-HPLC method for saline and phosphate formulations (all with 0.01% Polysorbate-20): baseline versus 24 months at 2 to 8 ° C.
[0048] Figure 13 illustrates the exemplary data comparing SDS-PAGE, Coomassie stain for saline and phosphate formulations (all with 0.01% Polysorbate-20) at baseline and 1 month @ 40 ° C
[0049] Figures 14A and B illustrate exemplary data comparing SDS-PAGE, Coomassie stain for saline and phosphate formulations (all with 0.01% Polysorbate-20) in 6 months 2 5 ° C and another 16 months at 2-8 ° C
[0050] Figure 15 depicts exemplary tissues showing the brain of a 3 mg treatment group animal. Positive I2S stain on meningeal cells. 4X.
[0051] Figure 16 depicts exemplary tissues showing the brain of a 30 mg treatment group animal. Positive I2S staining in neurons and meningeal cells. 4X
[0052] Figure 17 depicts exemplary tissues showing the brain of the 100 mg treatment group animal. Positive I2S staining neurons and meningeal cells was stronger than in the 3 and 30 mg treated animals. 4X
[0053] Figure 18 depicts exemplary tissues showing the brain of a 150 mg treatment group animal. A large population of neurons was 12S positive along with strongly positive meningeal cells.
[0054] Figure 19 depicts exemplary tissues showing positive I2S neurons and glial cells, along with meningeal cells, within layer I of the brain in a 30 mg treatment group animal. 40X
[0055] Figure 20 depicts exemplary tissues showing I2S positive neurons, glial cells, along with perivascular cells, within layer III of the brain in a 30 mg treatment group animal. 40X
[0056] Figure 21 depicts exemplary tissues showing I2S positive neurons and glial cells within layer VI of the brain adjacent to white matter in a 30 mg treatment group animal. 40X
[0057] Figure 22 depicts exemplary tissues showing strongly positive I2S staining in the neurons (brain) of a 150 mg treatment group animal. 100X
[0058] Figure 23 depicts an exemplary tissue showing cervical spinal immunostaining I2S in a 150 mg treatment group. 4X
[0059] Figure 24 depicts an exemplary tissue showing strong I2S immunostaining in the lumbar spinal cord of a 150 mg treatment group animal. 4X
[0060] Figure 25 depicts an exemplary tissue showing strongly positive I2S immunostaining of meningial cells, glial cells and epiperiendoneurium (connective cells) was found in the lumbar section of a 150 mg treatment group animal. 40X
[0061] Figure 26: Neurons in the lumbar spinal cord of a 150 mg treatment group animal were strongly positive for I2S. 40X
[0062] Figure 27 depicts exemplary results of a liver from a 3 mg treatment group animal. Only sinusoidal cells were I2S positive. 40X
[0063] Figure 28 depicts exemplary results from a liver of a 30 mg treatment group animal. Hepatocytes and sinusoidal cells were I2S positive. 40X
[0064] Figure 29 depicts exemplary results from a liver of a 100 mg treatment group animal. I2S immunostaining was much stronger in sinusoidal cells and hepatocytes. 40X
[0065] Figure 30 depicts exemplary results from a liver of a 150 mg treatment group animal. Strongly positive I2S staining has been identified in hepatocytes and sinusoidal cells. 40X
[0066] Figure 31 depicts exemplary results from a heart of a 3 mg treatment group animal. I2S immunostaining was negative. 40X
[0067] Figure 32 depicts exemplary results from a heart of a 30 mg treatment group animal interstitial cells were I2S positive. 40X
[0068] Figure 33 depicts exemplary results from a 100 mg treatment group animal heart. Positive interstitial cell stains for I2S. 40X
[0069] Figure 34 depicts exemplary results from a 150 mg treatment group animal heart. Strongly positive interstitial cell, staining for I2S. 40X
[0070] Figure 35 depicts exemplary results of a kidney from a 3 mg treatment group animal. I2S immunostaining was negative. 40X
[0071] Figure 36 depicts exemplary results of a kidney from a 30 mg treatment group animal. Glomerular and interstitial cells were I2S positive.
[0072] Figure 37 depicts exemplary results of a kidney from a 100 mg treatment group animal. Glomerular and interstitial cell augmentation, staining for I2S. 40X
[0073] Figure 38 depicts exemplary results of a kidney from a 150 mg treatment group animal. Positive I2S staining of proximal tubular, glomerular and interstitial cells. 40X
[0074] Figure 39 illustrates the results of immunohistochemistry (IHC) studies evaluating CNS tissues of monkeys cynomolgus administered weekly doses of iduronate-2-sulfatase (I2S). As determined by (IHC), there was widespread cell deposition of I2S throughout the CNS. In the matter of ash I2S, it was detected in the neurons of the brain, cerebellum, brain stem and spinal cord of all groups in a dose-dependent manner. On a gray surface of the higher dose groups, a large number of brain neurons were positive for I2S staining in the superficial cortex (Figure 39A). I2S was also detected in neurons in the thalamus (Figure 40B), hippocampus (Figure 40C), caudate nucleus (Figure 40 D) and medullary (Figure 40E). Meningial and perivascular cells were also positive staining I2S (Figure 40F). The scale bars identified correspond to 25pm.
[0075] Figure 40 graphically compares the spacing of iduronate-2-sulfatase (I2S) in the cranial and spine pools by plotting the amount of I2S in such pools in relation to the time after administration.
[0076] Figure 41 illustrates the deposition of gray matter dose dependent on intrathecally-administered iduronate-2-sulfatase (I2S) for non-human primates over six months. The staining intensity shown corresponds to the accumulation of iduronate-2-sulfatase in the thalamus. The present Figure 42, the nuclei are marked by DAPI and appear as blue and protein (I2S) appears as green.
[0077] Figure 42 illustrates the dose dependent accumulation of intrathecally-administered iduronate-2-sulfatase (I2S) to non-human primates after a single injection and after multiple injections over a six-month period. The staining intensity illustrated corresponds to the accumulation of I2S protein in the cerebral cortex.
[0078] Figure 43 demonstrates the cellular location of iduronate-2-sulfatase (I2S) throughout the brain of non-human primates. Figure 44A illustrates the cross-sectional view of brain tissue, extracted from the brain of non-human primates, while Figure 44B illustrates that certain areas of the region, corresponding to three areas of white matter tissue (designated Wl, W2 and W3), the substance white near the ventricle (VW) and the gray surface tissues (SG) of the section identified in Figure 43A.
[0079] Figure 44A-D illustrates neuronal and axonal association of intrathecally-administered iduronate-2-sulfatase (I2S) for non-human primates and oligodendrocyte absorption after monthly injections over a six-month period. In particular, Figure 44A, Figure 44B, Figure 440 and Figure 44D are illustrative of a brain staining filament intrathecally tissue from non-human primates administered iduronate-2-sulfatase (I2S) and correspond to three areas respectively. white matter (Wl, W2 and W3) and the gray surface (SG) regions, identified in Figure 44B. Figure 45A illustrates the absorption of the I2S oligodendrocyte intrathecally administered in the white matter (W1) tissues. Figure 45B and Figure 45 C illustrate oligodendrocyte uptake and axonal association of I2S intrathecally administered in the white matter tissues W2 and W3, respectively. Figure 45 D illustrates the neuronal uptake of I2S intrathecally-administered in the gray surface (SG) tissues.
[0080] Figure 45 illustrates the cellular identification of iduronate-2-sulfatase in white matter near the ventricle (VW) of a non-human primate. As shown in the overlay image, iduronate-2-sulfatase is not associated with myelin (red). The present Figure 46, the nuclei are marked by DAPI (lower left) protein (I2S) appears in the upper left box.
[0081] Figure 46 illustrates the stain on healthy Beagle dog tissues that have been intracerebroventricularly (ICV) or intrathecally (that) administered a single injection of iduronate-2-sulfatase (I2S). As represented in Figures 47A-47 H, I2S was widely distributed throughout the gray matter of both he and ICV groups as determined by immunohistochemistry (IHC). Figures 47A and 47B illustrate that in the cerebral cortex, neurons were positive for I2S in all six neuronal layers, from the molecular surface layer to the deep inner layer in the TI and ICV groups. Figures 47 and 47 D illustrate that in the cerebellar cortex of the groups he and ICV that I2S was detected in neurons, including Purkinje cells. Likewise, 47F and 47E figures illustrate that, in IT and ICV groups, a large population of neurons in the hippocampus were positive for I2S. Finally, h and g images demonstrate that! 2S-positive neurons were also found in the thalamus and caudate nucleus in both it and ICV groups. In the present Figure 47, I2S staining is indicated with the arrows.
[0082] Figure 47 illustrates comparatively to corpus callosum tissues of iduronate-2-sulfatase (IKO) mice that were untreated or I2S was administered intrathecally (abbreviation V = vacuole). As described, the IKO-treated mice exhibited a reduction in cell vacuolization characteristic of certain diseases of lysosomal storage in the corpus callosum and fornix tissues of the IKO I2S-treated mouse.
[0083] Figure 48A illustrates a marked reduction in the presence of membrane proteins from associate lysosomes 1 (LAMP1), a pathological biomarker of lysosomal diseases, in the superficial tissues of the cerebral cortex of the treated IKO rat (Figure 4 9A) in relation to the mouse of untreated IKO control (Figure 4 9B) both under 20X and 40X magnification.
[0084] Figure 49 depicts an exemplary intrathecal drug delivery device (IDDD).
[0085] Figure 50 depicts an exemplary low-profile implantable intrathecal access system PORT-A-CATH ®.
[0086] Figure 51 depicts an exemplary intrathecal drug delivery device (IDDD).
[0087] Figure 52 depicts an intrathecal specimen drug delivery device (IDDD), which allows home administration for CNS enzyme replacement therapy (ERT).
[0088] Figure 53 illustrates the exemplary effect of vacuolization after a single intracerebral injection of idursulfase in neurons (Purkinje cells).
[0089] Figure 54 illustrates the exemplary I2S brain activity by dose and region.
[0090] Figure 55 illustrates the exemplary immunohistochemistry location data of idursulfase at different depths of the cerebral cortex.
[0091] Figure 56 illustrates exemplary I2S activity in monkey spinal cord following intrathecal dosing with idursulfase.
[0092] Figure 57 illustrates the exemplary I2S activity in the liver, heart and kidney monkey after intrathecal dosing with idursulfase.
[0093] Figure 58 depicts an exemplary scheme for a scheduling Hunter-IT assessment program.
[0094] Figure 59 illustrates exemplary measurements of I2S concentrations in different parts of brain tissue after the 30 mg dose. Different plots correspond to different measurement times.
[0095] Figure 60 illustrates exemplary I2S concentration measurements after administration over time by various routes of administration for the different product concentrations.
[0096] Figure 61 is an exemplary illustration of PET images of 124I-labeled idursulfase-IT in cynomolgus monkeys at t = 5 hours after IV, IT-L or ICV measurement.
[0097] Figure 62 illustrates and example diagram of an IDDD intrathecal drug delivery device.
[0098] Figure 63 describes several characteristics of an IDDD on an individual's body (Figure 64A) and displayed on a flat surface (Figure 64B).
[0099] DEFINITIONS
[0100] In order for the present invention to be more easily understood, certain terms are first defined below. Additional definitions for the following terms and other terms are established during the specification.
[0101] Approximately or about: In this document, the term "approximately" or "about", when applied to one or more values of interest, refers to a value that is similar to an indicated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13 %, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in any direction (greater than or less ) of the stated reference value, unless otherwise stated or otherwise evident from the context (except where such number exceeds 100% of a possible value).
[0102] Improvement: As used here, the term "improvement" is intended to prevent, reduce or palliate a state, or improve an individual's state. Improvement includes, but does not require, complete recovery or complete prevention of a disease condition. In some modalities, improvement includes increasing levels of relevant protein or its activity that is deficient in tissues of the disease in question.
[0103] Biologically active: As used here, the phrase "biologically active" refers to a characteristic of any agent that has activity in a biological system and particularly in an organism. For example, an agent that, when administered to an organism, has a biological effect on that organism, is considered biologically active. Namely modalities, where a protein or polypeptide is biologically active, a part of the protein or polypeptide that shares at least one biological activity of the protein or polypeptide is usually referred to as a "biologically active" portion.
[0104] Bulking agent: As used here, the term "bulking agent" refers to a compound that is added to the dough to the lyophilized mixture and contributes to the physical structure of the lyophilized cake (for example, facilitates the production of a essentially uniform lyophilized cake, which maintains an open pore structure). Exemplary bulking agents include mannitol, glycine, sodium chloride, hydroxyethyl starch, lactose, sucrose, trehalose, polyethylene glycol and dextran.
[0105] Cation-independent mannose-6-phosphate receptor (CI-MPR): As used here, the term "mannose-6-phosphate receptor (CI-MPR)" refers to a cell receptor that binds mannose-6-phosphate (M6P) tags from the precursors of acid hydrolase in the Golgi apparatus that are destined for transport to the lysosome. In addition to mannose-6-phosphates, CI-MPR also binds to other proteins, including IGF-II. CI-MPR is also known as "M6P / IGF-II receptor," "CI-MPR / IGF-II receptor", "IGF-II receptors" or "IGF2 receptor". These respective terms and abbreviations are used interchangeably here.
[0106] Simultaneous immunosuppressive therapy: As used here, the term "simultaneous immunosuppressive therapy" includes any immunosuppressive therapy used as pre-treatment, preconditioning or in parallel with a treatment method.
[0107] Diluent: As used herein, the term "diluent" refers to a pharmaceutically acceptable (for example, safe and non-toxic for administration to a human) diluting substance useful for the preparation of a reconstituted formulation. Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (for example saline phosphate), sterile saline, touch solution or dextrose solution.
[0108] Dosage form: As used here, the terms "dosage form" and "unit dosage form" refer to a physically discrete unit of a therapeutic protein for the patient being treated. Each unit contains a predetermined amount of active material calculated to produce the desired therapeutic effect. It will be understood, however, that the total dosage of the composition will be decided by the attending physician and the scope of application of common sense.
[0109] Enzyme replacement therapy (ERT): As used here, the term "enzyme replacement therapy (Tre)" refers to any therapeutic strategy that corrects an enzyme deficiency by providing the missing enzyme. In some embodiments, the missing enzyme is provided by intrathecal administration. In some embodiments, the missing enzyme is supplied through infusion into the bloodstream. Once administered, the enzyme is taken up by the cells and transported to the lysosome, where the enzyme acts to eliminate the material accumulated in lysosomes due to enzyme deficiency. Normally, for lysosome enzyme replacement therapy to be effective, the therapeutic enzyme is delivered to lysosomes in suitable cells in target tissues where the storage defect is manifest.
[0110] Improve, increase or reduce: As used here, the terms "improve", "increase" or "reduce" or grammatical equivalents, indicate that they are in relation to a reference measure, as an individual measure before the start of the treatment described in this document, or a measure in an individual control (or of several control individuals) in the absence of treatment described in this document. A "control" individual is an individual afflicted with the same form of lysosomal storage disease as the individual to be treated, which is about the same age as the individual to be treated (in order to ensure that the stages of the disease in the individual Treaty and the comparable control individual (s).
[0111] Individual, individual, patient: As used here, the title "terms", "individual" or "patient" refer to a human being or an individual of non-human mammals. The individual (also referred to as "patient" or "individual") being treated is an individual (fetus, baby, child, teenager or human adult) suffering from a disease.
[0112] Intrathecal administration: As used here, the term "intrathecal administration" or "intrathecal injection" refers to an injection into the spinal canal (intrathecal space around the spinal cord). Various techniques can be used, including, without limitation, injection of lateral cerebroventricular through a trepanation or cistern or lumbar puncture or the like. In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present invention refers to IT administration or delivery via the lumbar area or region, i.e., lumbar IT administration or delivery. As used here, the term "lumbar region" or "lumbar area" designates the area between the third and fourth lumbar vertebrae (lower back) and, more inclusive, the region of the L2-S1 spine.
[0113] Ligand: As used here, the term "ligand" refers to, in a fusion protein, a different amino acid sequence that appears in a particular position in the natural protein and is generally designed to be flexible or to interpose a structure , like an a-helix, between two halves of protein. A binder is also referred to as a spacer.
[0114] Lyoprotectant: As used herein, the term "lyoprotectant" refers to a molecule that prevents or reduces the physical and / or chemical instability of a protein or other substance after freeze-drying and subsequent storage. Exemplary lyoprotectants include sugars such as sucrose or trehalose; an amino acid such as monosodium glutamate or histidine; methylamine as betaine; a lyotropic salt such as magnesium sulfate: a polyol such as trihydrate or higher sugar alcohols, for example glycerin, erythritol, glycerol, arabitol, xylitol, sorbitol and mannitol; propylene glycol; polyethylene glycol; Pluronics; and their combinations. In some embodiments, a lyoprotectant is a non-reducing sugar, such as trehalose or sucrose.
[0115] Lysosomal enzyme: As used here, the term "lysosomal enzyme" refers to any enzyme that is able to reduce materials accumulated in lysosomal mammals or that can rescue or ameliorate one or more symptoms of lysosomal storage disease. Lysosomal enzymes suitable for the invention include wild-type or modified lysosomal enzymes and can be produced using synthetic and recombinant methods or purified from sources of nature. Exemplary lysosomal enzymes are listed in Table 1.
[0116] Lysosomal enzyme deficiency: As used here, "lysosomal enzyme deficiency" refers to a group of genetic disorders that result from deficiency in at least one of the enzymes that are required to break down macromolecules (for example, the enzyme substrates ) to peptides, amino acids, monosaccharides, nucleic acids and fatty acids in lysosomes. As a result, individuals suffering from lysosomal enzyme deficiency have accumulated materials in various tissues (eg, CNS, liver, spleen, intestine, blood vessel walls and other organs).
[0117] Lysosomal storage disease: As used here, the term "lysosomal storage disease" refers to any disease resulting from the deficiency of one or more lysosomal enzymes necessary to metabolize natural macromolecules. These diseases usually result in the accumulation of undegraded molecules in lysosomes, resulting in an increase in the number of storage granules (also called storage vesicles). These diseases and several examples are described in more detail below.
[0118] Polypeptide: As used here, a "" polypeptide, in general, is a sequence of characters of at least two amino acids linked together by a peptide bond. In some embodiments, a polypeptide may include amino acids of at least 3-5, each of which is linked to others by means of at least one peptide bond. Those of ordinary skill in the art will appreciate polypeptides that sometimes include "unnatural" amino acids or other entities that, however, are able to optionally integrate into a polypeptide chain.
[0119] Replacement enzyme: As used here, the term "replacement enzyme" refers to an enzyme that can act to replace, at least in part, the deficient or missing enzyme in a disease to be treated. In some embodiments, the term "replacement enzyme" refers to an enzyme that can act to replace, at least in part, the deficient or absent lysosomal enzyme in a lysosomal storage disease to be treated. In some embodiments, a replacement enzyme is able to reduce materials accumulated in lysosome mammals or that can rescue or ameliorate one or more symptoms of lysosomal storage disease. Replacement enzymes suitable for the invention include wild-type or modified lysosomal enzymes and can be produced using synthetic and recombinant methods or purified from sources of nature. A replacement enzyme can be a synthetic recombinant enzyme, gene activated or natural.
[0120] Soluble: As used here, the term "soluble" refers to the ability of a therapeutic agent to form a homogeneous solution. In some embodiments, the solubility of the therapeutic agent in the solution in which it is administered and why it is transported to the destination site of the action (for example, brain cells and tissues) is sufficient to allow delivery of a therapeutically effective amount therapeutic agent to the action target site. Several factors can affect the solubility of therapeutic agents. For example, relevant factors that can affect protein solubility include ionic strength, amino acid sequence and the presence of other co-solubilizing agents or salts (for example, calcium salts). In some embodiments, pharmaceutical compositions are formulated in such a way that calcium salts are excluded from such compositions. In some embodiments, therapeutic agents in accordance with the present invention are soluble in their corresponding pharmaceutical composition. It will be appreciated that, while isotonic solutions are generally preferred for drugs administered parenterally, the use of isotonic solutions may limit adequate solubility for some therapeutic agents and, in particular, some proteins and / or enzymes. Slightly hypertonic solutions (eg, up to 175 mM sodium chloride in 5 mM sodium phosphate at pH 7.0) and sugar containing solutions (eg, up to 2% sucrose in 5 mM sodium phosphate at pH 7.0) has shown to be well tolerated in monkeys. For example, the most common composition in approved CNS bolus formulation is saline (NaCl in 150 mM water).
[0121] Stability: As used here, the term "stable" refers to the ability of the therapeutic agent (for example, a recombinant enzyme) to maintain its therapeutic effectiveness (for example, all or most of its physiochemical integrity and / or biological activity) for long periods of time. The stability of a therapeutic agent and the ability of the pharmaceutical composition to maintain the stability of such therapeutic agent, can be assessed over long periods of time (for example, at least 1, 3, 6, 12, 18, 24, 30, 36 months or more). In general, pharmaceutical compositions described herein have been formulated such that they are able to stabilize or alternatively delay or prevent degradation, of one or more therapeutic agents formulated therewith (for example, recombinant proteins). In the context of a formulation a stable formulation is one in which the therapeutic agent there essentially maintains its and / or physical chemical integrity and biological activity on storage and during processes (such as freezing, mechanical mixing and lyophilization). For protein stability, it can be measured by the formation of high molecular weight aggregates (HMW), loss of enzymatic activity, generation of peptide fragments and changing load profiles.
[0122] Individual: In this document, the term "individual" represents any mammal, including humans. In certain embodiments of the present invention it is an adult, a teenager or a child. Also provided by the present invention are the performance and / or pharmaceutical compositions of in-utero treatment methods.
[0123] Substantial homology: The phrase "substantial homology" is used in this document to refer to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be "substantially homologous" if they contain homologous residues in corresponding positions. Homologous residues can be identical residues. Alternatively, homologous residues may be non-identical residues that will be appropriately similar and / or structural functional characteristics. For example, as is known to those of ordinary skill in the art, certain amino acids are usually classified as "hydrophobic" or "hydrophilic" amino acids, and / or as having "polar" or "non-polar" side chains replacing an amino acid for another of the same type, they can often be considered a "homologous" substitution.
[0124] As is well known in the art, amino acid or nucleic acid sequences can be compared using any of a variety of algorithms, including those available in commercial computer programs such as LINED to nucleotide and BLASTP, BLAST clearance and PSI- BLAST for amino acid sequences. Examples of which such programs are described in Altschul, et al., Basic local alignment search tool, J. Mol. Biol., 215 (3): 403-410, 1990; Altschul, et al., Methods in Enzymology; Altschul, et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25: 3389-3402, 1997; Baxevanis, et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.), Bioinformatics Methods and Protocols {Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to identifying homologous sequences, the programs mentioned above usually provide an indication of the degree of homology . In some modalities, two sequences are considered substantially homologous, if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are homologous along a relevant section of residues. In some modalities, the relevant section is a complete sequence. In some modalities, the relevant section is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.
[0125] Substantial identity: The phrase "substantial identity" is used in this document to refer to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be "substantially identical" if they contain identical residues in corresponding positions. As is well known in the art, amino acid or nucleic acid sequences can be compared using any of a variety of algorithms, including those available in commercial computer programs such as ALIGNED for nucleotide sequences and BLASTP, BLAST clearance and PSI-BLAST for sequences of amino acids. Examples of which such programs are described in Altschul, et al., Basic local alignment search tool, J. Mol. Biol., 215 (3): 403-410, 1990; Altschul, et al., Methods in Enzymology; Altschul et al., Nucleic Acids Res. 25: 3389-3402, 1997; Baxevanis et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to identifying identical sequences, the programs mentioned above usually provide an indication of the degree of identity . In some embodiments, two strings are considered to be substantially identical, if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residences are identical across a relevant stretch of residues. In some modalities, the relevant section is a complete sequence. In some modalities, the relevant section is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.
[0126] Synthetic CSF: As used here, the term "synthetic CSF" refers to a solution that has pH, electrolyte composition, glucose content and osmolarity compatible with cerebrospinal fluid. Synthetic CSF is also referred to as artificial CSF. In some embodiments, synthetic CSF is a BA Elliott solution.
[0127] Suitable for delivery of CNS: As used here, the phrase "suitable for delivery of CNS" or "suitable for intrathecal delivery" with respect to pharmaceutical compositions of the present invention generally refers to the properties of solubility, tolerability and stability of such compositions, as well as the ability of such compositions to deliver an effective amount of the therapeutic agent contained therein to the target delivery site (e.g., the CSF or the brain).
[0128] Target tissues: As used here, the term "target tissues" refers to all tissue that is affected by the lysosomal storage disease to be treated or any tissue in which the deficient lysosomal enzyme is normally expressed. In some embodiments, target tissues include tissues in which there is a detectable or abnormally high amount of substrate, for example stored in the tissue's cell lysosomes, in patients suffering from or susceptible to lysosomal storage disease. In some modalities, target tissues include those tissues that exhibit disease associated with a disease, symptom or resource. In some embodiments, target tissues include tissues in which the deficient lysosomal enzyme is normally expressed at a high level. As used here, a target tissue can be a target brain tissue, a spinal cord target tissue and / or a peripheral target tissue. Exemplary target tissues are described in detail below.
[0129] Therapeutic portion: As used here, the term "therapeutic portion" refers to a part of a molecule, which makes the therapeutic effect of the molecule. In some embodiments, a therapeutic moiety is a polypeptide with therapeutic activity.
[0130] Therapeutically effective amount: As used here, the term "therapeutically promoting amount" refers to an amount of a therapeutic protein (eg, replacement enzyme), which confers a therapeutic effect on the treated individual, in a proportion reasonable beneficitrisk applicable to any medical treatment. The therapeutic effect can be objective (that is, measurable by some test or marker) or subjective (that is, an individual gives an indication of or feels an effect). In particular, the "therapeutically promoting amount" refers to an amount of a therapeutic protein or composition effective to treat, alleviate or prevent a desired disease or condition, or have a detectable therapeutic or preventive effect, such as by improving symptoms associated with the disease, preventing or delaying the onset of the disease, and / or also decreasing the severity or frequency of the symptoms of the disease. The therapeutically effective amount is generally administered in a dosage regimen that can comprise several unit doses. For any specific therapeutic protein, a therapeutically promoting amount (and / or an appropriate unit dose within an effective dosage regimen) can vary, for example, depending on the route of administration, in combination with other pharmaceutical agents. In addition, the specific amount therapeutically promoting (unit dose of and / or) for a given patient may depend on a variety of factors, including the disorder being treated and the severity of the disease; the activity of the specific pharmaceutical agent employed; the specific composition used; the patient's age, body weight, general health, sex and diet; the time of administration, route of administration, rate of and / or excretion or metabolism of the specific fusion protein employed; the duration of treatment; and as factors as it is well known in the medical arts.
[0131] Tolerable: As used here, the terms "tolerable" and "tolerance" refer to the ability of the pharmaceutical compositions of the present invention to not cause an adverse reaction in the individual to whom such composition is administered, or, alternatively, not to cause a serious adverse reaction in the individual to whom such composition is administered. In some embodiments, the pharmaceutical compositions of the present invention are well tolerated by the individual to whom such a composition is administered.
[0132] Treatment: As used here, the term "treatment" (also "treating" or "treatment") refers to any administration of a therapeutic protein (for example, the lysosomal enzyme) that partially or completely relieves the improvement , relieves, inhibits, delays onset, reduces the severity of and / or reduces the incidence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition (e.g., hunter's syndrome, Sanfilippo B syndrome) . Such treatment may be of an individual who shows no signs of the disease in question, disorder and / or condition and / or of an individual who displays only the first signs of the disease, disorder, and / or condition. Alternatively or in addition, this treatment may be for an individual who has one or more established signs of the disease in question, condition and / or disorder. DETAILED DESCRIPTION OF THE INVENTION
[0133] The present invention provides, among other things, improved methods and compositions for the effective direct delivery of a therapeutic agent to the central nervous system (CNS). As discussed above, the present invention is based on the unexpected discovery that a replacement enzyme (eg, an I2S protein) for a lysosome storage disease (eg, hunter's syndrome) can be introduced directly into the cerebrospinal fluid ( CSF) of an individual in need of treatment at a high concentration without inducing serious repercussions on the individual. Most surprisingly, the present inventors found that the replacement enzyme can be delivered in a simple saline or buffer-based formulation, without using synthetic CSF. Even more unexpectedly, delivery of intrathecal in accordance with the present invention does not result in substantial adverse effects, such as severe immune response, on the individual. Therefore, in some embodiments, delivery of intrathecal in accordance with the present invention can be used in the absence of simultaneous immunosuppressive treatment (for example, without inducing immunological tolerance by pretreatment or preconditioning).
[0134] In some embodiments, delivery of intrathecal in accordance with the present invention allows efficient diffusion in various brain tissues, resulting in the effective delivery of the enzyme substitution in various target brain tissues in deep and / or superficial brain regions, shallow. In some embodiments, delivery of intrathecal in accordance with the present invention has resulted in a sufficient amount of replacement enzymes entering the peripheral circulation. As a result, in some cases, intrathecal delivery according to the present invention has resulted in the delivery of the replacement enzyme in peripheral tissues, such as liver, heart, spleen and kidneys. This discovery is unexpected and may be particularly useful for the treatment of diseases by storing lysosomes with CNS and peripheral components, which would normally require regular intrathecal and intravenous administration. It is contemplated that intrathecal delivery according to the present invention may allow reduced frequency of and / or dosage of the iv injection without a compromise the therapeutic effects in the treatment of peripheral symptoms.
[0135] The present invention provides several unexpected and beneficial features that allow efficient and convenient delivery of replacement enzymes to various target brain tissues, resulting in an effective treatment of diseases that have CNS indications.
[0136] Various aspects of the invention are described in detail in the following sections. The use of sections is not intended to limit the invention. Each section can apply to any aspect of the invention. In this application, the use of "or" means "and / or", unless otherwise specified. Replacement of enzymes Protein iduronate-2-sulfatase (I2S)
[0137] In some embodiments, inventive methods and compositions provided by the present invention are used to deliver an Iduronate-2-sulfatase (I2S) protein to the CNS for treatment of hunter's syndrome. An appropriate I2S protein can be any molecule or part of a molecule that can substitute for naturally occurring protein Iduronate-2-sulfatase (I2S) activity or rescue one or more phenotypes or symptoms associated with! 2S-deficiency. In some embodiments, a replacement enzyme suitable for the invention is a polypeptide having an N-terminal and a C-terminal and an identical or substantially similar amino acid sequence for maturing the human I2S protein.
[0138] Normally, human I2S protein is produced as a form of precursor. The precursor form of human I2S contains a signal peptide (1-25 of the precursor full length of amino acid residues), a propeptide (amino acid residues 26-33 of the full length precursor) and a chain (residues 34-550 of the precursor of the total length) that can be processed into the 42 kDa chain (residues 34-455 of the full-length precursor) and the kDa chain 14 (residues 446-550 of the full-length precursor). Usually, the precursor form is also referred to as complete in the precursor or complete I2S protein, which contains 550 amino acids. The mature amino acid sequences (SEQ ID NO: 1) having peptide signal removed and complete in the precursor (SEQ ID NO: 2) of a typical wild-type or naturally occurring human I2S protein are shown in Table 1 Table 1. Human iduronate-2-sulfatase


[0139] Therefore, in some embodiments, a replacement enzyme suitable for the present invention is mature human I2S protein (SEQ ID NO: 1). In some embodiments, a suitable substitute enzyme can be a homologous or an analog of the mature human I2S protein. For example, a homologous or a mature human analog I2S protein may be a modified mature human I2S protein containing one or more amino acid substitutions, deletions, insertions and / or in comparison to a naturally occurring or naturally occurring I2S protein (for example, SEQ ID NO: 1), while maintaining substantial I2S protein activity. Therefore, in some embodiments, a replacement enzyme suitable for the present invention is substantially homologous to mature human I2S protein (SEQ ID NO: 1). In some embodiments, a replacement enzyme suitable for the present invention has an amino acid sequence of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO: 1. In some embodiments, a replacement enzyme suitable for the present invention is substantially identical when I2S human protein matures (SEQ ID NO: 1). In some embodiments, a replacement enzyme suitable for the present invention has an amino acid sequence of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 1. In some embodiments, a replacement enzyme suitable for the present invention contains a fragment or portion of mature human I2S protein.
[0140] Alternatively, a replacement enzyme suitable for the present invention is complete in the I2S protein. In some embodiments, a suitable substitute enzyme can be a homolog or a complete analog in the human I2S protein. For example, a homologous or a complete human analogue in the I2S protein can be a complete I2S protein in the modified human containing one or more amino acid substitutions, deletions, inserts and / or in comparison to a complete I2S protein in the wild-type or naturally occurring (for example, SEQ ID NO: 2), while maintaining substantial I2S protein activity. Therefore, in some embodiments, a replacement enzyme suitable for the present invention is substantially homologous to the complete human I2S protein (SEQ ID NO: 2). In some embodiments, a replacement enzyme suitable for the present invention has an amino acid sequence of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO: 2. In some embodiments, a replacement enzyme suitable for the present invention is substantially identical to SEQ ID NO: 2. In some embodiments, a replacement enzyme suitable for the present invention has an amino acid sequence of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 2. In some embodiments, a replacement enzyme suitable for the present invention contains a fragment or a portion of the complete human I2S protein. As used here, a complete I2S protein does not normally contain the signal peptide sequence. Other lysosome storage diseases and replacement enzymes
[0141] It is contemplated, that inventive methods and compositions according to the present invention can be used to treat other diseases, in particular those diseases having symptoms of and / or the etiology of CNS, including, but not limited to, aspartylglucosaminurie , cholesterol ester storage disease, Wolman disease, cystinosis, Danon disease, Fabry disease, Farber lipogranulomatosis, Farber disease, fucosidosis, types of galactosialidosis I / II, Gaucher disease types I / II / III, Leukodystrophy, Globoid cells, Krabbe disease, glycogen storage disease II, Pompe disease, Gangliosidosis GM1 types I / II / III, GM2-gangliosidosis type I, Tay Sachs disease, GM2-gangliosidosis type II, Sandhoff disease, GM2- gangliosidosis, a-mannosidosis types I / II, .beta.- mannosidosis, metachromatic leukodystrophy, type I mucolipidosis, types I / II sialidosis, types II / III mucolipidosis, cell I diseases, type IIIC pseudo-Hurler polydistrophy type, type of mucopol isaccharidosis and mucopolysaccharidosis type II, mucopolysaccharidosis type IIIA, Sanfilippo syndrome, mucopolysaccharidosis type IIIB, mucopolysaccharidosis type IIIC, mucopolysaccharidosis type IV, mucopolysaccharidosis type IV, mucopolysaccharidosis type IV, mucopolysaccharidosis, mucopolysaccharidosis type VI mucopolysaccharidosis type IX, multiple sulphatase deficiency, ceroid neuronal lipofuscinosis, CLN1 disease, Batten disease CLN2, types of Niemann-Pick AB disease, Niemann-Pick type C diseaseNiemann-Pick type C2 disease, pycnodysostosis, types of disease Schindler I / II, Gaucher disease and sialic acid storage disease.
[0142] A detailed review of the genetic etiology, clinical manifestations and molecular biology of lysosomal diseases is detailed in Scriver et al., Eds., The Metabolic and Molecular Basis of Inherited Disease, 7.sup.th Ed., Vol. II, McGraw Hill, (1995). Thus, enzymes deficient in the above diseases are known to those of skill in the art, some of which are exemplified in Table 2 below: Table 2.



[0143] Inventive methods according to the present invention can be used to deliver several other substitution enzymes. As used herein, replacement enzymes suitable for the present invention can include any enzyme that can act to replace the at least partial activity of the lysosomal enzyme deficient or absent in a lysosomal storage disease to be treated. In some embodiments, a replacement enzyme is able to reduce the substance accumulated in the lysosomes or which can rescue or ameliorate one or more symptoms of lysosomal storage disease.
[0144] In some embodiments, a suitable substitute enzyme can be any lysosomal enzyme known to be associated with the lysosomal storage disease being treated. In some embodiments, a suitable substitute enzyme is an enzyme selected from the enzyme listed in Table 2 above.
[0145] In some embodiments, a replacement enzyme suitable for the invention may have a wild-type or natural sequence. In some embodiments, a replacement enzyme suitable for the invention may have a modified sequence, having significant homology or identifying the wild-type or naturally occurring sequence (for example, having at least 50%, 55%, 60%, 65 %, 70%, 75%, 80%, 85%, 90%, 95%, 98% sequence identity with wild or naturally occurring sequence).
[0146] A replacement enzyme suitable for the present invention can be produced by any available means. For example, replacement enzymes can be recombinant produced using a host cell system designed to express an enzymatic-encoding nucleic acid substitution. Alternatively or in addition, replacement enzymes can be produced by activating endogenous genes. Alternatively or in addition, substitution enzymes can be partially or totally prepared by chemical synthesis. Alternatively or in addition, replacement enzymes can also be purified from natural sources.
[0147] In the event that recombinant enzymes are produced, any expression system can be used. To give just a few examples, known expression systems include, for example, egg, baculovirus, plant, fungi or mammalian cells.
[0148] In some embodiments, enzymes suitable for the present invention are produced in mammalian cells. Non-limiting mammalian cells that can be used in accordance with the present invention examples of BALB / c rat myeloma line (NSO / 1, ECACC No: 85110503); human retinoblasts (PER.C6, CruCell, Leiden, Netherlands); monkey kidney strain CV1 transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney lineage (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36: 59,1977); human fibrosarcoma cell line (for example, HT1080); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells +/- DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216, 1980); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23: 243-251, 1980); monkey kidney cells (CV1 ATCC CCL 70); Green African monkey kidney cells (VERO-76, ATCC CRL-1 587); human cervical carcinoma cells (HeLa, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); rat mammary tumor (060562 MMT, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci., 383: 44-68, 1982); MRC 5 cells; FS4 cells; and a strain of human hepatoma (Hep G2).
[0149] In some embodiments, inventive methods according to the present invention are used to provide replacement enzymes, produced from human cells. Some embodiments, inventive methods according to the present invention are used to provide replacement enzymes, produced from CHO cells.
[0150] In some embodiments, replacement enzymes delivered using an inventive method contain a group that binds to a receptor on the surface of brain cells to facilitate cell absorption and / or targeting lysosomes. For example, one such receptor may be the independent cationic mannose-6-phosphate receptor (CI-MPR) that binds to the residues of (M6P) - mannose-6-phosphate. In addition, CI-MPR also binds other proteins, including IGF-II. In some embodiments, a replacement enzyme suitable for the present invention contains M6P residues on the surface of the protein. In some embodiments, a replacement enzyme suitable for the present invention may contain bisphosphorylated oligosaccharides, which have the highest binding affinity for CI-MPR. In some embodiments, a suitable enzyme contains up to about an average of at least about 20% bisphosphorylated oligosaccharides per enzyme. In other embodiments, it may contain a suitable enzyme about 10%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% bis-oligosaccharides phosphorylated by enzyme. While such bisphosphorylated oligosaccharides may be naturally present on the enzyme, it should be noted that the enzymes can be modified to have such an oligosaccharide. For example, suitable substitute enzymes can be modified by certain enzymes capable of catalyzing the transfer of UDP-GlcNAc N-acetylglucosamine-L-phosphate to the 6 'position of α-1,2-linked mannoses in lysosomal enzymes. Methods and compositions for producing and using such enzymes are described by, for example, Canfield et al. in Pat. No. 6,537,785 and U.S. Pat. No. 6,534,300, each incorporated herein by reference.
[0151] In some embodiments, replacement enzymes for use in the present invention can be conjugated or fused to a targeting group of lysosomes capable of binding to a receptor on the surface of brain cells. A suitable lysosome targeting grouping can be IGF-I, IGF-II, RAP, p97 and variants, homologues or fragments thereof (for example, including those peptides with a sequence of at least 70%, 75%, 80%, 85 %, 90%, or 95% identical to a mature human mature peptide sequence (IGF-I, IGF-II, RAP, p97).
[0152] In some embodiments, replacement enzymes suitable for the present invention have not been modified to improve delivery or transport of these agents through the BBB and the CNS.
[0153] In some embodiments, a therapeutic protein includes a peptide from and / or a membrane-penetrating targeting portion (e.g., a lysosome targeting sequence). In some embodiments, a targeting and / or sequence a membrane-penetrating peptide is an intrinsic part of the therapeutic moiety (for example, through a chemical bond, through a fusion protein). In some embodiments, a targeting sequence contains a group of mannose-6-phosphate. In some embodiments, a targeting sequence contains an IGF-I portion. In some embodiments, a targeting sequence contains an IGF-II Portion. Formulations
[0154] In some embodiments, desired enzymes are delivered in stable formulations for intrathecal delivery. Certain embodiments of the invention are based, at least in part, on the discovery that various formulations disclosed herein facilitate the effective delivery and distribution of one or more therapeutic agents (for example, an I2S enzyme) to target tissues, organelles and / or of CNS cells. Among other things, formulations described here are capable of solubilizing high concentrations of therapeutic agents (for example, an I2S enzyme) and are suitable for delivering these therapeutic agents to the CNS of individuals for the treatment of diseases, having an etiology of e / or the CNS component (for example, hunter's syndrome). The compositions described here are further characterized by better stability and improved tolerance when administered to an individual's CNS (for example, intrathecally) in need of it.
[0155] Prior to the present invention, traditional uncapped isotonic saline and Elliott's B solution, which is artificial CSF, were normally used for intrathecal delivery. A comparison showing the CSF compositions in relation to Elliott's solution B is included in Table 3 below. As shown in Table 3, the concentration of the Elliot B solution is closely parallel to that of the CSF. Elliott B solution, however, contains a very low concentration of buffer and therefore cannot provide the adequate buffering capacity necessary to stabilize therapeutic agents (eg proteins), especially over long periods of time (eg during storage conditions). storage). In addition, B solution in Elliott contains some salts that may be incompatible with the formulations that are intended to deliver some therapeutic agents and in particular proteins or enzymes. For example, the calcium salts present in Elliott's solution B are able to mediate protein precipitation and thus decrease formulation stability. TABLE 3


[0156] Thus, in some embodiments, formulations, suitable for delivery of CNS according to the present invention are not synthetic or artificial from CSF.
[0157] In some embodiments, formulations for delivery of the CNS have been formulated such that they are able to stabilize, or alternatively delay or prevent the degradation, of a therapeutic agent, formulated therewith (for example, an I2S enzyme). As used herein, the term "stable" refers to the ability of the therapeutic agent (for example, an I2S enzyme) to maintain its therapeutic efficacy (for example, all or most of its physio-chemical integrity and / or intended biological activity) for long periods of time. The stability of a therapeutic agent and the ability of the pharmaceutical composition to maintain the stability of such a therapeutic agent, can be evaluated over long periods of time (for example, preference for at least 1, 3, 6, 12, 18, 24, 30, 36 months or more). In the context of a formulation a stable formulation is one in which the therapeutic agent there essentially maintains its and / or physical chemical integrity and biological activity on storage and during processes (such as freezing, mechanical mixing and lyophilization). For protein stability, it can be measured by the formation of high molecular weight aggregates (HMW), loss of enzymatic activity, generation of peptide fragments and changing load profiles.
[0158] Stability of the therapeutic agent is of particular importance. Stability of the therapeutic agent may be further evaluated in relation to the biological integrity of the activity or physico-chemical properties of the therapeutic agent over long periods of time. For example, stability at a given point in time can be compared with stability at a previous point in time (e.g., formulation day 0) or against unformulated therapeutic agent and the results of this comparison expressed as a percentage. Preferably, they maintain the pharmaceutical compositions of the present invention at least 100%, at least 99%, at least 98%, at least 97% at least 95%, at least 90%, at least 85%, at least 80%, at least at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% of biological activity physiochemical integrity or therapeutic agent over an extended period of time (for example, measured over at least about 6-12 months, at room temperature or under accelerated storage conditions).
[0159] In some embodiments, therapeutic agents (e.g., desired enzymes) are soluble in formulations of the present invention. The term "soluble", with respect to the therapeutic agents of the present invention, refers to the ability of these therapeutic agents to form a homogeneous solution. Preference to the solubility of the therapeutic agent in the solution in which it is administered and why it is transported to the destination site of the action (for example, brain cells and tissues) is sufficient to allow the delivery of a therapeutically promoting amount of the agent for the target site of the action. Several factors can affect the solubility of therapeutic agents. For example, relevant factors that can affect protein solubility include ionic strength, amino acid sequence and the presence of other co-solubilizing agents or salts (eg, calcium salts). In some embodiments, pharmaceutical compositions are formulated in such a way. that calcium salts are excluded from such compositions.
[0160] Suitable formulations, aqueous, pre-lyophilized, lyophilized or reconstituted form, may contain a therapeutic agent of interest in various concentrations. In some embodiments, formulations may contain a protein or therapeutic agent of interest at a concentration in the range of about 0.1 mg / ml to 100 mg / ml (for example, about 0.1 mg / ml to 80 mg / ml, about 0.1 mg / ml to 60 mg / ml, about 0.1 mg / ml to 50 mg / ml, about 0.1 mg / ml to 40 mg / ml, about 0.1 mg / ml to 30 mg / ml, about 0.1 mg / ml to 25 mg / ml, about 0.1 mg / ml to 20 mg / ml, about 0.1 mg / ml to 60 mg / ml, about 0.1 mg / ml to 50 mg / ml, about 0.1 mg / ml to 40 mg / ml, about 0.1 mg / ml to 30 mg / ml, about 0.1 mg / ml to 25 mg / ml, about 0.1 mg / ml to 20 mg / ml, about 0.1 mg / ml to 15 mg / ml, about 0.1 mg / ml to 10 mg / ml, about 0.1 mg / ml to 5 mg / ml, about 1 mg / ml to 10 mg / ml, about 1 mg / ml to 20 mg / ml, about 1 mg / ml to 40 mg / ml, about 5 mg / ml to 100 mg / ml, about 5 mg / ml to 50 mg / ml, or about 5 mg / ml to 25 mg / ml ml). In some embodiments, formulations according to the invention may contain a therapeutic agent in a concentration of approximately 1 mg / ml, 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 40 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, or 100 mg / ml.
[0161] The formulations of the present invention are characterized by their tolerability, as aqueous solutions or reconstituted lyophilized solutions. As used herein, the terms "tolerable" and "tolerance" refer to the ability of the pharmaceutical compositions of the present invention not to cause an adverse reaction in the individual to whom such composition is administered, or, alternatively, not to cause a serious adverse reaction. in the individual to whom such a composition is administered. In some embodiments, the pharmaceutical compositions of the present invention are well tolerated by the individual to whom such compositions are administered.
[0162] Many therapeutic agents, and in particular the proteins and enzymes of the present invention, require controlled pH and specific excipients to maintain their solubility and stability in the pharmaceutical compositions of the present invention. Table 4 below identifies typical exemplary aspects of protein formulations, considered to maintain the solubility and stability of the protein therapeutic agents of the present invention. TABLE 4
Earplugs
[0163] The pH of the formulation is an additional factor, which is capable of altering the solubility of a therapeutic agent (for example, an enzyme or protein) in an aqueous formulation or for a pre-lyophilization formulation. Accordingly, the formulations of the present invention preferably comprise one or more buffers. In some embodiments, the aqueous formulations comprise an amount of buffer sufficient to maintain the ideal pH of said composition between about 4.0-8.0 (for example, about 4.0, 4.5, 5.0, 5.5, 6.0, 6.2, 6.4, 6.5, 6.6 , 6.8, 7.0, 7.5, or 8.0). In some embodiments, the pH of the formulation is between about 5.0-7.5, between about 5.5-7.0, between about 6.0-7.0, between about 5.5-6.0, between about 5.5-6.5, between about 5.0-6.0 , between about 5.0-6.5 and between about 6.0-7.5. Suitable buffer includes, for example, acetate, citrate, histidine, phosphate, succinic acid, tris (hydroxymethyl) aminomethane ("Tris") and other organic acids. The concentration of the buffer and the pH range of the pharmaceutical compositions of the present invention are factors in controlling or adjusting the tolerability of the formulation. In some embodiments, a buffering agent is present in a concentration ranging from about 1 mM to about 150 mM, or between about 10 mM to about 50 mM, or between about 15 mM to about 50 mM, or between about 20 mM to about 50 mM, or between about 25 mM to about 50 mM. In some embodiments, a suitable buffering agent is present at a concentration of approximately 1 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM 50 mM, 75 mM, 100 mM, 125 mM or 150 mM. Tonicity
[0164] In some embodiments, formulations, aqueous form, pre-lyophilized, lyophilized or reconstituted, contain an isotonic agent to keep the formulations isotonic. Normally, "isotonic" means that the formulation of interest has essentially the same osmotic pressure as human blood. Isotonic formulations will generally have an osmotic pressure of about 240 mOsm / kg to about 350 mOsm / kg. Isotonicity can be measured using, for example, a vapor pressure or freezing point type osmometers. Exemplary isotonic agents include, but are not limited to, glycine, sorbitol, Manita, sodium chloride and assimilation. In some embodiments, suitable isotonic agents may be present in pre-lyophilized and / or aqueous formulations in concentrations of about 0.01-5% (for example, 0.05, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.75, 1.0 , 1.25, 1.5, 2.0, 2.5, 3.0, 4.0 or 5.0%) by weight. In some embodiments, lyophilization formulations contain an isotonic agent to maintain pre-lyophilization formulations or reconstituted isotonic formulations.
[0165] While isotonic solutions are generally preferred for drugs administered parenterally, the use of isotonic solutions can alter solubility for some therapeutic agents and in particular some protein and / or enzymes. Slightly hypertonic solutions (eg, up to 175 mM sodium chloride in 5 mM sodium phosphate at pH 7.0) and sugar-containing solutions (eg, up to 2% sucrose in 5 mM sodium phosphate at pH 7.0) has shown be well tolerated. The most common composition in approved CNS bolus formulation is saline (about 150 mM NaCl in water). Stabilizing agents
[0166] In some embodiments, formulations may contain a stabilizing agent, or lyoprotectant, to protect the protein. Typically, a suitable stabilizing agent is a sugar, a non-reducing sugar and / or an amino acid. Exemplary sugars include, but are not limited to, dextran, lactose, manita, mannose, sorbitol, raffinose, sucrose and trehalose. Exemplary amino acids include, but are not limited to, arginine, glycine and methionine. Additional stabilizing agents can include sodium chloride, hydroxyethyl starch and polyvinylpyrolidone. The amount of stabilizing agent in the lyophilized formulation is generally that of the isotonic formulation. However, reconstituted hypertonic formulations may also be suitable. In addition, the amount of stabilizing agent should not be too low that an unacceptable amount of degradation / aggregation of the therapeutic agent occurs. Exemplary concentrations of stabilizing agent in the formulation can range from about 1 mM to about 400 mM (for example, from about 30 mM to about 300 mM, and from about 50 mM to about 100 mM), or alternatively, from 0.1% to 15% (for example, from 1% to 10%, from 5% to 15%, from 5% to 10%) by weight. In some embodiments, the ratio between the amount of mass of the stabilizing agent and the therapeutic agent is about 1: 1. In other embodiments, the ratio between the amount of mass of the stabilizing agent and the therapeutic agent can be about 0.1: 1, 0.2: 1, 0.25: 1, 0.4: 1, 0.5: 1, 1: 1, 2: 1, 2.6: 1, 3: 1, 4: 1, 5: 1, 10: 1, or 20: 1. In some embodiments, suitable for lyophilization, the stabilizing agent is also a lyoprotectant.
[0167] In some embodiments, liquid formulations suitable for the present invention contain amorphous materials. In some embodiments, liquid formulations suitable for the present invention contain a substantial amount of amorphous material (for example, sucrose-based formulations). In some embodiments, liquid formulations suitable for the present invention contain partially crystalline / partially amorphous materials. Volume Agents
[0168] In some embodiments, formulations suitable for additional lyophilization may include one or more bulking agents. A "bulking agent" is a compound that is added to the freeze dried mixture and contributes to the physical structure of the freeze dried cake. For example, a bulking agent can improve the appearance of the lyophilized cake (for example, essentially uniform lyophilized cake). Suitable bulking agents include, but are not limited to, sodium chloride, lactose, manita, glycine, sucrose, trehalose, hydroxyethyl starch. Exemplary concentrations of bulking agents are from about 1% to about 10% (for example, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5% , 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, and 10.0%). Surfactants
[0169] In some modalities, it is advisable to add a surfactant for formulations. Exemplary surfactants include non-ionic surfactants such as Polysorbates (for example, Polysorbates 20 or 80); poloxamers (for example, Poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium laurel sulfate; octyl glycoside sodium; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (for example, lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl ofeyl-taurate; and the MONAQUAT ™ series (Mona Industries, Inc., Paterson, N.J.), polyethyl glycol, polypropyl glycol and copolymers of ethylene and propylene glycol (e.g., Pluronics, PF68, etc.). Typically, the amount of surfactant added is such that it reduces protein aggregation and minimizes particle formation or effervescence. For example, a surfactant can be present in a formulation in concentrations of about 0.001-0.5% (for example, about 0.005-0.05%, or 0.005-0 0.01%). In particular, a surfactant can be present in a formulation in concentrations of approximately 0.005%, 0.01%, 0.02%, 0.1%, 0.2%, 0.3%, 0.4%, or 0.5%, etc. Alternatively, or in addition, the surfactant can be added to the lyophilized formulation, pre-lyophilized formulation and / or the reconstituted formulation.
[0170] Other pharmaceutically acceptable carriers, excipients or stabilizers such as those described in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980) can be included in the formulation (and / or the lyophilized formulation and / or the reconstituted formulation), provided that they do not impair the desired characteristics of the formulation. Acceptable carriers, excipients or stabilizers are non-toxic to recipients in the dosages and concentrations used and include, but are not limited to, additional buffering agents; preservatives; co-solvents; antioxidants, including ascorbic acid and methionine; chelating agents such as EDTA; metal complexes (for example, Zn-protein); biodegradable polymers such as polyesters; and / or forming salt contractions such as sodium.
[0171] Formulations, in aqueous form, pre-lyophilized, lyophilized or reconstituted, in accordance with the present invention can be evaluated based on the analysis of product quality, reconstitution time (if lyophilized), reconstitution quality (if lyophilized) , high molecular weight, humidity and glass transition temperature. Typically, quality analysis and protein products include analysis of product degradation rate using methods including, but not limited to, HPLC exclusion size (SE-HPLC), cation-HPLC exchange (CEX-HPLC), diffraction X-ray (XRD), modulated Differential scanning calorimetry (mDSC), inverted HPLC phase (RP-HPLC), multi-angle light scattering (MALS), fluorescence, ultraviolet absorption, nephelometry, capillary electrophoresis (CE), SDS-PAGE and their combinations. In some embodiments, evaluation of the product in accordance with the present invention may include an appearance evaluation step (liquid or cake aspect).
[0172] Generally, formulations (lyophilized or aqueous) can be stored for long periods at room temperature. Storage temperature can usually range from 0 ° C to 45 ° C (for example, 4 ° C, 20 ° C, 25 ° C, 45 ° C etc.). Formulations can be stored for a period of months to years. Storage time will generally be 24 months, 12 months, 6 months, 4.5 months, 3 months, 2 months or 1 month. Formulations can be stored directly in the container used for administration, eliminating transfer steps.
[0173] Formulations can be stored directly in container lyophilization (if lyophilized), which can also function as the reconstitution vessel, eliminating transfer steps. Alternatively, lyophilized formulations can be measured in smaller increments for product storage. Storage should generally avoid circumstances that lead to protein degradation, including but not limited to exposure to sunlight, UV radiation, other forms of electromagnetic radiation, excessive or cold heat, rapid thermal shock and mechanical shocks. Lyophilization
[0174] Inventive methods in accordance with the present invention can be used to lyophilize all materials, in particular therapeutic agents. Typically, a pre-lyophilization formulation still contains an adequate choice to prevent the compound of interest from degradation (for example, protein aggregation, deamidation, and / or oxidation) during lyophilization and storage of excipients or other components, such as stabilizers, buffer, agents, bulking agents and surfactants. The lyophilization formulation can include one or more additional ingredients including lyoprotectants or stabilizing agents, buffers, bulking agents, isotonicity agents and surfactants.
[0175] After the substance of interest and any additional components are mixed together, the formulation is lyophilized. Lyophilization generally includes three main stages: freezing, primary drying and secondary drying. Freezing is necessary to convert water to ice or some amorphous formulation components to crystalline form. Drying primer is the process step, when ice is removed from the frozen product by direct sublimation at low pressure and temperature. Secondary drying is the process step, when limited water is removed from the product matrix using the diffusion of residual water on the evaporation surface. Product temperature during secondary drying is usually higher than during primary drying. See, Tang X. et al. (2004) "Design of freeze-drying processes for pharmaceuticals: Practical advice," Pharm. Res., 21: 191-200; Nail S.L. et al. (2002) "Fundamentals of freeze-drying," in the development and manufacture of pharmaceutical protein products. Nail S.L.New York editor: Kluwer Academic / Plenum Publishers, pp 281-353; Wang et al. (2000) "Freeze-drying and development of solid protein pharmaceuticals," Int. J. Pharm., 203: 1-60; Williams N.A. et al. (1984) "The freeze-drying of pharmaceuticals; A literature review". J. Parenteral Set. Technol., 38: 48-59. Generally, any lyophilization process can be used in connection with the present invention.
[0176] In some embodiments, an annealing step can be introduced during the initial freezing of the product. The annealing step can reduce the total cycle time. Without wishing to be bound by all theories, it is anticipated that the annealing step can help promote the crystallization of the excipient and the formation of larger ice crystals due to the recrystallization of small crystals formed during supercooling, which, in turn, improves reconstitution. Typically, an annealing step includes an interval or temperature fluctuation during freezing. For example, the freezing temperature can be -40 ° C, and the annealing step will increase the temperature to, for example, -10 ° C and maintain this temperature for a period of time. The annealing step time can vary from 0.5 hours to 8 hours (for example, 0.5, 1.0 1.5, 2.0, 2.5, 3, 4, 6 and 8 hours). The annealing temperature can be between freezing temperature and 0 ° C.
[0177] Lyophilization can be performed in a container, such as a tube, a bag, a bottle, a tray, a test tube (for example, a glass vial), syringe or any other suitable containers. Containers can be disposable. Lyophilization can also be performed on a large or small scale. In some cases, it may be desirable to lyophilize the protein formulation in the container in which the protein reconstitution is in order to avoid a transfer step. The container in the present case, for example, is a 3, 4, 5, 10, 20, 50 or 100 cc road.
[0178] Many different freeze dryers are available for this purpose as a pilot scale hull dryer (SP Industries, USA), Genesis (SP Industries) laboratory freeze dryers, or any freeze dryers capable of controlling the process parameters of lyophilization determined. Freeze-drying is carried out by freezing and then sublimating the ice from the frozen content at a temperature suitable for primary drying. Initial freezing brings the formulation to a temperature below about -20 ° C (for example, -50 ° C, -45 ° C, -40 ° C, -35 ° C, -30 ° C, -25 ° C, etc.) in normally not more than about 4 hours (for example, not more than about 3 hours, not more than about 2.5 hours, not more than about 2 hours). In these conditions, the temperature is usually below the eutectic point or the collapse temperature of the formulation. Typically, the shelf temperature for primary drying will vary from about -30 to 25 ° C (as long as the product remains below the melting point during primary drying) at an appropriate pressure, usually ranging from about 20 to 250 ° C mTorr. The formulation, size and type of holding sample container (eg glass bottle) and the volume of liquid will mainly dictate the time needed for drying, which can vary from a few hours to several days. A secondary drying stage is carried out at about 0-60 ° C, depending mainly on the type and size of the container and the type of therapeutic proteins employed. Again, the volume of liquid will mainly dictate the time needed for drying, which can vary from a few hours to several days.
[0179] As a general proposition, lyophilization will result in a lyophilized formulation in which the moisture content is less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1% and less than about 0.5%. Reconstitution
[0180] While the pharmaceutical compositions of the present invention are generally aqueous after administration of an individual, in some embodiments the pharmaceutical compositions of the present invention are lyophilized. Such compositions must be reconstituted by adding one or more diluents, prior to administration to an individual. At the desired stage, usually at an appropriate time before administration to the patient, lyophilized formulation can be reconstituted with a diluent such that the concentration of protein in the reconstituted formulation is desirable.
[0181] Different diluents can be used in accordance with the present invention. In some embodiments, a suitable diluent for reconstitution is water. The water used as the diluent can be treated in a variety of ways, including reverse osmosis, distillation, deionization, filtrations (eg, activated carbon, microfiltration, nanofiltration) and combinations of these treatment methods. In general, water should be suitable for injection including, but not limited to, sterile water or bacteriostatic water for injection.
[0182] Additional specimen diluents include a pH buffered solution (eg, phosphate buffered saline), sterile saline, Elliot's solution, touch solution or dextrose solution. Suitable diluents may optionally contain a preservative. Exemplary preservatives include aromatic alcohols such as benzyl or phenol alcohol. The amount of preservative used is determined by evaluating different concentrations of preservatives for compatibility with the protein and the preservative effectiveness test. For example, if the condom is an aromatic alcohol (such as benzyl alcohol), it may be present in an amount of about 0.1-2.0%, about 0.5-1.5%, or about 1.0-1.2%.
[0183] Diluents suitable for the invention may include a variety of additives, including, but not limited to, pH buffering agents, (for example Tris, histidine) salts (for example, sodium chloride) and other additives (for example , sucrose) including those described above (for example, isotonic stabilizing agents, agents).
[0184] According to the present invention, a lyophilized substance (for example, proteins) can be reconstituted to a concentration of at least 25 mg / ml (for example, at least 50 mg / ml, at least 75 mg / ml, at least minus 100 mg / ml) and at any interval between them. In some embodiments, a lyophilized substance (for example, proteins) can be reconstituted to a concentration ranging from about 1 mg / ml to 100 mg / ml (for example, from about 1 mg / ml to 50 mg / ml, from 1 mg / ml to 100 mg / ml, from about 1 mg / ml to about 5 mg / ml, from about 1 mg / ml to about 10 mg / ml, from about 1 mg / ml to about from 25 mg / ml, from about 1 mg / ml to about 75 mg / ml, from about 10 mg / ml to about 30 mg / ml, from about 10 mg / ml to about 50 mg / ml , from about 10 mg / ml to about 75 mg / ml, from about 10 mg / ml to about 100 mg / ml, from about 25 mg / ml to about 50 mg / ml, from about 25 mg / ml to about 75 mg / ml, from about 25 mg / ml to about 100 mg / ml, from about 50 mg / ml to about 75 mg / ml, from about 50 mg / ml to about 100 mg / ml). In some embodiments, the protein concentration in the reconstituted formulation may be higher than the concentration in the pre-lyophilization formulation. High protein concentrations in the reconstituted formulation are considered particularly useful where subcutaneous or intramuscular delivery of the reconstituted formulation is intended. In some embodiments, the protein concentration in the reconstituted formulation can be about 2-50 times (e.g., about 2-20, about 2-10 times, or about 2-5 times) of the pre-lyophilized formulation. In some embodiments, the protein concentration in the reconstituted formulation can be at least about 2 times (e.g., at least about 3, 4, 5, 10, 20, 40 times) of the pre-lyophilized formulation.
[0185] Reconstitution according to the present invention can be carried out in any container. Exemplary containers suitable for the invention include, but are not limited to, such as tubes, vials, syringes (e.g., single or double-chamber), bags, bottles and trays. Suitable containers can be made of any materials such as glass, plastic, metal. Containers can be disposable or reusable. Reconstitution can also be performed on a large or small scale.
[0186] In some cases, it may be desirable to lyophilize the protein formulation in the container in which protein reconstitution is in order to avoid a transfer step. The container in this case, for example, can be a 3, 4, 5, 10, 20, 50 or 100 cc test tube. In some embodiments, a suitable container for lyophilization and reconstitution is a double-chamber syringe (for example, Lio-jet® (Vetter) syringes). For example, a double-chamber syringe can contain both the lyophilized substance and the diluent, each in a separate chamber, separated by a stopper (see example 5). To reconstitute, a plunger can be attached to the stopper on the side of the diluent and pressed to move the diluent in the product chamber so that the diluent can come into contact with the lyophilized substance and reconstitution can take place as described in this document (see example 5) .
[0187] The pharmaceutical compositions, formulations and related methods of the invention are useful for delivering a variety of therapeutic agents to an individual's CNS (e.g., intrathecally, intraventricularly or intracisternally) and for the treatment of associated diseases. The pharmaceutical compositions of the present invention are particularly useful for the delivery of proteins and enzymes (e.g., enzyme replacement therapy) to individuals suffering from lysosomal storage disorders. Lysosome storage diseases represent a group of relatively rare inherited metabolic disorders that result from defects in lysosome function. Lysosomal diseases are characterized by the accumulation of undigested macromolecules within lysosomes, which results in an increase in the size and number of such lysosomes and, finally, in cell dysfunction and clinical abnormalities. CNS Delivery
[0188] It is anticipated that several stable formulations described here are generally suitable for the delivery of CNS from therapeutic agents. Stable formulations according to the present invention can be used for the delivery of CNS through various techniques and routes, including, but not limited to, intraparenchymal, intracerebral, cerebral intraventricular (ICV), intrathecal (e.g., IT-lumbar, IT - magna cistern) administrations and other techniques and routes for injection directly or indirectly to CNS and / or CSF. Intrathecal Delivery
[0189] In some embodiments, a replacement enzyme is delivered to the CNS in a formulation described here. In some modalities, a replacement enzyme is delivered to the CNS by the administration for the cerebrospinal fluid (CSF) of an individual in need of treatment. In some embodiments, intrathecal administration is used to deliver a desired replacement enzyme (for example, an I2S protein) in CSF. As used here, intrathecal administration (also known as intrathecal injection) refers to an injection into the spinal canal (intrathecal space around the spinal cord). Various techniques can be used, including, without limitation, injection of lateral cerebroventricular through a trepanation or cistern or lumbar puncture or the like. Exemplary methods are described in Lazorthes et al. Advances in Drug Delivery Systems and Applications in Neurosurgery, 143-192 and Omaya et al., Cancer Drug Delivery, 1: 169-179, the contents of which are incorporated herein by reference.
[0190] According to the present invention, an enzyme can be injected into any region around the spinal canal. In some modalities, an enzyme is injected into the lumbar area or the cisterna magna or intraventricularly into a cerebral ventricle space. As used here, the term "lumbar region" or "lumbar area" designates the area between the third and fourth lumbar vertebrae (lower back) and, more inclusive, the region of the L2-Sl spine. Typically, intrathecal injection through the lower back or lumber area is also known as the "lumbar IT delivery" or "lumbar IT administration". The term "cisterna magna" refers to the space around and below the cerebellum through the opening between the skull and the upper part of the spine. Normally, intrathecal injection through a large cistern is also known as "large cistern delivery". The term "cerebral ventricle" refers to cavities in the brain that are continuous with the central channel of the spinal cord. Typically, injections through cerebral ventricle cavities are called intraventricular Cerebral Delivery (ICV).
[0191] In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present invention refers to lumbar administration or delivery, for example, delivered between the third and fourth lumbar vertebrae (lower back) and, more inclusive, the L2-S1 spine region. It is contemplated that lumbar-administration or delivery distinguishes on delivery of magna cisterna in which lumbar administration or delivery according to our invention provides better and more effective delivery to the distal spinal canal, while delivery of magna cistern, among other things, does not normally deliver well for the distal spinal canal. Intrathecal Delivery Device
[0192] Various devices can be used for intrathecal delivery according to the present invention. In some embodiments, a device for intrathecal administration contains a fluid access port (for example, injectable port); a hollow body (for example, catheter) with a flow port the first in fluid communication with the fluid access port and a second flow port, configured for insertion into the spinal cord; and a safety mechanism to ensure insertion of the hollow body into the spinal cord. As an example of limitation not shown in Figure 62, a suitable fixation mechanism contains one or more nobs mounted on the surface of the hollow body and an adjustable suture ring over the one or more nobs to prevent the hollow body (eg, catheter) slip out of the spinal cord. In various embodiments, the fluid access door comprises a reservoir. In some embodiments, the fluid access port consists of a mechanical pump (for example, an infusion pump). In some embodiments, an implanted catheter is connected to a reservoir (for example, for cake delivery), or an infusion pump. The fluid access port can be implanted or external.
[0193] In some modalities, intrathecal administration can be performed by a lumbar puncture (ie, in a slow bolus) or through a catheter-delivery system (ie, infusion or bolus). In some modalities, the catheter is inserted between the laminae of the lumbar vertebrae and the tip is inserted into the tecal space to the desired level (usually L3-L4) (Figure 63).
[0194] For intravenous administration, a single dose volume suitable for intrathecal administration is usually small. Normally, the intrathecal delivery according to the present invention maintains the balance of the CSF composition, as well as the individual's intracranial pressure. In some embodiments, intrathecal delivery is performed without the corresponding removal of CSF from an individual. In some embodiments, an appropriate single dose volume may be, for example, less than about 10 ml, 8 ml, 6 ml, 5 ml, 4 ml, 3 ml, 2 ml, 1.5 ml, 1 ml, or 0.5 ml. In some embodiments, an appropriate single dose volume may be about 0.5-5 ml, 0.5-4 ml, 0.5-3 ml, 0.5-2 ml, 0.5-1 ml, 1-3 ml, 1-5 ml, 1.5 -3 ml, 1-4 ml, or 0.5-1.5 ml. In some embodiments, delivery of intrathecal in accordance with the present invention involves a step of removing a desired amount of CSF first. In some embodiments, less than about 10 ml (for example, less than about 9 ml, 8 ml, 7 ml, 6 ml, 5 ml, 4 ml, 3 ml, 2 ml, 1 ml) of CSF is first removed before IT administration. In such cases, it may be a suitable single dose volume for example, more than about 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 15 ml, or 20 ml.
[0195] Several other devices can be used for the purpose of intrathecal administration of therapeutic composition. For example, formulations containing desired enzymes can be given using an Ommaya reservoir which is in common use for intrathecally administering drugs for meningeal carcinomatosis (Lancet 2: 983-84, 1963). More specifically, in this method, a ventricular tube is inserted through a hole formed in the anterior horn and is connected to an Ommaya reservoir installed under the scalp, and the reservoir is pierced subcutaneously to deliver the specific enzyme intrathecally being replaced, which is injected into the reservoir. Other devices for intrathecal administration of therapeutic compositions or formulations to an individual are described in Pat. No. 6,217,552, incorporated by reference. Alternatively, the drug can be given, for example, by a single injection or continuous infusion intrathecally. It is to be understood that the dosage treatment can be in the form of a single or multiple dose administration.
[0196] For injection, formulations of the invention can be formulated in liquid solutions. In addition, the enzyme can be formulated in solid form and redissolved or suspended immediately before use. Lyophilized forms are also included. The injection can be, for example, in the form of a bolus injection or continuous infusion (for example, using infusion pumps) of the enzyme.
[0197] In one embodiment of the invention, the enzyme is administered by the side of the brain ventricular injection into the brain of an individual. The injection can be done, for example, through a burr hole made in the skull of individuals. In another embodiment, the enzyme and / or other pharmaceutical formulation is administered through a shunt surgically inserted into an individual's cerebral ventricle. For example, the injection can be done in one of the lateral ventricles, which are larger. In some modalities, injection into third and fourth smaller ventricles can also be done.
[0198] In another embodiment, the pharmaceutical compositions used in the present invention are administered by injection into an individual's cisterna magna or lumbar area.
[0199] In another embodiment of the method of the invention, the pharmaceutically acceptable formulation provides sustained delivery, for example, "slow release" of the enzyme or other pharmaceutical composition used in the present invention, an individual at least one, two, three, four weeks or long periods of time after the pharmaceutically acceptable formulation is administered to the individual.
[0200] As used herein, the term "sustained delivery" refers to the continuous delivery of a pharmaceutical formulation of the invention in vivo over a period of time after administration, preferably at least several days, a week or several weeks. Sustained delivery of the composition can be demonstrated, for example, the continued therapeutic effect of the enzyme over time (for example, sustained delivery of the enzyme can be demonstrated by continued reduced amount of storage granules in the individual). Alternatively, sustained delivery of the enzyme can be demonstrated by detecting the presence of the enzyme in vivo over time. Delivery to target fabrics
[0201] As discussed above, one of the important and surprising features of the present invention is that therapeutic agents, in particular, replacement enzymes administered using inventive methods and compositions of the present invention are able to effectively and widely diffuse across the surface of the brain penetrate multiple layers or regions of the brain, including deep regions of the brain. In addition, inventive methods and compositions of the present invention effectively deliver therapeutic agents (for example, an I2S enzyme) to various tissues, neurons or spinal cord cells, including the lumbar region, which is difficult to target by existing CNS delivery methods. such as ICV injection. In addition, inventive methods and compositions of the present invention deliver a sufficient amount of therapeutic agents (for example, an I2S enzyme) to the blood stream and various peripheral tissues and organs.
[0202] Thus, some incorporations, a therapeutic protein (for example, an I2S enzyme) is delivered to an individual's central nervous system. In some embodiments, a therapeutic protein (for example, an I2S enzyme) is delivered to one or more of the target tissues of the brain, spinal cord, and / or peripheral organs. As used herein, the term "target tissues" refers to all tissue that is affected by the lysosomal storage disease to be treated or any tissue in which the deficient lysosomal enzyme is normally expressed. In some embodiments, target tissues include tissues in which there is a detectable or abnormally high amount of substrate, for example stored in the tissue's cell lysosomes, in patients suffering from or susceptible to lysosomal storage disease. In some modalities, target tissues include those tissues that exhibit disease associated with a disease, symptom or resource. In some embodiments, target tissues include tissues in which the deficient lysosomal enzyme is normally expressed at a high level. As used herein, a target tissue can be a target brain tissue, and / or a spinal cord tissue a peripheral target tissue. Exemplary target tissues are described in detail below. Target brain tissues
[0203] In general, the brain can be divided into different tissues, layers and regions. For example, meningeal tissue is a membrane system that surrounds the central nervous system, including the brain. The meninges contain three layers, including dura mater, arachnoid matter and sink matter. In general, the main function of meninges and cerebrospinal fluid is to protect the central nervous system. In some embodiments, a therapeutic protein in accordance with the present invention is delivered to one or more layers of the meninges.
[0204] The brain has three main subdivisions, including the brain, cerebellum and brain stem. The cerebral hemispheres, which are located above most other brain structures, are covered with a cortical layer. Underneath the brain is the brain stem, which resembles a rod to which the brain is attached. At the back of the brain, below the brain and behind the brain stem, is the cerebellum.
[0205] The diencephalon, which is located near the midline of the brain and above the midbrain, contains the thalamus, metathalamus, hypothalamus, epithalamus, prethalamus and pretectum. The midbrain, also called the midbrain, contains the tectum, tegumentum, ventricular mesocoelia and cerebral peduncles, the red nucleus and the third cranial nerve nucleus. The midbrain is associated with vision, hearing, motor control, sleep-vigilance, alertness and temperature regulation.
[0206] Tissue regions of the central nervous system, including the brain, can be characterized based on the depth of the tissues. For example, CNS tissues (eg, brain) can be characterized as shallow tissues, decomposing tissues, or deep tissues.
[0207] In accordance with the present invention, a therapeutic protein (for example, a replacement enzyme) can be delivered to any appropriate target tissue (s) of the brain associated with a particular disease to be treated in an individual. Some embodiments, a therapeutic protein (for example, a replacement enzyme), in accordance with the present invention is delivered to the shallow or shallow brain target tissue. In some embodiments, a therapeutic protein in accordance with the present invention is delivered to the target decomposing brain tissue. In some embodiments, a therapeutic protein in accordance with the present invention is delivered to the target tissue deep in the brain. In some embodiments, a therapeutic protein in accordance with the present invention is delivered to a combination of target surface or surface brain tissue, brain decomposing target tissue, target tissue and / or deep brain tissue. In some embodiments, a therapeutic protein in accordance with the present invention is delivered to a deep tissue of the brain at least 4mm, 5mm, 6mm, 7mm, 8mm, 9mm, 10mm or more below (or inside) the outer surface of the brain.
[0208] In some embodiments, therapeutic agents (for example, enzymes) are delivered to one or more superficial or superficial tissues of the brain. In some embodiments, the target surface or surface tissues of the brain are located within 4 mm of the brain surface. In some embodiments, the target surface or surface tissues of the brain are selected from pia mater, tissues of cerebral cortical ribbon, hippocampus, Virchow-Robin space, blood vessels within the VR space, the hippocampus, parts of the hypothalamus on the surface lower brain, optic nerves and tract the olfactory bulb and projections and their combinations.
[0209] In some embodiments, therapeutic agents (for example, enzymes) are delivered to one or more deep tissues of the brain. In some embodiments, the target surface or surface tissues of the brain are located 4 mm (for example, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm or 10 mm) or below (or internal) the brain surface. In some modalities, targeting deep brain tissues include the cerebral cortical ribbon. In some embodiments, targeting deep brain tissues include one or more of the diencephalon (eg, the hypothalamus, thalamus, prethalamus, subthalamus, etc.), metencephalon, lentiform nuclei, basal ganglia, caudate, putamen, amygdala, globus pallidus and their combinations.
[0210] In some embodiments, therapeutic agents (for example, enzymes) are delivered to one or more tissues of the cerebellum. In certain embodiments, the target of one or more tissues of the cerebellum is selected from the group consisting of tissues of the molecular layer, tissues of the Purkinje cell layer, tissues of the granular cell layer, cerebellar peduncles and combination thereof. In some embodiments, therapeutic agents (eg, enzymes) are delivered to one or more deep cerebellar tissues, including, but not limited to, Purkinje cell layer tissues, Granular cell layer tissues, Cerebellar deep white matter tissues ( for example, in relation to the layer of deep granular cells) and tissue of deep Cerebellar nuclei.
[0211] In some embodiments, therapeutic agents (for example, enzymes) are delivered to one or more brain stem tissues. In some embodiments, the target of one or more brain stem tissues includes brain stem tissue, white matter tissue and / or brain stem.
[0212] In some embodiments, therapeutic agents (eg, enzymes) are delivered to various brain tissues, including, but not limited to, gray matter, white matter, periventricular areas, pia-arachnoid, meninges, neocortex, cerebellum, tissues deep in the cerebral cortex, midbrain, molecular layer, caudate putamen region / deep regions of the pons or medulla and their combinations.
[0213] In some embodiments, therapeutic agents (eg, enzymes) are delivered to various cells in the brain, including, but not limited to, neurons, glial cells, meningeal cells and / or perivascular cells. Some modalities, a therapeutic protein is delivered to oligodendrocytes of deep white matter. Spinal cord
[0214] In general, regions or tissues of the spinal cord can be characterized based on the depth of the tissues. For example, the spinal cord tissues can be characterized as superficial or shallow, decomposing tissues, tissues, deep tissues of and / or.
[0215] In some embodiments, therapeutic agents (for example, enzymes) are delivered to one or more superficial or shallow tissues of the spinal cord. In some embodiments, a shallow or shallow target tissue of the spinal cord is located within 4 mm of the spinal cord's surface. In some embodiments, a shallow or shallow target tissue of the spinal cord contains a single material and / or tract of white matter.
[0216] In some embodiments, therapeutic agents (for example, enzymes) are delivered to one or more deep tissues of the spinal cord. In some embodiments, a deep target of the spinal cord tissue is located within 4 mm of the spinal cord surface. In some embodiments, a deep target of spinal cord tissue contains individual gray spinal cord and / or ependymal cells.
[0217] In some modalities, therapeutic agents (for example, enzymes) are delivered to neurons in the spinal cord. Peripheral target tissues
[0218] As used here, peripheral organs or tissues refer to any organs or tissues that are not part of the central nervous system (CNS). Targeted peripheral tissues may include, but are not limited to, the blood system, liver, kidneys, heart, endothelium, bone marrow and bone marrow derived from cells, spleen, lung, lymph nodes, bone, cartilage, ovary and testis. In some embodiments, a therapeutic protein (for example, a replacement enzyme) in accordance with the present invention is delivered to one or more of the target peripheral tissues. Biodistribution and bioavailability
[0219] In several modalities, once delivered to the target tissue, a therapeutic agent (for example, an I2S enzyme) is located intracellular. For example, a therapeutic agent (for example, the enzyme) can be located in the exons, axons, lysosomes, mitochondria or vacuole of a target cell (for example, neurons such as Purkinje cells). For example, in some modalities intrathecally-administered enzymes demonstrate translocation dynamics, such that the enzyme moves within the perivascular space (for example, by pulsation-assisted convection mechanisms). In addition, active axonal transport mechanisms relating to the association of the enzyme or protein administered with neurofilaments may also contribute to or otherwise, facilitate the distribution of intrathecally-administered proteins or enzymes in the deeper tissues of the central nervous system.
[0220] In some embodiments, a therapeutic agent (for example, an I2S enzyme) delivered in accordance with the present invention can achieve therapeutically or clinically effective levels or activities in various target tissues described herein. As used herein, a therapeutically or clinically effective level of activity is a level of activity sufficient to confer a therapeutic effect on a target tissue. The therapeutic effect can be objective (that is, measurable by some test or marker) or subjective (that is, an individual gives an indication of or feels an effect). For example, a therapeutically or clinically effective level or activity may be an activity that is sufficient to alleviate the symptoms associated with the disease in the target tissue (e.g., GAG storage) or enzyme level.
[0221] In some embodiments, a therapeutic agent (for example, a replacement enzyme) delivered in accordance with the present invention can reach an enzyme level or activity that is at least 5%, 10%, 20%, 30%, 40 %, 50%, 60%, 70%, 80%, 90%, 95% is the normal level or activity of the corresponding lysosomal enzyme in the target tissue. In some embodiments, a therapeutic agent (for example, a replacement enzyme) delivered according to the present invention can reach an enzyme level or activity that is increased at least 1 time, 2 times, 3 times, 4 times, 5 times , 6 times, 7 times, 8 times, 9 times or 10 times compared to a control (for example, endogenous levels or activities without treatment). In some embodiments, a therapeutic agent (for example, a replacement enzyme) delivered according to the present invention can achieve an enzymatic increase in level or activity of at least approximately 10 nmol / hr / mg, 20 nmol / hr / mg, 40 nmol / hr / mg, 50 nmol / hr / mg, 60 nmol / hr / mg, 70 nmol / hr / mg, 80 nmol / hr / mg, 90 nmol / hr / mg, 100 nmol / hr / mg, 150 nmol / hr / mg, 200 nmol / hr / mg, 250 nmol / hr / mg, 300 nmol / hr / mg, 350 nmol / hr / mg, 400 nmol / hr / mg, 450 nmol / hr / mg, 500 nmol / hr / mg, 550 nmol / hr / mg or 600 nmol / hr / mg in a target tissue.
[0222] Some modalities, creative methods according to the present invention are particularly useful for targeting the lower back. In some embodiments, a therapeutic agent (for example, a replacement enzyme) delivered in accordance with the present invention can achieve an increase in enzyme level or activity in the lumbar region of at least approximately 500 nmol / hr / mg, 600 nmol / hr / mg, 700 nmol / hr / mg, 800 nmol / hr / mg, 900 nmol / hr / mg, 1000 nmol / hr / mg, 1500 nmol / hr / mg, 2000 nmol / hr / mg, 3000 nmol / hr / mg, 4000 nmol / hr / mg, 5000 nmol / hr / mg, 6000 nmol / hr / mg, 7000 nmol / hr / mg, 8000 nmol / hr / mg, 9000 nmol / hr / mg, or 10,000 nmol / hr / mg.
[0223] In general, therapeutic agents (e.g., replacement enzymes) delivered in accordance with the present invention have sufficiently long half an hour in the CSF and target tissues of the brain, spinal cord and peripheral organs. In some embodiments, a therapeutic agent (for example, a replacement enzyme) delivered according to the present invention can have a half-life of at least approximately 30 minutes, 45 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 16 hours, 18 hours, 20 hours, 25 hours, 30 hours, 35 hours, 40 hours, up to 3 days, up to 7 days, up to 14 days, up to 21 days or up to a month. In some embodiments, a therapeutic agent (for example, a replacement enzyme) delivered in accordance with the present invention can maintain detectable level or activity in the CSF or bloodstream after 12 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, 54 hours, 60 hours, 66 hours, 72 hours, 78 hours, 84 hours, 90 hours, 96 hours, 102 hours, or one week after administration. Detectable level or activity can be determined using various methods known in the art.
[0224] In certain embodiments, a therapeutic agent (for example, a replacement enzyme) delivered in accordance with the present invention achieves a concentration of at least 30pg / ml in the individual's CNS tissues and cells after administration (for example, one week , 3 days, 48 hours, 36 hours, 24 hours, 18 hours, 12 hours, 8 hours, 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less, after intrathecal administration of the pharmaceutical composition for the individual). In certain embodiments, a therapeutic agent (for example, a replacement enzyme) delivered in accordance with the present invention achieves a concentration of at least 20pg / ml, at least 15pg / ml, at least 10pg / ml, at least 7.5pg / ml ml, at least 5pg / ml, at least 2.5pg / ml, at least 1.0pg / ml or at least 0.5pg / ml in the target of the individual's tissues or cells (eg brain tissue or neurons) after administration of such an individual (for example, a week, 3 days, 48 hours, 36 hours, 24 hours, 18 hours, 12 hours, 8 hours, 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less after intrathecal administration of such pharmaceutical compositions to the individual). Treatment of Hunter syndrome and other diseases by storage of lysosomes
[0225] Lysosome storage diseases represent a group of relatively rare inherited metabolic disorders that result from defects in lysosome function. Lysosomal diseases are characterized by the accumulation of undigested macromolecules, including the enzyme substrates, within the lysosomes (see Table 1), which results in an increase in the size and number of such lysosomes and, ultimately, in cell dysfunction and clinical abnormalities.
[0226] Inventive methods described herein can advantageously facilitate the delivery of one or more therapeutic agents (for example, replacement enzymes for one or more) of specific organelles. For example, because lysosomal storage disorders such as Hunter's syndrome are characterized by the accumulation of glycosaminoglycans (GAG) in the lysosomes of the affected cells, lysosomes represent a desired target organelle for the treatment of lysosomal disorders.
[0227] Inventive methods and compositions of the present invention are particularly useful for the treatment of these diseases, having a CNS or component etiology. Lysosome storage diseases having a CNS or component etiology include, for example and without Sanfilippo syndrome type A limitation, Sanfilippo type B syndrome, Hunter syndrome, Metachromatic leukodystrophy and Globoid cell leukodystrophy. Prior to the present invention, traditional therapies are limited in that they are administered to individuals intravenously and are generally only effective in treating the somatic symptoms of the underlying enzyme deficiency. The compositions and methods of the present invention can advantageously be administered directly to the CNS of an individual suffering from a disease having such a CNS etiology, obtaining a therapeutic concentration in the affected cells and tissues of the CNS (for example, brain), thus, overcome the limitations associated with traditional systemic administration of such therapeutic agents.
[0228] In some embodiments, inventive methods and compositions of the invention are useful for treating neurological and somatic sequelae or symptoms of lysosomal storage disorders. For example, some embodiments of the invention relate to the compositions and methods of delivering one or more therapeutic agents to an individual's CNS (for example, intrathecally, intraventricularly or intracisternally) for the treatment of CNS or neurological sequelae and manifestations of a lysosomal storage disease, while also treating the systemic or somatic manifestations of that lysosomal storage disease. For example, some compositions of the present invention can be administered to an individual intrathecally, thus delivering one or more therapeutic agents to the individual's CNS and treating neurological sequelae, together with intravenous administration of one or more therapeutic agents to deliver such agents therapies for the cells and tissues of the systemic circulation (for example, cells and tissues of the heart, lungs, liver, kidney or lymph nodes) to treat somatic sequelae. For example, an individual having or otherwise affected by a lysosomal storage disease (for example, Hunter syndrome) can be administered a pharmaceutical composition, comprising one or more therapeutic agents (for example, iduronate-2-sulfatase) intrathecally at least once a week, biweekly, monthly, bimonthly or more to treat neurological sequelae, while a different therapeutic agent is administered to the individual intravenously on a more frequent basis (for example, once a day, every day, three times per week or weekly) to treat systemic or somatic manifestations of the disease.
[0229] Hunter syndrome, or Mucopolisacaridosis II (MPS II), is an X-linked hereditary metabolic disorder resulting from a deficiency of the enzyme iduronate-2-sulfatase (I2S). I2S is located at lysosomes and plays an important role in the catabolism of glycosaminoglycans (GAGs) heparan - and dermatan sulfate. In the absence of an enzyme, these substrates accumulate inside the cells, ultimately causing engorgement, followed by tissue destruction and cell death. Due to the widespread expression of the enzyme, various types of cells and organ systems are affected in patients with MPS II.
[0230] A clinical defining characteristic of this disorder is the degeneration of the central nervous system (CNS), which results in cognitive impairment (for example, decreased IQ). In addition, MRI scans of affected individuals have revealed white matter lesions, dilated perivascular spaces in the brain parenchyma, ganglia, corpus callosum and brain stem; atrophy; and ventriculomegally (Wang et al. Molecular Genetics and Metabolism, 2009). The disease usually manifests itself in the first years of life with organomegaly and skeletal abnormalities. Some affected individuals experience a progressive loss of cognitive function, with most affected individuals dying from complications associated with the disease in their first or second decade.
[0231] Compositions and methods of the present invention can be used to effectively treat individuals suffering from or susceptible to Hunter's syndrome. The terms, "treat" or "treatment", as used here, refer to improving the symptoms of one or more associated with the disease, preventing or delaying the onset of one or more symptoms of the disease, and / or decreasing the severity or the frequency of one or more symptoms of the disease.
[0232] In some modalities, treatment to partial or complete relief, improvement, relief, inhibition, delaying onset, reducing the incidence of and / or severity of neurological impairment in a patient with Hunter syndrome. As used here, the term "neurological deficiency" includes several symptoms associated with impairment of the central nervous system (for example, the brain and spinal cord). Neurological deficiency symptoms can include, for example, for example, cognitive impairment; white matter lesions; dilated perivascular spaces in the cerebral parenchyma, ganglia, corpus callosum, and / or brain stem; atrophy; and / or ventriculomegally, among others.
[0233] In some modalities, treatment refers to a lysosomal decrease (for example, vomiting) in various tissues. In some modalities, treatment refers to a lysosomal decrease in target brain tissues, spinal cord neurons, and / or target peripheral tissues. In certain incorporations, lysosomal is decreased by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70 %, 75%, 80%, 85%, 90%, 95%, 100% or more compared to a control. In some modalities, lysosomal is reduced at least 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times compared to a control. In some modalities, lysosomal is measured by the presence of lysosomal storage granules (for example, zebra stripe morphology). The presence of lysosomal storage granules can be measured by various means, known in the art, such as by histological analysis.
[0234] In some modalities, treatment refers to reduced vacuolization in neurons (for example, neurons that contain Purkinje cells). In certain incorporations, vacuolization in neurons is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% , 70%, 75%, 80%, 85%, 90%, 95%, 100% or more compared to a control. In some embodiments, vacuolization is reduced at least 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times compared to a control. The presence of and reduction of vacuolization can be measured by various means, known in the art, such as by histological analysis.
[0235] In some modalities, treatment refers to the increased activity of the I2S enzyme in various tissues. In some modalities, treatment refers to increased activity of the I2S enzyme in target brain tissues, spinal cord neurons and / or target peripheral tissues. In some embodiments, I2S enzyme activity is increased by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65 %, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% 1000% or more compared to a control. In some embodiments, I2S enzyme activity is increased at least 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times compared to a control. In some embodiments, increased I2S enzyme activity is at least approximately 10 nmol / hr / mg, 20 nmol / hr / mg, 40 nmol / hr / mg, 50 nmol / hr / mg, 60 nmol / hr / mg, 70 nmol / hr / mg, 80 nmol / hr / mg, 90 nmol / hr / mg, 100 nmol / hr / mg, 150 nmol / hr / mg, 200 nmol / hr / mg, 250 nmol / hr / mg, 300 nmol / hr / mg, 350 nmol / hr / mg, 400 nmol / hr / mg, 450 nmol / hr / mg, 500 nmol / hr / mg, 550 nmol / hr / mg, 600 nmol / hr / mg or more. In some embodiments, I2S enzyme activity is increased in the lower back or in the cells in the lower back. In some embodiments, increased I2S enzyme activity in the lower back is at least approximately 2000 nmol / hr / mg, 3000 nmol / hr / mg, 4000 nmol / hr / mg, 5000 nmol / hr / mg, 6000 nmol / hr / mg , 7000 nmol / hr / mg, 8000 nmol / hr / mg, 9000 nmol / hr / mg, 10,000 nmol / hr / mg, or more. In some embodiments, I2S enzyme activity is increased in the distal spinal cord or in distal spinal cord cells.
[0236] In some modalities, treatment refers to slowing the progression of loss of cognitive ability. In certain incorporations, there is a decrease in the progression of loss of cognitive ability by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60 %, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more compared to a control. In some modalities, treatment refers to a decrease in developmental delay. In certain incorporations, development delay is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% , 70%, 75%, 80%, 85%, 90%, 95%, 100% or more compared to a control.
[0237] In some modalities, treatment refers to increased survival (eg survival time). For example, treatment can result in an increase in a patient's life expectancy. In some embodiments, treatment according to the present invention results in an increase in a patient's life expectancy by more than about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 105%, about 110%, about 115%, about 120%, about 125%, about 130%, about 135%, about 140%, about 145%, about 150%, about 155%, about 160%, about 165%, about 170%, about 175%, about 180%, about 185%, about 190%, about 195%, about 200% or more, compared to the average life expectancy of one or more control individuals with similar disease without treatment. In some embodiments, treatment in accordance with the present invention results in an increase in a patient's life expectancy for more than about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years or more, compared to the average life expectancy of one or more control individuals with similar disease without treatment. In some embodiments, treatment in accordance with the present invention results in the patient's long-term survival. As used here, the term "long-term survival" refers to a survival time or life expectancy greater than about 40 years, 45 years, 50 years, 55 years, 60 years or more.
[0238] The terms, "improve", "increase" or "reduce" in this document, indicate that they are in relation to a control. In some embodiments, an appropriate control is a reference measure, such as an individual measure before the start of the treatment described in this document, or a measure in an individual control (or several control subjects) in the absence of treatment described in this document. . A "control" individual is an individual afflicted with Hunter syndrome, who is about the same sex of and / or age as the individual being treated (in order to ensure that the stages of the disease in the treated individual and the comparable control individual (s)).
[0239] The individual (also referred to as "patient" or "individual") being treated is an individual (fetus, baby, child, teenager or human adult) with Hunter syndrome, or the potential to develop Hunter syndrome. The individual may have residual activity of and / or in expression of endogenous I2S, or no measurable activity. For example, the individual with Hunter Syndrome may have levels of I2S expression that are less than about 30-50%, less than about 25-30%, less than about 20-25%, less than about 15 -20%, less than about 10-15%, less than about 5- 10%, less than about 0.1-5% of normal I2S expression levels.
[0240] In some modalities, the individual is an individual who has recently been diagnosed with the disease. Usually, early treatment (starting as soon as possible after treatment diagnosis) is important to minimize the effects of the disease and maximize the benefits of treatment. Immunological tolerance
[0241] Generally, intrathecal administration of a therapeutic agent (for example, a replacement enzyme) according to the present invention does not result in serious adverse effects on the individual. As used here, serious adverse effects induce, but are not limited to, substantial immune response, toxicity or death. As used here, the term "substantial immune response" refers to severe or severe immune responses, such as adaptive T-cell immune responses.
[0242] Thus, in many embodiments, creative methods according to the present invention do not involve simultaneous immunosuppressive therapy (i.e., any immunosuppressant used as a pretreatment / preconditioning or in parallel for the method). In some embodiments, creative methods according to the present invention do not involve an induction of immunological tolerance in the individual to be treated. In some embodiments, creative methods according to the present invention do not involve pre-treatment or preconditioning of the individual using T-cell immunosuppressive agent.
[0243] In some embodiments, intrathecal administration of therapeutic agents can mount an immune response against these agents. Thus, in some embodiments, it may be useful to process the individual to receive the tolerant replacement enzyme for enzyme replacement therapy. Immunological tolerance can be induced using several methods known in the art. For example, an initial 30-60 day regimen of a T cell immunosuppressive agent such as cyclosporin A (CsA) and an antiproliferative agent such as azatioprine (Aza), combined with weekly intrathecal infusions of low doses may be used. a desired replacement enzyme.
[0244] Any immunosuppressive agent known to the skilled artisan can be employed in conjunction with a combination therapy of the invention. Such immunosuppressive agents include but are not limited to cyclosporin, FK506, rapaicin, CTLA4-Ig, and anti-TNF agents such as etanercept (see for example Moder, 2000, Ann. Allergy-Asthma Immunol. 84, 280-284; Nevins, 2000 , Curr. Opin. Pediatr. 12, 146-150; Kurlberg et al., 2000, Scand. J. Immunol. 51, 224-230; Ideguchi et al., 2000, Neuroscience 95, 217-226; Potteret al., 1999, Ann. NY Acad. Sci. 875, 159-174; Slavik et al., 1999, Immunol. Res. 19, 1-24; Gaziev et al., 1999, Bone Marrow Transplant. 25, 689-696; Henry , 1999, Clin. Transplant. 13, 209-220; Gummert et al., 1999, J. Am. Soc. Nephrol. 10, 1366-1380; Qi et al., 2000, Transplantation 69, 1275-1283). The anti-IL2 receptor (alpha subunit) antibody daclizumab (eg Zenapax.TM.), Which has been shown to be effective in transplant patients, can also be used as an immunosuppressive agent (see for example Wiseman et al., 1999, Drugs 58 , 1029-1042; Beniaminovitz et al., 2000, N. Engl J. Med. 342, 613-619; Ponticelli et al., 1999, Drugs RD 1, 55-60; Berard et al., 1999, Pharmacotherapy 19, 1127-1137; Eckhoff et al., 2000, Transplantation 69, 1867-1872; Ekberg et al., 2000, Transpl. Int. 13, 151-159). Additional immunosuppressive agents include, but are not limited to, anti-CD2 (Branco et al., 1999, Transplantation 68, 1588-1596; Przepiorka et al., 1998, Blood 92, 4066-4071), anti-CD4 (Marinova-Mutafchieva et al., 2000, Arthritis Rheum. 43, 638-644; Fishwild et al., 1999, Clin. Immunol. 92, 138-152), and anti-CD40 ligand (Hong et al., 2000, Semin. Nephrol. 20, 108-125; Chirmule et al., 2000, J. Virol. 74, 3345-3352; Ito et al., 2000, J. Immunol. 164, 1230-1235). Administration
[0245] Inventive methods of the present invention contemplate a single as well as several administrations of one therapeutically promoting the amount of the therapeutic agents (for example, substitution enzymes) described herein. Therapeutic agents (for example, replacement enzymes) can be administered at regular intervals, depending on the nature, severity and extent of the individual's condition (for example, a lysosomal storage disease). In some embodiments, therapeutically promoting a quantity of the therapeutic agents (for example, replacement enzymes) of the present invention can be administered intrathecally periodically at regular intervals (for example, once a year, once every six months, once each five months, once every three months, bimonthly (once every two months), monthly (once a month), biweekly (once every two weeks), weekly, daily or continuously).
[0246] In some embodiments, intrathecal administration can be used in conjunction with other routes of administration (for example, intravenously, subcutaneously, intramuscularly, parenterally, transdermally, or transmucosally (for example, orally or by via nasal)). Some modalities, other routes of administration (for example, intravenous administration) can be performed no more frequently than biweekly, monthly, once every two months, once every three months, once every four months, once once every five months, once every six months, per year of administration. In some embodiments, the method most comprises of administering the I2S replacement enzyme intravenously to the individual. In certain incorporations, intravenously it is not more frequent than weekly administration (for example, not more frequent than biweekly, monthly, once every two months, once every three months, once every four months , once every five months or once every six months). In certain incorporations, intravenous administration is more frequent than monthly administration, such as twice a week, weekly, fortnightly, or monthly twice. In some modalities, intravenous and intrathecal administrations are carried out on the same day. In some embodiments, intravenous and intrathecal administrations are not performed within a certain period of time from the other, as not within at least 2 days, within at least 3 days, within at least 4 days, within at least at least 5 days, within at least 6 days, within at least 7 days, or within at least one week. In some modalities, intravenous and intrathecal administrations are performed at alternate times, as alternate administrations weekly, each week, twice a month or monthly. In some embodiments, an intrathecal administration replaces an intravenous administration on an administration schedule, such as on an intravenous administration table weekly, biweekly, twice monthly, or monthly, each third, fourth or fifth administration on that list can be replaced by one administration intrathecal in place of an intravenous administration. In some modalities, an intravenous administration replaces an intrathecal administration in an administration schedule, such as in a weekly intrathecal administration schedule, every week, twice monthly, or monthly, each third, fourth or fifth administration in this list can be replaced by an intravenous administration instead of intrathecal administration. In some embodiments, intravenous and intrathecal administrations are performed sequentially, such as performing intravenous administrations first (for example, weekly, biweekly, twice monthly, or monthly dosing for two weeks, one month, two months, three months, four months, five months, six months, a year or more) followed by intrathecal administrations (eg weekly, fortnightly, twice monthly, or monthly dosing for more than two weeks, one month, two months, three months, four months, five months, six months, a year or more). In some modalities, intrathecal administrations are performed first (for example, weekly, biweekly, twice monthly, monthly, once every two months, every three months dosing for two weeks, one month, two months, three months, four months, five months, six months, a year or more) followed by intravenous administrations (eg weekly, fortnightly, twice monthly, or monthly dosing for more than two weeks, one month, two months, three months, four months , five months, six months, a year or more).
[0247] In some embodiments, Hunter syndrome is associated with peripheral symptoms and the method includes administering enzyme replacement intrathecally but does not involve administering the replacement enzyme intravenously to the individual. In certain embodiments, the intrathecal administration of the I2S enzyme improves or reduces one or more of the peripheral symptoms associated with the individual's I2S deficiency.
[0248] As used herein, the term "therapeutically promoting amount" is largely determined on the basis of the total amount of the therapeutic agent contained in the pharmaceutical compositions of the present invention. Generally, a therapeutically promoting amount is sufficient to achieve a significant advantage for the individual (eg, treatment, modulation, cure, preventing and / or ameliorating the underlying disease or condition). For example, a therapeutically promoting amount may be sufficient to achieve a desired prophylactic and / or therapeutic effect, as sufficient to modulate the lysosomal enzyme receptors or their activity to thereby treat such lysosomal storage disease as well and symptoms ( for example, reducing or eliminating the presence or incidence of "zebra bodies" or cellular vacuolization after administration of the compositions of the present invention to an individual). Generally, the amount of a therapeutic agent (for example, a recombinant lysosomal enzyme) administered to an individual in need of it will depend on the individual's characteristics. Such characteristics include the condition, severity of the disease, general health, age, sex and body weight of the individual. A person skilled in the art will readily be able to determine adequate doses depending on these and other related factors. In addition, objective and subjective, trials, optionally, can be employed to identify the ideal dosage ranges.
[0249] The therapeutically effective amount is generally administered in a dosage regimen that can comprise several unit doses. For any specific therapeutic protein, a therapeutically promoting amount (and / or an appropriate unit dose within an effective dosage regimen) can vary, for example, depending on the route of administration, in combination with other pharmaceutical agents. In addition, the specific amount therapeutically promoting (unit dose of and / or) for a given patient may depend on a variety of factors, including the disorder being treated and the severity of the disease; the activity of the specific pharmaceutical agent employed; the specific composition used; the patient's age, body weight, general health, sex and diet; the time of administration, route of administration, rate of and / or excretion or metabolism of the specific fusion protein employed; the duration of treatment; and as factors as it is well known in the medical arts.
[0250] In some embodiments, the therapeutically effective dose ranges from about 0.005 mg / kg brain by weight to 500 mg / kg brain by weight, for example, from about 0.005 mg / kg brain by weight to 400 mg / kg brain weight, from about 0.005 mg / kg brain weight to 300 mg / kg brain weight, from about 0.005 mg / kg brain weight to 200 mg / kg brain weight, from about 0.005 mg / kg brain weight to 100 mg / kg brain weight, from about 0.005 mg / kg brain weight to 90 mg / kg brain weight, from about 0.005 mg / kg brain brain weight to 80 mg / kg brain weight, from about 0.005 mg / kg brain weight to 70 mg / kg brain weight, from about 0.005 mg / kg brain weight to 60 mg / kg brain weight, from about 0.005 mg / kg brain weight to 50 mg / kg brain weight, from 0.005 mg / kg brain weight to 40 mg / kg brain weight, from 0.005 mg / kg of the brain by weight to 30 mg / kg brain weight, from about 0.005 mg / kg brain weight to 25 mg / kg brain weight, from 0.005 mg / kg brain weight to 20 mg / kg brain weight, from 0.005 mg / kg brain weight to 15 mg / kg brain weight, from about 0.005 mg / kg brain weight to 10 mg / kg brain weight.
[0251] In some embodiments, the effective therapeutic dose is greater than about 0.1 mg / kg of the brain by weight, greater than about 0.5 mg / kg of the brain by weight, greater than about 1.0 mg / kg of the brain in weight, greater than about 3 mg / kg brain weight, greater than about 5 mg / kg brain weight, greater than about 10 mg / kg brain weight, greater than about 15 mg / kg brain brain weight, greater than about 20 mg / kg brain weight, greater than about 30 mg / kg brain weight, greater than about 40 mg / kg brain weight, greater than about 50 mg / kg brain weight, greater than about 60 mg / kg brain weight, greater than about 70 mg / kg brain weight, greater than about 80 mg / kg brain weight, greater than about 90 mg / kg brain weight, greater than about 100 mg / kg brain weight, greater than about 150 mg / kg brain weight, greater than about 200 mg / kg brain weight, greater than about 250 mg / kg of brain weight, greater than about 30 0 mg / kg brain weight, greater than about 350 mg / kg brain weight, greater than about 400 mg / kg brain weight, greater than about 450 mg / kg brain weight, greater than about 500 mg / kg of the brain by weight.
[0252] In some embodiments, the effective therapeutic dose can also be defined per mg / kg of body weight. As an individual technician would like to receive, brain weights and body weights can be correlated. Dekaban AS. "Changes in brain by weight during the span of human life: relation of the brain by weight to body heights and body weight," Ann Neurol 1978; 4: 345-56. Thus, in some modalities, the dosages can be converted as shown in Table 5. TABLE 5.

[0253] In some embodiments, the effective therapeutic dose can also be defined per mg / 15 cc of CSF. As an individual technician would like to receive, therapeutically effective doses based on the brain's weight and body weight can be converted to mg / 15 cc of CSF. For example, the volume of CSF in adult humans is approximately 150 mL (Johanson CE, et al. "Multiplicity of cerebrospinal fluid functions: New challenges in health and disease," Cerebrospinal Fluid Res. 2008 May 14; 5: 10) . Therefore, single dose injections of 0.1 mg to 50 mg of protein for adults would be approximately 0.01 mg / 15 cc of CSF (0.1 mg) to 5.0 mg / 15 cc of CSF (50 mg) doses in adults.
[0254] It should also be understood that, for any particular individual, specific dosage regimens should be adjusted over time, according to the individual need and the professional judgment of the person administering or supervising the administration of enzyme replacement therapy and that Dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed invention. Kits
[0255] The present invention further provides kits or other articles of manufacture that contain the formulation of the present invention and provides instructions for its use and / or reconstitution (if lyophilized). Kits or other articles of manufacture may include a container, an IDDD, a catheter and any other articles, devices or equipment useful in intertecal administration and associated surgery. Suitable containers include, for example, bottles, vials, syringes (for example, pre-filled syringes), ampoules, cartridges, reservoirs or lyro-jets. The container can be made up of a variety of materials such as glass or plastic. In some embodiments, a container is a pre-filled syringe. Suitable pre-filled syringes include, but are not limited to, borosilicate glass syringes with baked silicone coating, borosilicate glass syringes with powdered silicone, or plastic resin syringes without silicone.
[0256] Typically, the container may contain suspension formulations and a label for, or associated with, the container that may indicate the use of and / or reconstitution. For example, the label may indicate that the formulation is reconstituted to protein concentrations, as described above. The label may further indicate that the formulation is useful or intended for, for example, IT administration. In some embodiments, a container may contain a single dose of a stable formulation containing a therapeutic agent (for example, a replacement enzyme). In several embodiments, a single dose of the stable formulation is present in a volume of less than about 15 ml, 10 ml, 5.0 ml, 4.0 ml, 3.5 ml, 3.0 ml, 2.5 ml, 2.0 ml, 1.5 ml, 1.0 ml, or 0.5 ml. Alternatively, a container holding the formulation can be a multipurpose vial, which allows for repeat administrations (for example, 2-6 administrations) of the formulation. Kits or other articles of manufacture may include a second container, comprising an appropriate diluent (for example, BWFI, saline, buffered saline). After mixing the diluent and the formulation, the final protein concentration in the reconstituted formulation will generally be at least 1 mg / ml (for example, at least 5 mg / ml, at least 10 mg / ml, at least 25 mg / ml, at least 50 mg / ml, at least 75 mg / ml, at least 100 mg / ml). Kits or other articles of manufacture can still include other desirable materials from a commercial and user point of view, including other buffers, thinners, filters, needles, IDDDs, catheters, syringes and package inserts with instructions for use.
[0257] The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention. All literature citations are incorporated by reference. EXAMPLES EXAMPLE 1: Biodistribution
[0258] The main objective of this study was to determine whether recombinant human I2S could be delivered to the brain of adult MPS II rats via lumbar intrathecal route. TABLE 6: Six groups of male 8-12 rats
Injection schedule: animals received up to 3 injections of idursulfase (DL 10) via the intrathecal-lumbar route: Groups A & D: 3 doses of I2S were administered on days 1, 8 and 15 Group B: 2 doses of I2S were administered on days 1 and 8 Groups C & E: Untreated control mice (IKO) Group F: Untreated wild type control mice MATERIALS AND METHODS Animals:
[0259] Rats were housed in groups of up to 4 by the cage in a colony quarter under a 12-hour light-dark cycle. Rodent diet (LabDiet-5001, St Louis, MO) and water (Lexington, MA municipal purified water by reverse osmosis) available ad libitum for the duration of the experiment. Animal care was carried out in accordance with the guidelines outlined in the Care and Use of Laboratory Animals guide (National Academy Press, Washington D.C., 1996). The current IKO breeding colony was established from the four female rats heterozygous for the IKO mutation that were obtained from Dr. Joseph Muenzer (University of North Carolina). Carrier females were bred with male mice of the C57BL / 6 strain (C57BL / 6NTac, Laconic, Hudson, NY), producing heterozygous females and male ko mice of heterozygotes, such as wild-type males and female littermates. All descendants were genotypes by PCR analysis of tissue DNA. All rats used in this experiment were identified as either heterozygous from male IKO (- / O) or wild (WT) littermate mice (+ / 0) between 8 and 12 weeks of age. Idursulfase:
[0260] Twenty-two mL recombinant human I2S idursufase was dialyzed against four changes of 2 L phosphate buffered serum (PBS). The I2S was then concentrated through the Vivaspin column and resuspended in a final volume of 1 ml of PBS, followed by filter sterilization using a 0.2 pm filter. The final concentration was 51 mg / ml. Intrathecal-lumbar injection:
[0261] Adult rats were anesthetized with 1.25% 2,2,2 tribromoethanol (Avertin) at 200-300 pL / 10 grams of body weight (250-350 mg / kg) by intraperitoneal injection. Dorsal hair was removed between the base of the tail and the shoulder blades and the shaved area was cleaned with povidine / betadine followed by isopropyl alcohol. A small median (1-2 cm) skin incision was made along the lumbosacral spine and the crossing of the dorsal midline and the cranial aspect of the ileo wings (singular ileo) was identified. The muscle in the iliac fossa (middle gluteus) is a heart shaped muscle, and the two sides of the upper part of the "heart" approximate the location of the ileo wings. A 32 needle gauge for a tight gas into which glass of 10-20 pL Hamilton's syringe was inserted, until resistance from the underlying bone was felt. Injection of 10 pL of the test article at an approximate rate of 2 pL / 20 seconds (10 pL / 2 minutes) was performed. The skin incision was closed using wound clips as appropriate and the animal was allowed to recover in a recovery chamber before being returned to the appropriate cage. Histology procedures:
[0262] Animals were euthanized one hour after the last injection.
[0263] Tissues of the brain and liver were collected and fixed in 10% neutral buffered formalin, then processed and embedded in paraffin. Five pm sections were prepared for hematoxylin / eosin (H&E) and immunohistochemical staining (IHC). Hematoxylin and eosin staining:
[0264] Sections of the brain and liver were stained with H&E. The staining results showed nuclei such as purple and pink to red cytoplasm. Stained H&E slides were used to assess histopathological morphology. Immunohistochemistry:
[0265] To assess I2S biodistribution, deparaffinized and rehydrated brain and liver sections were incubated overnight with mouse monoclonal antibody 2C4-2B2 (Maine Biotechnology Services, Portland, ME) against recombinant human I2S to detect injected I2S (or an irrelevant mouse IgG as a negative control antibody; Vector Laboratories, Burlingame, CA). After an overnight incubation at 2-8 ° C, a secondary goat anti-mouse that IgG conjugated to horseradish peroxidase was added. After an additional 30 minutes of incubation at 37 ° C, Tyramide-Alexa Fluor 488 labeling solution (Invitrogen Corp., Carlsbad, CA) was added for another 10 minutes. Sections were assembled using an anti-disappearance mounting medium (VectaShield; Vector Laboratories) containing 1.5 pg / ml 4'-6-diamidino-2-phenylindol (DAPI) as a nuclear contrast dye and observed with a multi-channel fluorescent microscope Nikon. The staining results in I2S positive cells as green, with nuclei in blue and areas of black background.
[0266] For efficacy analysis, sections of the brain and liver were stained with an anti-LAMP-1 mouse (associated lysosome membrane protein as a lysosome marker) IgG (Santa Cruz Biotechnology, Santa Cruz, California) as the primary antibody. An IgG mouse as an irrelevant antibody was used as a negative control. The ABC (avidin biotin complex kits from Vector Labs, Burlingame, California) method was used to amplify the target marker.
[0267] Briefly, deparaffinized sections were rehydrated and incubated with the primary antibody. Following incubation overnight at 2-8 ° C, a biotinylated secondary anti-rabbit IgG rat (Vector Labs, Burlingame, California) was added and incubated at 30 minutes at 37 ° C, then the samples were washed and treated with avidin-biotin-peroxidase complex (Vector Laboratories) for 30 minutes. For color development, 3,3-diaminobenzidine tetrahydrochloride (DAB) was used as the chromagen. Sections were then counterstained with hematoxylin and laminules. The staining results showed LAMP-1 positive cells like brown and nuclei in blue.
[0268] Representative photos were taken and the area of LAMP-1 positive cells was analyzed with Image-Pro Plus software (Media Cybernetics, Inc., Bethesda, MD) and statistical comparisons were performed using the student t test. Electron microscope method:
[0269] Tissues from 3 doses of treated animal I2S were corrected from the brain 2.5% PFA / 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4 at 4 degrees for overnight. Then, the samples were washed in cacodylate buffer (0.1M, pH7.4) and post-fixed in osmium tetroxide, dehydrated in alcohols and propylene oxide and in Epon resin. Ultrathin sections were cut at 100nm, stained with lead citrate and examined under a Tecnai ™ G2 Spirit BioTWIN transmission electron microscope. Results
[0270] In the brain, as determined by immunohistochemistry (IHC), no I2S was found in vehicle control animals. In contrast, meningeal cells, brain neurons and cerebellum were positively stained for I2S in I2S injected animals. The color signal was stronger in animals given 3 doses (Figure 1).
[0271] In brain tissues of rats treated with IKO vehicle, cell vacuolization, a histopathological mark of diseases by storage of lysosomes, was found in every brain compared to wild-type animals. I2S treated IKO rats, there was a generalized reduction in cell vacuolization from the surface of the cerebral cortex, caudate nucleus, thalamus, cerebellum, white matter compared to untreated (Figure 2). Abnormally high lysosomal activity was found by associated lysosomal membrane proteins 1 (LAMP-1) staining, an indicator of activity status and lysosomal disease, microglial, meningeal and perivascular cells of IKO rats treated with vehicle in relation to wild type animals. The rats treated with I2S intrathecal marked reductions in LAMP-1 immunostaining. This reduction was characterized by a decrease in the number of positive LAMP-1 cells and lighter staining. The reduction was found across the entire brain from the surface of the cerebral cortex, caudate nucleus, thalamus, cerebellum, the white matter (Figure 3) at the dose of 2 and 3 of the treated animals. Morphometric analyzes of LAMP-1 immunostaining from various regions of the brain confirmed that there were significant reductions in LAMP-1 positive staining in all areas of the brain assessed (Figure 4).
[0272] Examination of electron microscopy of brain cells in rats treated with IKO vehicle revealed vacuole enlargements containing amorphous granular storage material and inclusions with laminate and zebra-like body structures. These pathological characteristics typical of the lysosome at the ultrastructural level were reduced in injected mice of the intrathecal-lumbar I2S (Figure 5).
[0273] In the liver, there was no positive I2S stain in the vehicle treated animals. In the intrathecally injected I2S rats, a large amount of clearly injected I2S was found in the sinusoidal cells (Figure 6), which indicated the I2S injected into the intrathecal space circulated with CSF and was then absorbed through arachnoid granulations in the circulatory system.
[0274] In the liver tissues of rats treated with IKO vehicle, severe cell vacuolization and abnormally high lysosomal activity demonstrated by H&E staining and strong LAMP-1 immunostaining were found in comparison with WT rats. Marked reduction in cell vacuolization and LAMP-1 immunostaining in livers was found after intrathecal treatment with I2S. H&E staining revealed intracytoplasmic vacuolization to disappear almost completely with an almost normal liver cell structure (Figure 7).
[0275] In IKO rats, recombinant human I2S was delivered to the brain via the intrathecal-lumbar route and injected I2S causes widespread histopathological improvement in a variety of regions in the brain.
[0276] Injected I2S was detected in meningeal cells and neurons in the brain.
[0277] Reduced cell vacuolization across the brain at light levels and electron microscopy.
[0278] LAMP-1 reduced lysosome marker throughout the brain.
[0279] Intrathecal injected I2S entered the peripheral circulation and improved liver morphology and histological marker. Example 2: TOXICOLOGY
[0280] This example illustrates the clinical signs associated with idursulfase via monthly lumbar intrathecal bolus doses in cynomolgus monkeys. To achieve this, 14 male, cynomolgus monkeys were randomly assigned to five treatment groups, as shown in the following table. TABLE 7: EXPERIMENTAL DESIGN

[0281] Animals in all groups were dosed three times at monthly intervals than at the level of the lumbar spine. The 1 ml dose volume was released from the catheter system with 0.3 ml of PBS. One or two days before each dose, about 2 ml of CSF was collected from an IT spinal tap at the level of the cisterna magna. Blood samples (2 ml) were also collected at this time. Blood (2 ml) and CSF (0.1 ml) were collected from pre-dose animals from group 5, 0.5, 1, 2, 4, 8, 24 and 48 hours post dose after the first dose. Clinical signs were recorded at least twice a day. An autopsy was performed approximately 24 hours after the third dose and selected tissues were collected and stored.
[0282] On the first day, all three animals in group 4 (150 mg) exhibited a minimum tending to later quarters at the post dose of 3-12 minutes, duration of 5-15 minutes; This signal was considered related to the test article. There was no change in body weight, food consumption and examination of neurological / physical parameters that were considered related to the test article.
[0283] Analysis of serum and CSF samples and dosage solution analyzes are presented. Variations in endogenous idursulfase activity were observed in different cynomolgus monkey tissues; brain and spinal cord had greater endogenous activity than other peripheral organs examined, including liver, heart and kidney. Administration of Idursulfase has been associated with dose-dependent increases in idursulfase activity in various regions of the brain, as well as the brain stem and spinal cord. IT delivery did not result in an observable difference in distribution between the left and right brain hemispheres. There was a clear increase in dose-dependent activity of idursulfase in the following organs: brain, liver, heart and kidney. Immunostaining for idursulfase in the brain demonstrated a dose-dependent increase in staining intensity. In the 3 mg group, meningial cell and glial cell limited staining were observed under the meninges; neuronal staining was not evident in the animals in the 3 mg treatment group. Idursulfase staining was positive and dose dependent in the spinal cord, with the highest staining intensity in the lumbar region, where TI administration of idursulfase occurred. Idursulfase staining intensity in the liver, kidneys and heart was dose-dependent and consistent with increased idursulfase activity in these organs.
[0284] In conclusion, TI administration of idursulfase in doses up to 150 mg delivered at monthly intervals had no adverse effect. Thus, the unobserved level of adverse effects (NOAEL) was interpreted as 150 mg, the highest dose tested in this study. Idursulfase administration was associated with dose-dependent increases in CNS idursulfase activity and resulted in systemic I2S levels and activity in the liver, kidney and heart.
[0285] The test article, idursulfase, was supplied as dosing solutions 154 mM NaCl, 0.005% Polysorbate 20, pH 5.3-6.1. The nominal concentrations of the supplied dosage solutions were 0, 3, 30 or 150 mg / ml. The test article was stored in a freezer at -82 ° C to -79 ° C. Phosphate buffered saline (PBS), pH 7.2, was used as a washing agent after doses were administered and then serial CSF collections. PBS was obtained from Gibco, Invitrogen Corporation. Test article dosage preparation
[0286] On the first day of dosing for each time interval, a bottle of each concentration was removed from the freezer in the chest at -80 ° C and allowed to thaw on the bench at room temperature. Once thawed, the vials for groups 1, 2 and 3 were labeled, weighed, and 1 ml was removed through a 0.22 pm filter for each animal scheduled for dosing. After all doses were administered, the bottles were again placed in the refrigerator.
[0287] The next day (dosing day for animals 003, group 4 and group 5) dosing solutions for groups 1 and 4 were removed from the refrigerator and placed on the bench to reach the temperature. Once room temperature was obtained, vials for groups 1 and 4 were weighed, group 4 vial was labeled and 1 ml was removed by the filter for each animal scheduled for dosing in groups 1 and 4. The dosing solution for the group 5 was then prepared by injecting the appropriate amount of dosing solution from group 4 and 1 group (vehicle) into a sterile polypropylene bottle. The added quantity of groups 1 and 4 were recorded. The solution was gently mixed by inverting the flask and doses of 2-1 ml were removed through the filter of the animals in group 5. The flasks for groups 1 and 4 were again after completion of dosing and all flasks (groups 1- 5) were placed in the freezer.
[0288] Fourteen animals were randomly assigned to treatment groups, as described in the following Table.
[0289] The IT route of administration was selected because this is an intended route for human administration, He doses of idursulfase that were selected for this study (3, 30, 100, and 150 mg / ml) were chosen to assess biodistribution of different levels of enzyme doses in the central nervous system non-human primates (CNS) after three consecutive monthly IT bolus lumbar injections. Clinical observations
[0290] The overall incidence of clinical signs was minimal. None of the animals in group 1 (control), group 2 (3 mg), group 3 (30 mg) or group 5 (100 mg) had clinical signs that were considered related to the test article at any time during the study.
[0291] On the day, all three animals in group 4 (150 mg) (012-014) exhibited a minimum tending to later quarters at the 3-12 minute post dose, lasting 5-15 minutes. This signal was considered related to the test article and was not observed in any of the lower dose groups. There were no other clinical signs immediately after the first dose or in the days immediately following the administration of the test article. The only other sign observed for animals in group 4 was a single episode of emesis for Animal 013 on day 35.
[0292] Administration of the test article as a single, monthly intrathecal bolus was not associated with any gross or microscopic adverse changes when taking into account the changes inherent with an implanted drug delivery device. All groups, including the control group, had microscopic changes in meninges indicating inflammatory reactions to the drug delivery system. In animals that received doses of the test article of 30 mg and greater, there was a tendency for the inflammatory reaction in meninges to have a more pronounced eosinophilic component.
[0293] Because the differences between the control and test article treated animals were so slight, that the unobserved level of adverse effects (NOAEL) was interpreted as 150 mg, the highest dose tested in this study.
[0294] The overall inflammatory reaction in meninges in all groups (including controls) was slightly more pronounced than generally found in an intrathecal study of this duration in monkeys. However, this was considered possibly related to some characteristic of the vehicle or to the act of dosing 24 hours before the necropsy.
[0295] Brain idursulfase staining was positive in all treated animals except one animal in the 3 mg group, with the highest staining intensity found in the 150 mg group (Figures 16, 17, 18 and 19). In the 3 mg group, only meningial cells and some glial cells below the meninges were positive; uninjected idursulfase was detected in neurons. The highest dose groups (30, 100 and 150 mg), large populations of brain neurons were strongly positive for idursulfase staining, along with meningial cells, glial cells and perivascular cells. Immunostaining idursulfase revealed a wide distribution of the idursulfase injected into the brain neurons of layer I neurons on the surface near the meninges, for those within the deepest layer VI adjacent to the white matter (Figures 20, 21 and 22). Marked staining of neurons was also observed for the 150 mg dose group (Figure 23). In all animals (30-150 mg dose group), unmarked in the staining of neuronal idursulfase, a difference was found between the frontal, central and rear sections of the brain.
[0296] Idursulfase staining was positive, the spinal cords of all animals, with the highest staining intensity in the lumbar region (Figures 24 and 25). Immunostaining idursulfase was also dose dependent. Neurons, meningial cells, glial cells, perivascular cells and epi / peri / endoneurium (connective cells) involving nerve fibers were strongly positive for idursulfase stain in the 150 mg group (Figures 26 and 27).
[0297] In the liver, positive staining for idursulfase was found in sinusoidal cells (Kupffer cells and endothelial cells) of all animals. Idursulfase, however, was not detected in hepatocytes for the 3 mg treatment group (Figure 28), while positive idursulfase staining in hepatocytes was found in the highest dose groups, with the highest staining intensity in the 150 treatment group. mg (Figures 29, 30 and 31).
[0298] There was no positive staining for idursulfase in the animals in the 3 mg treatment group (Figure 22). On the other hand, interstitial cells were positively stained for idursulfase in the 1930s, 100 and 150 mg groups, with marked staining being seen in 150 mg group in terms of the number of positive cells and staining intensity (Figures 33, 34 and 35 ). Kidney
[0299] Little or no injected idursulfase was detected in the animals in the 3 mg dose group (Figure 36). However, positive staining, idursulfase, was found in glomerular cells and interstitial cells in groups 30 and 100 mg (Figures 37 and 38). The 150 mg group, immunostaining idursulfase further revealed idursulfase staining of proximal tubular cells, along with marked glomerular and interstitial cell staining (Figure 39). DISCUSSION
[0300] There were no clinical signs related to the test article or effects on weight class, food consumption, physical examination findings and neurological examination findings. On the first day, animals in group 4 (150 mg) exhibited a minimum tending to later quarters in the 3-12 minute post, dosage, duration 5 to 15 minutes; This signal was deemed to be related to the test article.
[0301] Administration of Idursulfase has been associated with dose-dependent increases in idursulfase activity in various regions of the brain, as well as the brain stem and spinal cord. The highest level of intensity staining in the spinal cord was in the lumbar region, where TI administration of idursulfase occurred. TI administration of idursulfase also resulted in systemic exposure with intensity of dose-dependent staining in the liver, kidneys and heart. Animals that received doses of the test and the 30 mg higher article had a tendency for the inflammatory reaction in meninges to have a more pronounced eosinophilic component, but this difference was not considered biologically significant.
[0302] TI administration of idursulfase in doses up to 150 mg delivered at monthly intervals had no adverse effect. Thus, the unobserved level of adverse effects (NOAEL) was interpreted as 150 mg, the highest dose tested in this example. Administration of Idursulfase was associated with dose-dependent increases in CNS idursulfase activity and resulted in systemic levels in the liver, kidneys and heart. EXAMPLE 3: IT PK (Serum and CSF) delivered to I2S
[0303] This example provides serum and cerebrospinal fluid analysis (CSF) associated with a 6-month toxicity study of Idursulfase administered via monthly intrathecal lumbar bolus injections and weekly intravenous bolus injections in Cynomolgus monkeys, to test article concentration (OK).
[0304] EXPERIMENTAL DESIGN
[0305] The purpose of this study was to evaluate the repeat intrathecal dose (IT) administration of idursulfase (12s) from a toxicology and safety pharmacology perspective over a six month period. The study design is shown in table 8. TABLE 8: STUDY DESIGN
DC = Device Control: Animats In group 1 not dosed with vehicle or test article. DC = Device Control: Animals in Group 1 not dosed with vehicle or test article Test article
[0306] Identification: Idursulfase IV Dosage (2.0 mg / mL)
[0307] IT-idursulfase dosage (0 mg / mL)
[0308] idursulfase (3 mg / ml)
[0309] idursulfase (30 mg / ml)
[0310] idursulfase (100mg / ml) Test methods:
[0311] Analyzes were performed using an ELISA (Enzyme-Linked Immunoadsorptive Assay) of the idursulfase concentration. The detection limit (LOD) = 1.25 ng / mL before multiplication by the dilution factor. Samples were selected at a 1:50 dilution. Therefore, the assay sensitivity is 62.5 ng / mL. Samples falling beyond the final high calibration curve were further diluted and retested at an appropriate dilution that resulted in a value within the curve range. In addition, selected samples were analyzed using an enzyme activity assay. The LOD for this assay is 0.18 mU / mL at a minimum sample dilution of 1: 150.
[0312] Animals in groups 1 and 2 that were treated with saline or vehicle, respectively, all had serum levels of idursulfase ranging between 138 ng / mL and <62.5 ng / mL (or <LOD) throughout the IV period and dosage. Of 200 CSF samples tested from group 1 and 2 animals, 62 demonstrated I2S levels above the LOD assay. Of these, 7 values were high (> 1,000 ng / mL). Another sample of the CSF collected pre-dose tested above 3,000 ng / mL of I2S.
[0313] The samples were then tested for idursulfase activity. In each case, that the activity results indicated the presence of I2S and when the approximate concentration of I2S was calculated based on the activity levels, the results were within 20 of those obtained by ELISA antigen. (See Table 9) Additional randomly chosen CSF samples with ELISA antigen results <LOD were also tested using the enzyme activity assay to rule out any non-specific activity. TABLE 9: RESULTS OF THE CSF SAMPLE SURVEY

[0314] In this study, serum and CSF samples were analyzed for idursulfase concentration. Serum samples were collected, according to the following schedule:
[0315] IV Doses: pre-dose and 2 hours post doses from 1 to 10, pre-dose and 4 hours post-doses 11 to 23 and at necropsy.
[0316] IT Doses: pre-dose and 2 hours after doses 1 and 2, pre-dose and 4 hours post-doses 3 to 6 and at necropsy.
[0317] CSF samples were collected according to the following schedule:
[0318] IV Doses: pre-dose 2 hours after dose 1 and 4 hours post-doses 3 and 6.
[0319] IT Doses: pre-dose and 2 hours post-doses 1 and 2, pre-dose and 4 hours post-doses 3 to 6 and at necropsy.
[0320] Generally, serum idursulfase faster than CSF idursulfase unchecked.
[0321] Serum levels of idursulfase in animals of groups 1 and 2 that were treated with saline or vehicle, respectively, were less than or equal to 138 ng / mL time at all points tested. Some animals had levels below the limit of detection assay (LOD).
[0322] CSF samples from groups 1 and 2 were above the LOD assay, with 7 notable exceptions that resulted in high levels (> 1,000 ng / mL). A CSF sample collected from a pre-dose 3 animal, also tested above 1,000 ng / mL idursulfase.
[0323] Samples giving these out-of-trend results were re-examined and confirmed. In addition, these samples were tested for the enzyme idursulfase activity. These activity results also confirmed high idursulfase levels within 20% of those obtained by testing the idursulfase mass (Table 9).
[0324] The specificity of the activity assay was validated within this sample cohort by randomly testing CSF samples with units of mass idursulfase below LOD and confirmed that idursulfase in these samples was actually LOD (data not shown). EXAMPLE 4: FORMULATION
[0325] This example summarizes the pharmaceutical development studies carried out to establish the formulations of Idursulfase-IT drug substance and drug product for phase I / II clinical trials.
[0326] Due to the limitation of suitable excipients for the delivery of CNS, the effort to develop formulations for intrathecal delivery of idursulfase has focused on reducing the level of phosphate and polysorbate 20, maintaining the stability equivalent to the I2S formulation for systemic delivery .
[0327] Three major stress screenings have been carried out studies to examine the effect of phosphate and polysorbate levels. These included freeze thaw, agitation, stress and thermal stresses. The results demonstrated that the saline formulation is more stable against the defrost stress of freezing the low protein concentration (2 mg / mL). At high protein concentration (100 mg / mL), the stress of freezing thaw did not cause a problem of instability for saline and phosphate containing formulations. The agitation stress study confirmed that 0.005% polysorbate 20 protected the protein against tremendous related stress. Thermal stability studies have shown that the saline formulation was more stable compared to formulations containing phosphate. In addition, the pH of the saline formulation can be maintained at 6.0 for 24 months at 2-8 ° C. The amount of residual phosphate associated with the protein, as well as the increased protein concentration was found to contribute to pH stability in the final formulation. Methods Effect of freeze / thaw stress on the stability of Idursulfase in saline and phosphate formulations
[0328] To examine the effect of freeze / thaw idursulfase stability in different formulations, the viral SEC pool was exchanged / concentrated using Centricon Plus four times in 150 mM NaCl or 137 mM NaCl with 20 mM sodium phosphate (both at pH 6.0). Protein concentrations were directed to 2 mg / ml and 100 mg / ml. All solutions were filtered through a 0.22 micron PVDF filter. The solutions were aliquoted in 1 ml of each inside the 2 ml borosilicate glass vials. The bottles were placed on the middle shelf of a lyophilization chamber and surrounded by placebo bottles. The samples were frozen in a programmed freeze / thaw cycle (performed for 1 hour at 20 ° C and frozen to -50 ° C at 1 ° C / min.) Then thawed in two stages at a rate of 0.03 ° C / min from - 50 ° C to -25 ° C, maintained for 24 hours at -25 ° C, and allowed to thaw at 2-8 ° C). After two or three freeze / thaw cycles, samples were analyzed for appearance and SEC-HPLC assays. Effect of shear / agitation stress on phosphate and salt solutions Idursulfase
[0329] Stirring studies have been conducted on idursulfase at different protein concentrations. Protein concentrations were tested at 2mg / ml, 8 mg / ml and 90-100 mg / ml at present 137 mM NaCl in 20 mM phosphate (pH 6.0) and 154 mM NaCl (pH 6.0) alone. To see if polysorbate was needed, various amounts of PS-20 were spiked in a test condition. The solutions were aliquoted in 1.2 mL in glass flasks of 2 mL each and then shaken on an orbital shaker at 250 rpm at ambient conditions for 24 hours. At baseline and 24 hours, appearance was analyzed, and 0.1 mL aliquots were sampled in freezing below ^ -65 ° C in 0.5 mL polypropylene tubes until SEC-HPLC analysis.
[0330] To first confirm the effect of the polysorbate level 20, a simulated freight study was carried out using a truck load of 3 hours of material, followed by a 1 hour air test at level 1 guarantee using random test options (conducted by Lansmont (Lansing, MI)). The samples were analyzed for the appearance of particles and soluble aggregates by SEC-HPLC.
[0331] Examining the effect of stirring stress on stability, a saline formulation (50 mg / mL, 154mM NaCl and 0.005% PS-20) was filled in 1.3 mL in a 3 mL type I glass vial and stoppered with a 13 mm stopper, which contained a Teflon bar-coated magnetic stir (8 mm long and 2 mm in diameter). The bottles were placed on a stirring plate at speed 6 (the choice of configuration 6 was maximum speed without causing excessive foam formation). Appearance was determined at 0, 2, 24, 48 and 72 hours. The baseline and the 72 hour stirred samples were tested with SEC-HPLC methods. Thermal stability studies for lead formulations
[0332] Six lead formulations were compared for thermal stability. These formulations were chosen based on two parameters. The first parameter was that the protein concentration needed to be within the therapeutic scales for the delivery of the CNS. The second parameter was to control the effect of phosphate concentration on stability. The SEC's viral filtered pool was stored in exchanged buffer and concentrated using Centricon Plus-80. Target concentrations of 50 and 100 mg / ml protein concentrations were achieved. The six formulations were spiked with 1% polysorbate 20 solution to a final concentration of 0.01% PS-20. The material was filtered through a 0.22 micron PVDF filter and 0.5 mL added to 2 mL borosilicate glass test tubes. These vials were placed in stressed stability (40 ° C), accelerated storage stability (25 ° C) and in real time (2-8 ° C) in an inverted position. The stability samples at each time point were tested by SEC-HPLC, OD320, SAX-HPLC, SDS-PAGE (Commassie), pH and activity. Understanding pH control in saline formulation
[0333] To understand how the pH in the saline formulation was maintained, the following studies were carried out. Testing the phosphate residue in saline formulations
[0334] The viral SEC filtered pool (2 mg / ml idursulfase, 137 mM NaCl, 20 mM sodium phosphate, pH 6.0) was concentrated and diafiltered in 150 mM NaCl using the Millipore TFF system and Millipore Pellicon Biomax 30, 50cm2 filter . The samples were to determine the amount of phosphate associated with proteins after 7X, 10X and 15X cycles of diafiltration in 0.9% saline (prepared in TK3). In addition, the permeate after 10 X diafiltration (protein containing no flow through filtration) and the saline solution used in the filtration step were also tested. Determine the effect of protein concentration on pH
[0335] To better understand the pH control without the presence of a buffer (phosphate), studies of the protein effect were performed. To determine the protein's contribution to pH, the material was diluted in 154 mM NaCl (saline) 30 mg / ml, 10 mg / ml, mg / ml 2, 1 mg / ml, mg / ml 0.1, 0, 01 mg / ml and saline alone. The material was aliquoted in 2 ml polypropylene tubes with a filling volume of 1 ml per tube. The samples were frozen at <-65 ° C for 1 hour, thawed in the environment for 30 minutes and the cycle repeated three times. The initial pH was measured and compared after 3X freeze / thaw cycles. The pH was also measured after exposure of the environment 24 hours (by opening the tube caps) of the samples to determine the effect of protein concentration may have on the pH change.
[0336] Due to the limitation of suitable excipients for the delivery of CNS, the effort for the development of formulations for intrathecal delivery of idursulfase was centered on the reduction of phosphate and polysorbate 20 level, maintaining the stability equivalent to I2S formulated for systemic administration. Three key stress selection studies have been carried out, including freeze-thaw, agitation, stress and thermal stresses. Freezing / thawing effect on Idursulfase in saline and phosphate formulations
[0337] As shown in Table 10, the protein concentration low of mg / ml 2, the 20 mM phosphate containing the formulation generated plus aggregates after ice Thaw stress. The saline formulation remained at the same level as the aggregates as the baseline. High protein concentration (100 mg / ml), freeze-thaw stress appeared to have any effect on stability in any of the formulations (table 11). The data indicated that the saline formulation alone has better stability against freeze thaw stress. TABLE 10: SOLUBLE AGGREGATION IN LOW PROTEIN CONCENTRATIONS
TABLE 11: SEG PROFILE TO DETERMINE SOLUBLE AGGREGATION IN HIGH PROTEIN CONCENTRATION

[0338] The amount of NaCl was adjusted to 137 mM, where the formulation contained 20 mM phosphate, to maintain comparable tonicity. Stress agitation effect on Idursulfase in solution
[0339] The stirring studies were carried out at three levels of protein concentration of 2 and 8 mg / ml 100. The data demonstrated that without polysorbate 20, precipitated in all the protein concentration occurred and a high level of aggregates was also observed soluble in mg / ml 2 (Table 12 aTable 14). However, in the presence of a very low P20 level such as 0.005%, precipitates and soluble aggregates were mostly prevented. The data indicated that a low level of polysorbate is necessary to protect the protein against tremendous stress. TABLES 12-14: SHAKING THE STUDY IN A LABORATORY MODEL (ROTATION AT 250 RPM, FOR 24 HOURS IN THE ENVIRONMENT) Table 12: ~ 2mg / ml in 137mM NaCl and 20mM Phosphate at pH 6


[0340] The control sample (without stirring) had a monomer of 99.8%.
[0341] To further confirm whether 0.005% is sufficient for stability against agitation, a simulated transport study was carried out, which was close to the actual transport condition, in the 100 mg / ml protein saline formulation with different levels of polysorbate 20. The results confirmed that 0.005% was sufficient (Table 15). TABLE 15: EFFECT OF POLYSORBATE 20 ON THE APPEARANCE AND SOLUBLE AGGREGATES OF 100 MG / ML IN SALINE SOLUTION AFTER STUDY OF SIMULATED SHIPPING

[0342] The stirring effect, using a magnetic stir bar on the stability of the saline formulation containing 50 mg / mL idursulfase with 0.005% polysorbate 20 is summarized in the Table. As shown, the protein is not susceptible to the stress caused by shaking, using a magnetic stir bar for 72 hours. The results confirmed that 0.005% was sufficient against agitation stress as well. TABLE 16: EFFECT OF POLYSORBATE 20 ON THE STABILITY OF 53 MG / ML IDURSULPHASE AGGRESSIVE AGITATION
Thermal stability for lead candidates
[0343] Six major formulations were examined over 24 months for the stability test. The results of these tests are discussed in this section. Appearance
[0344] The appearance of all formulations remained slightly opalescent and essentially particulate free under all temperatures and surviving tested for formulations of six. OD320
[0345] To examine the potential increase in turbidity, the OD320 values were determined and summarized in table 17. According to the frozen storage, the OD320 values for all formulations remained the same as the baseline after storage of 24 months. At 2-8 ° C, Saline formulations remain the same as the baseline after 24 months, but the phosphate containing formulations had an increased level in OD320 values. At the accelerated condition of 25 ° C, Saline formulations also had a slight increase in OD320 after 3-6 months, but the phosphate containing formulations showed a more significant increase. These results suggest that the saline formulation is more stable against thermal stress. TABLE 17: COMPARING OD320 FOR SALT AND PHOSPHATE FORMULATIONS *
All contain 0.01% Polysorbate 20 SEC — HPLC
[0346] The data summary for all formulations tested by HPLC-SEC is listed in the table. The conditions of frozen storage, there was no change after 24 months, compared to the baseline.
[0347] In the stressed condition of 40 ° C, after two weeks all formulations had high levels of soluble aggregates. In addition, the phosphate containing formulations also showed a "12 min" peak. However, after 1 month, the "12 min peak" peaks observed in the phosphate containing formulation appeared to disappear. In addition, the soluble aggregate level no longer increases for all formulations compared to the 2-week time point (Figure 8 and Table 18).
[0348] In the accelerated condition of 25 ° C, compared to the baseline, for all formulations, the increase in the level of soluble aggregates was minimal, after 6 months. However, all phosphate containing formulations showed the peak "12 min" (Figure 9 and Table 18).
[0349] The condition of long term storage of 2-8 ° C, after 24 months the growth of soluble aggregates for the entire formulation was also minimal after 24 months storage. Consistent with all conditions, the phosphate containing formulations also had a "12 min peak", which increased slightly over time (Figure 10 and Table 18)
[0350] These results indicate that Saline formulations had less changes compared to phosphate containing formulations in all storage conditions. TABLE 18: COMPARING SEG-HPLC AGGREGATION IN SALT PHOSPHATE FORMULATIONS * 50mg / ml, 154mM

All formulations contain 0.01% polysorbate 20 a: The values depicted are high molecular species that elute ~ 12 minutes in the current HPLC SEC method often referred to as the "12 minute peak." This peak is thought to be strongly associated with the presence phosphate in the formulation. SAX-HPLC
[0351] The summary for SAX-HPLC data is listed in Table 19. Under stressed / accelerated conditions, saline formulations had little more change (Figures 11 and 12), but under long-term storage conditions, there was no change for all formulations after 24 months (Table 19 and Figure 13). This indicates that saline formulations are stable for 24 months at 2-8C. TABLE 19: COMPARING CHANGES BY THE SAX- HPLC METHOD FOR SALT AND PHOSPHATE FORMULATIONS (ALL WITH

PH
[0352] Table 20 shows that the pH of all formulations remained comparable to the baseline for 24 months at 2-8 ° C. For Saline solution formulations, although there was no buffer, the pH kept constant 6.0 for 24 months. TABLE 20: COMPARING PH FOR SALT AND PHOSPHATE FORMULATIONS (ALL WITH 0.01% POLYSORBATE-20) IN 24 MONTHS AT 2-8 ° C

Enzyme activity
[0353] Compared to the reference standard, the specific activity for all formulations after 24 months at 2-8 ° C was equivalent within the assay range, which suggest idursulfase remained stable in the saline formulation for 24 months (Table 21). TABLE 21: RESULTS OF ACTIVITY BY IONIC EXCHANGE CHROMATOGRAPHY AFTER 24 MONTHS OF REAL TIME STABILITY (2-
* The specific activity of the reference standard was 56 U / mg during the 24-month sample tests. Detection of Residual Phosphate associated with Protein
[0354] The final UF / DF step when preparing the saline formulation was used to diafiltrate the 137 mM NaCI protein solution, 20 mM sodium phosphate in 150 mm NaCI. To examine how the number of diafiltration cycles affects the concentration of residual phosphate in the final product, a laboratory scale study was performed using the medicinal substance (2 mg / mL idursulfase, 137 mM NaCI, 20 mM sodium phosphate, pH 6.0 ). The medicinal substance was first concentrated at 50 mg / ml idursulfase and then diafiltered in 150 mM saline. Samples were taken at x 7 x 10 and 15 x diafiltration step and tested by TCP for phosphate content. The test results are summarized in table 22. As shown, the diafiltration saline does not contain any phosphate. After 7 x DF, the protein contained about 0.22 mM phosphate, which was greater than the calculated theoretical value. After 10 x DF, the protein retentate contained about 0.16 mM phosphate while the flow through was only about 0.07 mM phosphate, which indicated that the phosphate is binding to the protein. After 15 x DF, the phosphate level was dropped to about 0.07 mM.
[0355] The results of the study indicated that a phosphate residue of about 0.2 mm remained in the drug substance, which probably contributed to maintaining the pH of 6.0 for the saline formulation. TABLE 22: SODIUM PHOSPHATE, STAYING WITH THE PROTEIN AFTER VARIOUS STEPS OF DIAPHILTRATION

The starting saline buffer was tested and non-detectable phosphate was detected. Effect of protein concentration on the pH of the maintenance formulation
[0356] From the analysis of phosphate content, apparently phosphate binds to protein. Therefore, it is hoped that high protein can bind more phosphate, which can maintain a better pH. To examine this hypothesis, protein in saline was concentrated to different levels and pH of the solutions after different processing conditions were tested. The results are summarized in Table 23.
[0357] As shown, the initial pH of the solutions was maintained at about 6.0 regardless of the protein concentration. However, after exposure of the environment for 24 hours or three freeze-thaw cycles, the pH of solutions containing 0.1 mg / ml protein or less does not maintain a constant pH around 6.0. The pH of the solutions in the protein concentration above 1 mg / ml remained around 6.0. This confirmed that the protein concentration is a control factor in maintaining the pH of saline solutions. TABLE 23: EFFECT OF THE CONCENTRATION OF PROTEIN ON THE PH OF SALT FORMULATIONS WITHOUT BUFFER


[0358] The samples were stored at <-65 ° C for at least 1 hour, thawed at room temperature for 0.5 hour and this cycle was repeated three times.
[0359] The results of this study demonstrated that idursulfase in the saline formulation (50 mg / ml idursulfase, 0.005% polysorbate, 150 mM NaCl, pH 6.0) is stable for at least 24 months when stored at 2-8 C. This formulation appears to be more stable compared to the phosphate containing the formulation. The selection of 0.005% polysorbate 20 was enough to protect the protein from tremendous stress. In addition, the study also indicated that the pH of the saline formulation can be kept stable at 6.0 to 24 months at 2-8DC, in part due to the residual phosphate and high protein concentration in the final formulation. EXAMPLE 5. BIODISTRIBUTION
[0360] Having successfully demonstrated that intrathecal administration is an effective way to deliver I2S to the tissues of the CNS, further studies have been conducted to determine whether the I2S administered IT is able to deliver to deep brain tissues and whether there is localization cell of the IT-administered I2S. A recombinant human iduronate-2-sulfatase (I2S) formulation was prepared and formulated in a vehicle of 154 mM NaCl, 0.005% polysorbate 20 at pH 6.0.
[0361] Non-human primates were administered either 3 mg, 30 mg, or 100 mg of I2S monthly through an implanted intrathecal port for six consecutive months. The study design is summarized in Table 24 below. TABLE 24
aIdursulfase, unless otherwise specified. DC (device control); HE (intrathecal); IV (intravenous); NS (saline); PBS (phosphate buffered saline, pH 7.2).
[0362] Repeated monthly administration of I2S to non-human primates for six months was well tolerated with the highest dose tested and not associated with any significant toxicological adverse events. Twenty-four hours after the administration of the sixth and final dose of I2S, the individual non-human primates were sacrificed and CNS tissues from such non-human primates were examined.
[0363] As determined by immunohistochemistry (IHC), there was widespread cell deposition of I2S throughout the cells and tissues of the CNS. I2S protein was detected in all brain tissues by the IHC, with a gradient from cerebral cortex deposition to ventricular white matter. In the matter of ash I2S, it was detected in the neurons of the brain, cerebellum, brain stem and spinal cord of all groups in a dose-dependent manner. On a gray surface of the higher dose groups, a large number of brain neurons were positive for I2S staining in the superficial cortex (Figure 40A). I2S was also detected in neurons in the hippocampus (Figure 40), thalamus (Figure 40B), caudate nucleus figure 40) and medullary (Figure 40E). Meningial and perivascular cells were also positive for I2S staining (Figure 40F).
[0364] As illustrated in figures 41 and 42, I2S distribution is administered in the tissues of the CNS and in particular deposition in the gray matter, thalamus and cerebral cortex of the individual non-human primates is evident. In addition, figures 42 and 43 illustrate that the IT-administered I2S accumulates in the CNS depicted tissues of individual non-human primates in a dose-dependent manner. Co-location staining also revealed that the TI administration of I2S associates with neurons and oligodendrocytes. The IT-administered I2S also distributes and is located throughout the brain of the individual non-human primates as evidenced by Figure 44. In particular, Figure 45 illustrates neuronal uptake and axonal association of I2S after TI administration for non-human primates , as demonstrated by the filament staining. Also of particular interest, the present studies illustrate that I2S is selective for neuronal cells and such neuronal cells facilitate the distribution of intrathecally-administered I2S in deep brain tissues and appear to be associated with axonal structures, indicating axonal transport of I2S anterograde.
[0365] Table 25 below shows the pharmacokinetic data for various routes of administration and doses from a separate animal study. TABLE 25
l2S124I-tagged was administered to test animals, as shown in table 26 below and PET scan results are shown in Figure 62, Figure 63. TABLE 26

[0366] The present studies also demonstrated the cellular identification of I2S is administered in the white matter brain tissue near the ventricles of the individual non-human primates following TI administration. While the density of I2S staining in white matter was generally less than the gray matter, I2S was detected within oligodendrocytes (figure 46). In particular, Figure 46 illustrates the cellular identification of I2S in white matter brain tissues and further demonstrates that I2S does not appear to associate with myelin.
[0367] In addition to demonstrating the distribution of IT- administered deep I2S in brain tissues, the present studies also confirmed the location of I2S for target organelles, and important location of I2S for lysosomes, which are affected organelles in lysosomal storage disorders, such as Hunter's syndrome. In particular, I2S was located within lysosomes and also detected within axons. Figure 46 illustrates the location of the IT-administered I2S within individual non-human Primate oligodendrocyte lysosomes, thus confirming that the IT-administered I2S is capable of delivering to deep brain tissues and is capable of cellular localization.
[0368] In order to discern whether delivered I2S maintained biological activity, levels of I2S in the brain were measured using a specific activity assay. The activity in the brain of the 3 mg-group 24 hours after the last dose was apparently not different from the baseline levels in the control devices and animal control vehicles. Enzyme activity in the brain of 30 mg and 100 mg-dosed animals was above baseline at cell necropsy location (24-hour post-dose).
[0369] Further animal testing to discern the biodistribution of the I2S following it delivers to the brain is shown in Figure 60, and the sample numbers correspond to Table 27 below. TABLE 27: LOCATION OF SAMPLES


EXAMPLE 6. IT vs. ICV DELIVERY
[0370] The I2S distribution patterns observed in the example above was also a healthy Beagle recapitulated in dogs given a single dose he or ICV. Male Beagle dogs were randomized using computer generated numbers in two groups (Group 1 (ICV), N = 3; Group 2 (IT); N = 4). All had catheters implanted in the subarachnoid space in the lumbar spine or in the left lateral cerebral ventricle (for dosing) and in the large cistern (by sampling). All catheters enclosed in a subcutaneous titanium access port. An additional dog was used as a non-dosed surgical control.
[0371] A single bolus injection of 1 ml of I2S (30 mg / ml in 20 mM sodium phosphate, pH 6.0; 137 mM sodium chloride; 0.02% polysorbate-20) was administered IT or ICV, followed by a rinse with solution phosphate buffered saline (PBS, pH 7.2) of 0.3 ml. Clinical signs were monitored and sacrifice occurred 24 hours after the dose. Tissue samples from the brain and spinal cord were collected for quantitative I2S analyzes, as determined by ELISA, the I2S and IHC enzyme activity and compared between the studied groups.
[0372] I2S was widely distributed throughout the gray matter of the he and ICV groups, as determined by the IHC. In the cerebral cortex, neurons were positive for I2S in all six neuronal layers, from the molecular surface layer to the inner bottom layer in TI and ICV groups, as illustrated by the Figure. 47 (A and B). In the cerebellar cortex of the he and ICV groups, I2S was detected in neurons, including Purkinje cells, as illustrated by Figure 47 (C and D). In IT and ICV groups a large population of neurons in the hippocampus was positive for I2S, as shown in Figure 47 (E and F). I2S positive neurons were also found in the thalamus and caudate nucleus in both groups, as shown in Figure 47 (G and H).
[0373] The present studies confirm, therefore, the ability of enzymes is administered to distribute into deep brain cells and tissues and support the utility of enzymes is administered as I2S for the treatment of CNS manifestations associated with diseases, such as Hunter's syndrome. EXAMPLE 7: MODEL OF MOUSE DEFICIENT IN Iduronate-2-sulfatase
[0374] Having demonstrated that I2S administered IT is capable of delivering to deep brain tissues and the cellular location of I2S, studies have been conducted to determine the therapeutic efficacy of the IT-administered I2S. Genetically iduronate-2-sulfatase knockout (IKO) mouse from Hunter syndrome has developed a model to study the ability of I2S is administered to alter disease progression. The I2S mouse knockout model was developed using a target disruption of the I2S locus that results in accumulation of glycosaminoglycans (GAG) in tissues and organs. The IKO mouse model has many of the physical characteristics of Hunter's syndrome in humans, including the characteristic features of coarse and skeletal defects. In addition, the IKO mouse model demonstrates elevated glycosaminoglycan (GAG) levels in urine and tissues throughout the body, such as widespread cell vacuolization that has been observed histopathologically.
[0375] In the present study, commercially available I2S (Elaprase ®) was concentrated and then in phosphate buffered saline (PBS). Six groups of male IKO rats, 8-12 weeks old, were treated with I2S (10 p. 1; mg / ml 26). Groups A and B (N = 3) were intrathecally administered three doses of 260pg (on days 1, 8 and 15) and doses of two 260pg (on days 1 and 8) of I2S, respectively. Group D was also treated with three doses of 260pg intrathecally administered on days 1, 8 and 15. Group C and E (N = 3) were untreated control groups and Group F (N3) was an untreated wild type control. Control mice were administered a vehicle without I2S. Rats were sacrificed 1 hour after the last injection, followed by tissue preparation for histopathological and immunohistochemical (IHC) analysis.
[0376] After the third injection, there was a generalized reduction in cell vacuolization on the surface of the cerebral cortex, caudate nucleus, thalamus and cerebellum in rats treated with I2S compared to rats treated with vehicle. Reductions in cell vacuolization have also been found in white matter after IT treatment. Distribution of I2S to the brain tissues of the IKO mouse was evident after TI administration.
[0377] Three weekly IT administrations of I2S in IKO rats also demonstrated a marked reduction in CNS cell vacuolization at microscopic levels of light and electronics. After TI administration of I2S, a reduction in cell vacuolization was evident compared to untreated IKO mice, suggesting that the IT-administered I2S is capable of altering disease progression. As illustrated in Figure 48, a reduction in cell vacuolization was evident in the corpus callosum and fornix of IKO rats after IT-administration of I2S. Figure 49 illustrates a marked reduction in the presence of lysosome 1 associated membrane protein (LAMP1), a pathological biomarker of lysosomal disease, in the superficial cerebral cortex tissues of the treated IKO rat.
[0378] In addition, electron microscopy demonstrated a reduction in the presence of storage inclusions in neurons in gray matter and vacuolization in oligodendrocytes in white matter. In particular, IT-administered IKO I2S rats also demonstrated a reduction in the palisated lamellar organs ("zebra") that are characteristic of certain diseases by storage of lysosomes. In particular, Figure 5 represents an electron microscope scan, illustrating a characteristic zebra reduction of bodies in the neurons of the IKO mouse that was administered I2S, relative to the untreated IKO mouse. Likewise, Figure 5 illustrates a scanning electron microscope for oligodendrocytes in the corpus callosum.
[0379] In addition, I2S IT administrations for IKO mice also demonstrated a marked reduction in lysosomal associated membrane protein pathological biomarker lysosomal disease 1 (LAMP1), an indicator of lysosomal disease and activity status, in cerebral cortex, caudate nucleus, thalamus, cerebellum and white matter. As shown in Figure 4 9A, a marked reduction in immunostaining LAMP1 is evident in the IKO mouse surface treated cerebral cortex compared to the untreated IKO control mouse surface cerebral cortex tissue illustrated in Figure 49B, reflecting an improvement in disease pathology.
[0380] Figure 20 quantitatively illustrates and compares the LAMP1 concentration measured in pm2 areas of brain tissue. Morphometric analyzes of LAMP-1 immunostaining from various regions of the brain confirmed that there were significant reductions in positive LAMP-1 staining in all areas of the brain assessed. As shown in Figure 4, in each evaluated brain tissue area (the cortex, caudate nucleus and putamen (CP), thalamus (TH), cerebellum (CBL) and white matter (WM)) the LAMP-positive area was reduced in the rats treated IKO compared to untreated IKO control rats and approached the LAMP-positive area of wild-type rats. Particularly notable is that the light-positive areas in each area of brain tissue analyzed were further reduced with continued treatment duration.
[0381] Reduction in the activity of abnormally high lysosomes correlated with dramatic morphological improvements in all areas of the brain. These results confirm that I2S administered IT is capable of altering disease progression, in a mouse model IKO genetically, further confirming the IT-administered ability of enzymes such as I2S to treat CNS manifestations associated with diseases such as syndrome Hunter. Example 8: TREATMENT OF PATIENTS WITH HUNTER'S DISEASE
[0382] Targeting CNS administration through, for example, IT delivery can be used to effectively treat patients with Hunter disease. This example illustrates a multicentric dose escalation study to assess the safety of up to 3 dose levels biweekly (EOW) for a total of 40 weeks of I2S administered via an intrathecal drug delivery device (IDDD) for patients with Hunter disease late childhood. Various exemplary intrathecal drug delivery devices suitable for human treatment are shown in Figures 45-48.
[0383] Up to 20 patients will be enrolled: 1: 5 cohort patients (lowest dose) 2: 5 cohort patients (intermediate dose) 3: 5 cohort patients (maximum dose) 5 patients will be randomized to no treatment.
[0384] Patients are selected for the study based on the inclusion of the following criteria: (1) appearance of the first symptoms before 30 months of age; (2) ambulatory at the time of screening (defined as the ability to stand up alone and walk forward 10 steps with one hand); (3) presence of neurological signs at the time of screening. Typically, patients with a history of hematopoietic stem cell transplantation are excluded.
[0385] Safety of rising doses of I2S administered by injection of IT for 40 weeks in children with delayed infant Hunter disease is determined. In addition, the clinical activity of I2S on crude motor function and single pharmacokinetics and repeated dose in serum and concentrations in cerebrospinal fluid (CSF) are evaluated.
[0386] The therapeutically effective amount of I2S is administered intrathecally at regular intervals, depending on the nature and extent of the effects of the disease and on an ongoing basis. Administration at an "interval", as used here, indicates that the therapeutically promoting amount is administered periodically (distinguishing a single dose). The range can be determined by standard clinical techniques. In some modalities, I2S is administered intrathecally approximately fortnightly. The administration interval for a single individual does not have to be a fixed interval, but it can be varied over time, depending on the individual's needs. For example, in times of physical illness or stress, anti-! 2S antibodies become present or increase, or if the symptoms of the disease worsen, the interval between doses may be reduced. Example 9- TREATMENT OF PATIENTS WITH HUNTER'S DISEASE
[0387] Targeting CNS administration through, for example, IT delivery can be used to effectively treat patients with Hunter disease. This example illustrates a multicentric dose escalation study to assess the safety of up to 3 doses per month for a total of 6 months of I2S administered through an intrathecal drug delivery device (IDDD) for patients with late childhood Hunter disease. Various exemplary intrathecal drug delivery devices suitable for human treatment are depicted in Figures 45-48 and an outline of the assay is shown in Figure 62.
[0388] Up to 16 patients will be enrolled: 1: 4 cohort patients (lowest dose-10 mg) 2: 4 cohort patients (intermediate dose-30 mg) 3: 4 cohort patients (highest dose-100 mg) 4 patients will be randomized to no treatment or device use.
[0389] Hunter Disease patients often develop cognitive and neurological impairment including delayed early developmental milestones (eg, walking, speech, toilet training), intellectual impairment, hyperactivity, aggression, hearing impairments, epilepsy and hydrocephalus. All nominations may be part of the judgment criteria. Patients are selected for the study based on the inclusion of the following criteria: (1) 3-18 years of age; (2) intelligence quotient of less than 77 or a decline of 15 to 30 IQ points in the past 3 years; (3) no CSF has closed or poorly controlled seizure disorder and (4) without comorbidities present anesthesia and / or surgical risks.
[0390] Safety of rising doses of I2S administered by injection of IT to 6 months in children with delayed infant Hunter disease is determined. In addition, the clinical activity of I2S on crude motor function and single pharmacokinetics and repeated dose in serum and concentrations in cerebrospinal fluid (CSF) are evaluated.
[0391] Objectives of the study will be to assess the safety and tolerability of increasing doses of I2S, as well as the long-term safety, tolerability and clearance of the IDDD. In addition, the concentration of I2S after single and repeated doses in CSF and peripheral blood, as well as the effects of I2S on CF biomarkers, and the urinary gag will be assessed. Additional assessment will include effects of I2S on clinical parameters such as physiological and neurocognitive assessments, neuro-function and brain structure volumes. In addition, the effects of treatment on daily life and the relationships between biomarkers and symptoms can be assessed.
[0392] Treatment of patients with Hunter disease by I2S IT delivery results in a reduction in the accumulation of sulfatide in various tissues (eg, the nervous system, heart, liver, kidneys, gallbladder and other organs).
[0393] While certain compounds, compositions and methods described herein have been specifically described in accordance with certain embodiments, the following examples serve only to illustrate the compounds of the invention and are not intended to limit the same.
[0394] Articles "a" and "one" as used herein in the specification and in the claim, unless clearly indicated to the contrary, must be understood to include the referring plurals. Complaints or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one or all members of the group are present in, employed, or otherwise relevant to a particular product or process, unless otherwise indicated or otherwise evident from the context. The invention includes modalities in which exactly one member of the group is present in, employed in or otherwise relevant to a particular product or process. The invention also includes modalities in which more than one, or members of the entire group are present in, employed in or otherwise relevant to a particular product or process. In addition, it should be understood that the invention encompasses all variations, combinations and permutations, in which one or more limitations, elements, clauses, descriptive terms, etc., one or more of the listed credits, another dependent claim on the same credit is introduced basis (or, as relevant, any other claim) unless otherwise indicated or less, it is evident to a person skilled in the art that a contradiction or inconsistency would arise. Elements are presented as lists, (for example, in the Markush group or similar format) it is to be understood that each subgroup of the elements is also disclosed, and any element (s) can be removed from the group. It should be understood that, in general, where the invention, or aspects of the invention, are / are referred to as comprising particular elements, features, etc., certain embodiments of the invention aspects of the invention consist or essentially consist of such elements, features, etc. . For the sake of simplicity these modalities have not in all cases been specifically stated in so many words here. It should also be understood that any personification or aspect of the invention can be explicitly excluded from the claims, regardless of whether the specific exclusion is recited in the specification. The publications, websites and other reference materials mentioned in this document to describe the background of the invention and to provide additional details about its practice hereby are incorporated by reference.

权利要求:
Claims (16)
[0001]
1. Use of a stable intrathecal formulation comprising an iduronate-2-sulfatase (I2S) protein at a concentration of 10 mg / ml or more, salt and a polysorbate surfactant, where the formulation comprises phosphate at a concentration not exceeding 10 mM characterized by being for the preparation of a medicine to treat Hunters syndrome.
[0002]
2. Use according to claim 1, characterized in that the I2S protein is present in a concentration ranging from 10 to 300 mg / ml, optionally in a concentration selected from 10 mg / ml, 30 mg / ml, 50 mg / ml ml or 100 mg / ml.
[0003]
Use according to claim 1 or 2, characterized in that the salt is NaCl, present as a concentration ranging from approximately 0-300 mM, optionally at a concentration ranging from 137-154 mM, optionally at a concentration of 154 mM.
[0004]
Use according to any one of claims 1 to 3, characterized in that the polysorbate surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and a combination thereof, and that optionally the surfactant of polysorbate is polysorbate 20 and is present in a concentration ranging from 0-0.02%, optionally in a concentration of 0.005%.
[0005]
Use according to any one of claims 1 to 4, characterized in that the formulation has a pH of 3-8, 5.5-6.5 or 6.0.
[0006]
Use according to any one of claims 1 to 4, characterized in that: (i) the formulation is a liquid formulation, or (ii) the formulation is formulated as a lyophilized dry powder.
[0007]
7. Stable formulation for intrathecal administration, characterized by comprising an iduronate-2-sulfatase (I2S) protein in a concentration of 10 mg / ml or more, salt and a polysorbate surfactant, in which the formulation comprises phosphate in a concentration not exceeding 10 mM.
[0008]
8. Stable formulation according to claim 7, characterized in that the I2S protein is present in a concentration ranging from 10-300 mg / ml, optionally in a concentration selected from 10 mg / ml, 30 mg / ml, 50 mg / ml or 100 mg / ml.
[0009]
Stable formulation according to claim 7 or 8, characterized in that the I2S protein comprises an amino acid sequence of SEQ ID no: 1.
[0010]
10. Stable formulation according to any of claims 7-9, characterized in that the salt is NaCl, in which optionally NaCl is present in a concentration ranging from approximately 0-300 mM, optionally in a concentration ranging from 137-154 mM, optionally at a concentration of 154 mM.
[0011]
A stable formulation according to any one of claims 7-11, characterized in that the polysorbate surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and a combination of these, in which optionally the surfactant polysorbate is polysorbate 20 and is present at a concentration ranging from 0-0.02%, optionally at a concentration of 0.005%.
[0012]
Stable formulation according to any one of claims 7-11, characterized in that the formulation additionally comprises a buffering agent, in which optionally the buffering agent is selected from the group consisting of acetate, histidine, succinate, Tris and combinations thereof.
[0013]
13. Stable formulation according to any one of claims 7-12, characterized in that the formulation has a pH of 3-8, 5.5-6.5 or 6.0.
[0014]
14. Stable formulation or use according to any one of claims 1 to 13, characterized in that: (i) the formulation is a liquid formulation, or (ii) the formulation is formulated as a lyophilized dry powder.
[0015]
15. A stable formulation according to any one of claims 7-14, characterized in that the formulation comprises an iduronate-2-sulfatase (I2S) protein in a concentration ranging from about 10-300 mg / ml, NaCI in a concentration of 154 mM, polysorbate 20 at a concentration of 0.005%, and a pH of 6.0, where optionally the I2S protein is at a concentration of 10 mg / ml, 30 mg / ml, 50 mg / ml, 100 mg / ml, or 300 mg / ml.
[0016]
16. Container characterized by comprising a single dosage form of a stable formulation, as defined in any one of claims 7 to 15, in which: (i) the container is selected from an ampoule, a test tube, a cartridge, a reservoir, lyo-ject or pre-filled syringe, optionally in which the container is a pre-filled syringe and is optionally selected from borosilicate glass syringes with baked silicone coating, borosilicate glass syringes with sprayed silicone , or plastic resin syringes without silicone, or (ii) the stable formulation is present in a volume less than about 5.0 ml, optionally less than about 3.0 ml.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2019203515B2|2021-01-28|Methods and compositions for cns delivery of iduronate-2-sulfatase

---

US11260112B2|2022-03-01|Methods and compositions for CNS delivery of iduronate-2-sulfatase

---

EP3626257B1|2021-08-04|Methods and compositions for cns delivery of arylsulfatase a

---

US20190125841A1|2019-05-02|Stable formulations for cns delivery of arylsulfatase a

同族专利:

---

公开号 | 公开日

---

JP2019006826A|2019-01-17|

---

PT2588130T|2016-11-25|

---

ES2896060T3|2022-02-23|

---

US20140271598A1|2014-09-18|

---

US11065308B2|2021-07-20|

---

US20170042977A1|2017-02-16|

---

HRP20211520T1|2021-12-24|

---

PE20130637A1|2013-06-13|

---

NZ702803A|2017-05-26|

---

AR081680A1|2012-10-10|

---

JP2016041755A|2016-03-31|

---

TW201701899A|2017-01-16|

---

CN106139133B|2020-12-04|

---

US20200405825A1|2020-12-31|

---

JP2021181489A|2021-11-25|

---

TW201825111A|2018-07-16|

---

JP2019038853A|2019-03-14|

---

CL2017002488A1|2017-12-15|

---

JP6898909B2|2021-07-07|

---

LT3626257T|2021-12-10|

---

PT3626258T|2021-10-19|

---

US20190183984A1|2019-06-20|

---

US9220677B2|2015-12-29|

---

RU2017125281A3|2020-11-09|

---

US20180085438A1|2018-03-29|

---

CL2012003657A1|2013-04-19|

---

SMT201600385B|2017-03-08|

---

JP6938456B2|2021-09-22|

---

TWI602573B|2017-10-21|

---

JP6466538B2|2019-02-06|

---

JP2019031575A|2019-02-28|

---

JP2016040337A|2016-03-24|

---

RU2761342C2|2021-12-07|

---

AR082025A1|2012-11-07|

---

US9814764B2|2017-11-14|

---

US20170042978A1|2017-02-16|

---

PE20170938A1|2017-07-13|

---

JP2018002734A|2018-01-11|

---

LT3103469T|2021-03-25|

---

CN106139133A|2016-11-23|

---

CL2012003656A1|2013-07-19|

---

PT2585104T|2019-10-30|

---

BR112012033214A2|2017-05-23|

---

DK3103469T3|2021-02-22|

---

LT3626258T|2021-12-10|

---

CL2016003159A1|2017-05-12|

---

JP2018002735A|2018-01-11|

---

HRP20210298T1|2021-04-16|

---

CN105233277A|2016-01-13|

---

HUE046409T2|2020-02-28|

---

JP6250616B2|2017-12-20|

---

ES2858726T3|2021-09-30|

---

US20130295077A1|2013-11-07|

---

JP6285409B2|2018-02-28|

---

PL2588130T3|2017-09-29|

---

US10646554B2|2020-05-12|

---

PT3626257T|2021-11-12|

---

PE20180130A1|2018-01-18|

---

PE20130578A1|2013-05-19|

---

RS62520B1|2021-11-30|

---

MX354776B|2018-03-20|

---

JP2016040335A|2016-03-24|

---

HK1218719A1|2017-03-10|

---

US11065307B2|2021-07-20|

---

JP2021167341A|2021-10-21|

---

DK3626258T3|2021-09-20|

---

AR081681A1|2012-10-10|

---

DK3626257T3|2021-11-08|

---

CN105664142A|2016-06-15|

---

AR081677A1|2012-10-10|

---

RU2018113327A3|2021-07-21|

---

JP2020079298A|2020-05-28|

---

JP6522072B2|2019-05-29|

---

SI3103469T1|2021-04-30|

---

PE20130589A1|2013-05-19|

---

RU2017125281A|2019-01-31|

---

RU2018137304A3|2022-02-22|

---

TW201206465A|2012-02-16|

---

CN105233277B|2019-01-01|

---

RU2018113327A|2019-03-01|

---

JP2017214434A|2017-12-07|

---

ES2895655T3|2022-02-22|

---

HRP20211660T1|2022-02-04|

---

TW201212936A|2012-04-01|

---

TWI609694B|2018-01-01|

---

JP6522073B2|2019-05-29|

---

JP2022024176A|2022-02-08|

---

PT2593131T|2019-10-30|

---

JP6346162B2|2018-06-20|

---

US10456454B2|2019-10-29|

---

TW201815411A|2018-05-01|

---

PE20130648A1|2013-07-03|

---

US20180071212A1|2018-03-15|

---

UA125060C2|2022-01-05|

---

HUE046856T2|2020-03-30|

---

MX2013000321A|2013-04-03|

---

JP2016037504A|2016-03-22|

---

PE20130579A1|2013-05-19|

---

AR081679A1|2012-10-10|

---

RS61683B1|2021-05-31|

---

CL2020000468A1|2020-09-04|

---

NZ702800A|2017-03-31|

---

US11260112B2|2022-03-01|

---

AR081678A1|2012-10-10|

---

PE20180801A1|2018-05-09|

---

TW201726161A|2017-08-01|

---

HK1214149A1|2016-07-22|

---

US20200046810A1|2020-02-13|

---

CN104857504A|2015-08-26|

---

PT3103469T|2021-03-04|

---

TW202112391A|2021-04-01|

---

JP6797876B2|2020-12-09|

---

JP2020079297A|2020-05-28|

---

JP2020079244A|2020-05-28|

---

JP2016094451A|2016-05-26|

---

SI3626258T1|2021-11-30|

---

SI3626257T1|2021-12-31|

---

CL2012003655A1|2013-04-19|

---

CL2012003654A1|2013-06-14|

---

RU2018137304A|2019-03-21|

---

HUE052944T2|2021-05-28|

---

TWI698252B|2020-07-11|

---

US20160158324A1|2016-06-09|

---

HUE031036T2|2017-06-28|

---

US20200113981A1|2020-04-16|

---

JP2021167340A|2021-10-21|

---

TWI669128B|2019-08-21|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3133001A|1959-11-26|1964-05-12|Muset Pedro Puig|Stabilization of enzymes|

---

US4743265A|1986-04-23|1988-05-10|Dij Catheter Corp|Articulated catheter placement device|

---

WO1994017819A1|1993-02-02|1994-08-18|Xoma Corporation|Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant|

---

US5863782A|1995-04-19|1999-01-26|Women's And Children's Hospital|Synthetic mammalian sulphamidase and genetic sequences encoding same|

---

US6118045A|1995-08-02|2000-09-12|Pharming B.V.|Lysosomal proteins produced in the milk of transgenic animals|

---

AUPN674895A0|1995-11-23|1995-12-14|Women's And Children's Hospital|Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same|

---

AT225184T|1997-08-22|2002-10-15|Seikagaku Kogyo Co Ltd|MEDICINES FOR THE TREATMENT OF INTERVERTEBRAL DISK THROUGH HERNIE|

---

PT1137762E|1998-12-07|2009-01-14|Genzyme Corp|Treatment of pompe`s disease|

---

US6217552B1|1999-03-01|2001-04-17|Coaxia, Inc.|Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma|

---

US20020052311A1|1999-09-03|2002-05-02|Beka Solomon|Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders|

---

US6642038B1|1999-09-14|2003-11-04|Genzyme Glycobiology Research Institute, Inc.|GlcNAc phosphotransferase of the lysosomal targeting pathway|

---

US20020099025A1|1999-12-30|2002-07-25|Heywood James A.|Treatment of neurological disorders|

---

US7629309B2|2002-05-29|2009-12-08|Zystor Therapeutics, Inc.|Targeted therapeutic proteins|

---

WO2003032913A2|2001-10-16|2003-04-24|Symbiontics Inc.|Methods and compositions for targeting proteins across the blood brain barrier|

---

ES2300439T3|2001-04-30|2008-06-16|Zystor Therapeutics , Inc.|SUBCELLULAR RECOGNITION OF THERAPEUTIC PROTEINS.|

---

US7560424B2|2001-04-30|2009-07-14|Zystor Therapeutics, Inc.|Targeted therapeutic proteins|

---

US20030072761A1|2001-10-16|2003-04-17|Lebowitz Jonathan|Methods and compositions for targeting proteins across the blood brain barrier|

---

DK1503788T3|2002-04-25|2011-10-17|Shire Human Genetic Therapies|Treatment of alpha-galactosidase A deficiency|

---

CA2487815A1|2002-05-29|2003-12-11|Symbiontics, Inc.|Targeted therapeutic proteins|

---

US20040005309A1|2002-05-29|2004-01-08|Symbiontics, Inc.|Targeted therapeutic proteins|

---

US6866844B2|2002-11-07|2005-03-15|Biomarin Pharmaceutical Inc.|Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme|

---

EP1587923B1|2003-01-22|2011-08-24|Duke University|Improved constructs for expressing lysosomal polypeptides|

---

DK2444102T3|2003-01-31|2015-07-13|Sinai School Medicine|Combination therapy for the treatment of protein deficiency disorders|

---

AU2004208962B2|2003-02-10|2010-07-15|To-Bbb Holding B.V.|Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions|

---

CN1788017B|2003-02-10|2013-04-24|to-BBB控股股份有限公司|Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions|

---

CA2525236C|2003-06-20|2015-03-24|Biomarin Pharmaceutical Inc.|Delivery of therapeutic compounds to the brain and other tissues|

---

US20050026823A1|2003-06-20|2005-02-03|Biomarin Pharmaceutical Inc.|Use of the chaperone receptor-associated protein for the delivery of therapeutic compounds to the brain and other tissues|

---

US7442372B2|2003-08-29|2008-10-28|Biomarin Pharmaceutical Inc.|Delivery of therapeutic compounds to the brain and other tissues|

---

EP2532742B1|2004-01-30|2018-08-08|Shire Pharmaceuticals Ireland Limited|Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject|

---

US20060029656A1|2004-02-03|2006-02-09|Biodelivery Sciences International, Inc.|Replacement enzyme cochleates|

---

WO2005077093A2|2004-02-06|2005-08-25|Biomarin Pharmaceutical Inc.|Manufacture of highly phosphorylated lysosomal enzymes and uses thereof|

---

AU2005212435B2|2004-02-10|2010-09-09|Biomarin Pharmaceutical Inc.|Acid alpha-glucosidase and fragments thereof|

---

US20050208090A1|2004-03-18|2005-09-22|Medtronic, Inc.|Methods and systems for treatment of neurological diseases of the central nervous system|

---

RU2006144851A|2004-06-15|2008-06-20|Бакстер Интернэшнл Инк. |APPLICATION OF EX-VIVO THERAPEUTIC PRODUCTS IN THE FORM OF SOLID MICROPARTICLES|

---

AT451472T|2004-08-11|2009-12-15|Basf Se|TIME TEMPERATURE INDICATOR ON ENZYME BASIS|

---

IL165334D0|2004-11-22|2006-01-15|Mediwound Ltd|Debriding composition from bromelain and methods of producing same|

---

EP1889628B1|2005-05-11|2013-12-11|JCR PHARMACEUTICALS Co., LTD.|Lipid liposome composition|

---

EP1888068B1|2005-06-08|2014-05-21|Amicus Therapeutics, Inc.|Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes|

---

AR059089A1|2006-01-20|2008-03-12|Genzyme Corp|INTRAVENTRICULAR ADMINISTRATION OF AN ENZYME FOR LISOSOMAL STORAGE DISEASES|

---

ES2697502T3|2006-02-09|2019-01-24|Genzyme Corp|Slow intraventricular administration|

---

CN101410408A|2006-04-04|2009-04-15|希尔制药爱尔兰有限责任公司|A process for concentration of a polypeptide|

---

NZ571610A|2006-04-04|2011-07-29|Zymenex As|A process for concentration of alpha mannosidase|

---

GB0611463D0|2006-06-09|2006-07-19|Novartis Ag|Organic compounds|

---

US20080140008A1|2006-12-06|2008-06-12|Medtronic, Inc.|Intrathecal catheter|

---

CA2680189A1|2007-03-06|2008-09-12|Saint Louis University|Modified enzyme and treatment method|

---

WO2009017005A1|2007-07-27|2009-02-05|Sharp Kabushiki Kaisha|Mobile station device, base station device, communication system and program|

---

BRPI0815416A2|2007-08-15|2014-10-21|Amunix Inc|COMPOSITIONS AND METHODS FOR MODIFYING PROPERTIES OF BIOLOGICALLY ACTIVE POLYPEPTIDES|

---

WO2009062348A1|2007-11-14|2009-05-22|Institute Of Microbiology, Chinese Academy Of Sciences|Methods for inhibiting influenza virus infection and their drugs|

---

SG186607A1|2007-11-30|2013-01-30|Abbott Lab|Protein formulations and methods of making same|

---

US7722865B2|2008-01-18|2010-05-25|Biomarin Pharmaceutical Inc.|Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof|

---

TW200936156A|2008-01-28|2009-09-01|Novartis Ag|Methods and compositions using Klotho-FGF fusion polypeptides|

---

WO2009131698A2|2008-04-23|2009-10-29|Iowa State University Research Foundation, Inc.|PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE AND USES THEREOF|

---

BRPI0912225A2|2008-05-07|2018-03-20|Zystor Therapeutics, Inc.|lysosomal targeting peptides and uses thereof|

---

US8436489B2|2009-06-29|2013-05-07|Lightsail Energy, Inc.|Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange|

---

US20110318327A1|2010-06-25|2011-12-29|Shire Human Genetic Therapies, Inc.|Treatment of sanfilippo syndrome type b|

---

EP2588132A4|2010-06-25|2014-10-15|Shire Human Genetic Therapies|Methods and compositions for cns delivery of -galactocerebrosidase|

---

KR102318997B1|2010-06-25|2021-10-29|샤이어 휴먼 지네틱 테라피즈 인크.|Methods and compositions for cns delivery of arylsulfatase a|

---

US8580922B2|2011-03-04|2013-11-12|Shire Human Genetic Therapies, Inc.|Peptide linkers for polypeptide compositions and methods for using same|

---

CA2805413A1|2010-06-25|2011-12-29|Shire Human Genetic Therapies, Inc.|Methods and compositions for cns delivery of heparan n-sulfatase|

---

KR20130043165A|2010-06-25|2013-04-29|샤이어 휴먼 지네틱 테라피즈 인크.|Methods and compositions for cns delivery of iduronate-2-sulfatase|

---

EP3875107A1|2010-06-25|2021-09-08|Shire Human Genetic Therapies, Inc.|Pharmaceutical formulation comprising a replacement enzyme for a lysosomal enzyme for use in treating lysosomal storage disease intrathecally|

---

LT3626258T|2010-06-25|2021-12-10|Shire Human Genetic Therapies, Inc.|Methods and compositions for cns delivery of iduronate-2-sulfatase|

---

JP2012062312A|2010-08-19|2012-03-29|Yoshikatsu Eto|Agent for treatment of hunter syndrome|US8497246B2|2006-08-18|2013-07-30|Armagen Technologies, Inc.|Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions|

---

CA2694762A1|2007-07-27|2009-02-05|Armagen Technologies, Inc.|Methods and compositions for increasing alpha-l-iduronidase activity in the cns|

---

JP2013507131A|2009-10-09|2013-03-04|アーメイゲン・テクノロジーズ・インコーポレイテッド|Methods and compositions for increasing iduronic acid 2-sulfatase activity in the CNS|

---

KR102318997B1|2010-06-25|2021-10-29|샤이어 휴먼 지네틱 테라피즈 인크.|Methods and compositions for cns delivery of arylsulfatase a|

---

LT3626258T|2010-06-25|2021-12-10|Shire Human Genetic Therapies, Inc.|Methods and compositions for cns delivery of iduronate-2-sulfatase|

---

CA2805413A1|2010-06-25|2011-12-29|Shire Human Genetic Therapies, Inc.|Methods and compositions for cns delivery of heparan n-sulfatase|

---

EP3875107A1|2010-06-25|2021-09-08|Shire Human Genetic Therapies, Inc.|Pharmaceutical formulation comprising a replacement enzyme for a lysosomal enzyme for use in treating lysosomal storage disease intrathecally|

---

EP3711778A1|2011-12-02|2020-09-23|Armagen, Inc.|Methods and compositions for increasing arylsulfatase a activity in the cns|

---

WO2013096899A2|2011-12-23|2013-06-27|Shire Human Genetic Therapies, Inc.|Stable formulations for cns delivery of arylsulfatase a|

---

EP2793933B1|2011-12-23|2019-04-17|Shire Human Genetic Therapies, Inc.|Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase|

---

WO2014186579A1|2013-05-15|2014-11-20|Regents Of The University Of Minnesota|Adeno-associated virus mediated gene transfer to the central nervous system|

---

US10538589B2|2015-01-14|2020-01-21|Armagen Inc.|Methods and compositions for increasing N-acetylglucosaminidaseactivity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU|

---

EP3292206B8|2015-05-07|2022-02-09|Takeda Pharmaceutical Company Limited|Glucocerebrosidase gene therapy for parkinson's disease|

---

MX2017014443A|2015-05-15|2018-08-01|Univ Minnesota|Adeno-associated for therapeutic delivery to central nervous system.|

---

US11052135B2|2015-12-30|2021-07-06|Green Cross Corporation|Methods and compositions for treating hunter syndrome|

---

JP2019506439A|2016-02-24|2019-03-07|バイオマリン ファーマシューティカル インコーポレイテッド|Targeted therapeutic lysosomal enzyme fusion proteins, related formulations and uses thereof|

---

JP2019518002A|2016-04-15|2019-06-27|ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア|Gene therapy to treat mucopolysaccharidosis type II|

---

EP3760220A4|2018-02-28|2022-01-19|Seikagaku Kogyo Co Ltd|Package and method for manufacturing same|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2019-01-29| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-06-11| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2019-12-03| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2020-04-07| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-11-03| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US35885710P| true| 2010-06-25|2010-06-25|

---

US36078610P| true| 2010-07-01|2010-07-01|

---

US61/360,786|2010-07-01|

---

US38786210P| true| 2010-09-29|2010-09-29|

---

US201161435710P| true| 2011-01-24|2011-01-24|

---

US61/435,710|2011-01-24|

---

US201161442115P| true| 2011-02-11|2011-02-11|

---

US61/422,115|2011-02-11|

---

US201161476210P| true| 2011-04-15|2011-04-15|

---

US61/476,210|2011-04-15|

---

US201161495268P| true| 2011-06-09|2011-06-09|

---

US61/495,268|2011-06-09|

---

PCT/US2011/041925|WO2011163649A2|2010-06-25|2011-06-25|Methods and compositions for cns delivery of iduronate-2-sulfatase|

---